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This thesis has been written by myself. The first
four and the last chapters are based on personal surveys
of the literature whilst the rest of the thesis describes
clinical studies performed mainly by myself with
assistance from colleagues in both the Departments of
Anaesthesia and Clinical Chemistry, Edinburgh and the




A brief history of the discovery of the anaesthetic
potential of nitrous oxide is given followed by a more
detailed history of the discovery of its specific toxic
depressant effect on bone marrow. The work demonstrating
that this effect is due to nitrous oxide reacting with
vitamin B12 and, consequently, inhibiting methionine
synthase is described. Because the clinical results of
this enzymatic inhibition in inhibiting DNA synthesis are
mediated through both the folate and methionine metabolic
pathways, these are discussed. Various theories on how
this mediation occurs are contrasted.
The clinical relevance of these potential toxic side
effects are discussed. Methods of assessing the toxicity
of nitrous oxide are analysed and it is concluded that
they are either too insensitive or require highly invasive
sampling. The use of the formiminoglutamic acid urine
excretion test in assessing folate metabolism is appraised
and the possibility of using this test to assess nitrous
oxide toxicity evaluated. Raised excretion is an index of
folate metabolic abnormalities.
This thesis then examines the toxicity of nitrous
oxide in clinical practice by using this test. Firstly, a
reproducible and accurate assay system for urinary
formiminoglutamic acid was designed and values for its
excretion in normal individuals determined. Then the
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amount excreted in subjects exposed to nitrous oxide under
a variety of conditions was found. It was demonstrated
that exposure to nitrous oxide during anaesthesia has
deleterious consequences on folate metabolism at an
exposure dose lower than was previously though because
subjects were found to excrete larger amounts of
formiminoglutamic acid for the first 2 days after exposure
to nitrous oxide. Excretion was raised with exposures of
greater than 90 minutes. Patients with cancer, who
theoretically are more susceptible to the toxic affects,
are similarly affected, but not to a significantly greater
degree. Chronic exposure of anaesthetists due to nitrous
oxide theatre pollution appears to have no effect. Nitrous
oxide therefore has a specific toxic effect at lower doses
than has been reported.
Finally, the place of nitrous oxide in modern
anaesthesia is discussed. Its advantages and disadvantages
are evaluated and the problems that may occur if it was
withdrawn from use in anaesthesia. The conclusion of this
thesis is that nitrous oxide due both to its specific
toxic effect on vitamin B12 and to its overall incidence
of other side effects has a poor cost-benefit index and
that it may be of advantage to the patient if it was
gradually withdrawn from use.
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CHAPTER ONE
NITROUS OXIDE AND METHIONINE SYNTHASE
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Introduction
Nitrous oxide (N20) is used in most modern general
anaesthetics because it is believed to have many
advantages and only a few minor problems. However,
evidence that has accumulated since 1978 contradicts this
view because N20 is now known to have a specific
inhibitory effect on DNA synthesis. This chapter will give
a brief resume of the history of N20 usage in anaesthesia,
describe how its bone marrow depressant effect was
discovered and indicate how it may occur. The second
chapter will describe folate and methionine metabolism
because they are central to N20 toxicity. The different
theories on how abnormalities in folate metabolism can
cause marrow depression will be examined.
Brief history of the use of Nitrous oxide in anaesthesia
Nitrous oxide was probably first discovered by Joseph
Priestley in 1772, after work by Dr Stephen Hale.
Priestley had added Walton pyrites (iron disulphide) to
nitric acid to form a red mixture that absorbed air
forming "nitrous air". Priestley found that the volume of
this air decreased when it was added to a water paste of
iron filings and brimstone. The gas formed preserved
animal substances from putrefaction and was lethal if
given to animals.
Thomas Beddoes and Humphrey Davy established the
Pneumatic Medical Institute in Bristol in 1799 to practise
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Pneumatic medicine. Davy noted that N20 inhalation reduced
the pain of toothache and gave pleasurable, excitable
sensations. He suggested that it had potential as an
anaesthetic although he took this no further. In America,
Gardner Colton gave a demonstration of this new gas as a
circus sensation. A local dentist, Horace Wells, noticed
that a drugstore clerk, Samuel Cooley, while under its
influence banged his leg, but felt no pain. He reasoned
that it might prevent pain occurring during dental
extraction and to test this, he inhaled N20 during the
removal of one of his own teeth. He found that it was an
effective analgesia and experimented on a further 15
patients with partial success. However, Wells attempted
to exhibit its analgesic properties in front of a medical
audience in Boston, but the demonstration was a failure
and Wells was booed out of theatre.
Ether and chloroform were being tested as potential
anaesthetics and were found to be more reliable than N20
and so were used in preference. However, in 1863, Gardner
Colton revived the usage of N20 in dentistry and was
successful in thousands of cases. Since then, it has been
used in many patients. It has been extensively
investigated and found to have only a few disadvantages.
It is a weak anaesthetic, it diffuses into closed spaces
causing either an increase in size or pressure of the
closed space and it causes hypotension in shocked
patients. These effects were felt to be minor and obvious.
However, a new, less predictable effect has been
discovered which may be much more serious.
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Nitrous oxide causes bone marrow depression
The first sign that N20 had a specific effect was
seen in the mid 1950's when Lassen and others (1954)
published 4 case histories describing a treatment for
tetanus which used curare to muscle relax the patient.
This was a new technique and because it was possible that
the patient could be conscious whilst paralysed, various
sedatives were used. Inhalation of 50% N20 in oxygen was
found to be successful. However, Lassen reported the death
of one patient and severe bone marrow depression occurred
in another two although this was initially thought to be
due to a side effect of the tetanus toxin.
Gormsen (1956) described the haematological
depression that occurred during the treatment of a patient
who had died 22 days after admission for tetanus. He had
been curarised and ventilated with N20. The other drugs
he received included penicillin, terramycin, achromycin,
chlorpromazine and cortisone. Granulocytopenia, leuco-
cytopenia and thrombocytopenia all developed and he needed
multiple blood transfusions to prevent anaemia. It was
thought that curare was responsible.
Lassen and others (1956) examined another 13 cases of
bone marrow depression occurring during this treatment.
Six patients had developed abnormal megaloblastic marrows
and their neutrophil and platelet counts were low. These
findings are similar to those of untreated pernicious
anaemia. The other 7 remained normal. Because the severity
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of the disease was similar in both groups, it was
considered unlikely that the depression was due to tetanus
itself. The only drug common to all 6 patients was N20.
Curare was used in only 3 of them.
It therefore appeared that N20 was responsible. To
conclusively prove this, 2 patients were given it in a
trial. In both cases their haematological profile became
megaloblastic after inhaling N20 for two or three days
and this became normal a few days after removing the gas.
It appeared that N20 could in some unknown manner cause
bone marrow depression if given for a long time.
Other work showed a similar effect (Wilson and
others, 1956, Sando and Lawrence, 1958). Stead and others
(1962) described a 10 year old boy who had received 50%
N20 intermittently over 2 3 days with a total exposure of
90 hours. Leukopenia developed after 21 days. On day 25,
N20 was stopped and his marrow was normal by day 33.
Interestingly, animal experiments failed to show
similar results (Lassen and Kristensen 1959). N20 was
found to be cytotoxic to embryonic cells. Because of this,
Lassen and Kristensen (1959) gave it to 2 patients
suffering from chronic myeloid leukaemia in an attempt to
kill the cancer cells. They found that prolonged
inhalation did decrease cell numbers, but that they
rapidly returned to normal when N20 was stopped. In
addition, both had changes in their mental state
experiencing elation, depression, lassitude and eventually
coma. These mental changes were the first description of
the effects that N20 can have on the nervous system.
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How N20 could cause this haematological depression
was unknown although it was initially considered that
impurities were responsible. Higher oxides of nitrogen
including nitric oxide and nitrogen dioxide were present
in the gas and workers exposed to these contaminants were
known to have developed leukopenia. It was thought that
the depression represented mild chronic poisoning
(Parbrook 1976). In addition, the leukopenia might have
been caused by either increased cell destruction or
altered distribution of the peripheral cells. Johnston and
others (1971) showed that erthropoietic depression
occurred within 2 days when rats were exposed to 80% N20.
RQ
They measured the distribution of radioactive Fe and
14C-thymidine (indices of erythropoeisis and nucleic acid
synthesis respectively) in the blood cells, liver, spleen
and marrow. Depression occurred initially in the spleen
and bone marrow and only afterwards in the peripheral
blood suggesting that N20 mainly affects the stem cells
and causes a decrease in cell synthesis. A decreased
response to exogenous erythropoietin in these rats further
supported this view.
Kreike and others (1977) exposed rats to either 0, 20
or 40% N20 for 35 days. With the highest dose, bone
marrows were depressed within 3 days whilst it took 14-21
days with 20% N20. Recovery occurred about 3 days after
N20 was withdrawn. In intermittently exposed rats a
tolerance developed to 40% N20 after 10 days. Therefore it
appeared that this bone marrow depression was time and
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concentration related and that rats have a mechanism of
bypassing it that takes a few days to develop.
Nitrous oxide has been given safely over long periods
During 1974-1976, Amess and his colleagues noticed
that 27 patients had developed acute megaloblastic bone
marrow changes 2-14 days after admission to an Intensive
Care Ward. Seventeen had been ventilated with 50% N20 for
1-8 days and the deoxyuridine suppression tests (dU test)
of some of these patients suggested a diagnosis of
untreated vitamin B12 deficiency. However, all had normal
plasma vitamin B12 concentrations (Amess and others 1976).
There were many possible reasons for this marrow
depression (Editorial 1982) although, it seemed probable
that N20 was, at least, partially responsible. However,
N20 had been inhaled previously over long periods with no
problems. Petrovsky and Yefuni (1965) had given 30-70%
N20 for post-operative pain relief to 102 patients for up
to 96 hours. Their peripheral blood remained normal
although bone marrow was not examined. Thompson (1976)
gave 35% N20 to 42 patients for up to 48 hours to relieve
the pain of myocardial infarction. No bone marrow
depression occurred. A patient was treated for pentazocine
addiction by inhalation of N20. He received it
continuously for 30 days, and then for 18 hours daily for
the next 15 days and finally for 6 hours daily for a
further 202 days. No abnormalities were seen in the first
92 days although he was given a multivitamin preparation.
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After discharge, he developed folic acid deficiency which
responded to oral replacement. Interestingly, 2 months
later he developed a neurological deficit which was
diagnosed as a vitamin deficiency and which responded to
vitamin B complex therapy (Kripke and Hechtman 1972). The
finding that some individuals can inhale N20 for a long
time without developing signs of marrow depression
complicates the issue of N20 toxicity.
Nitrous oxide and the deoxyuridine suppression test
To further investigate the marrow depressant effects
of N20, Amess and his colleagues (1978) designed a trial
involving the postoperative ventilation of 22 cardiac
surgical patients for 24 hours. Each subject was allocated
to one of three groups.
1) 8 received 50% N20 in oxygen for the whole
period.
2) 9 received 50% N20 in oxygen for the operation
(5-12 hours) followed by an air/oxygen mixture
for 18 hours.
3) 5 received no N20, but an air/oxygen mixture
for 24 hours with additional phenoperidine during
the operation to compensate for the lack of N20.
Bone marrow was aspirated before induction, 24 hours
later and in some cases after 6 days. Marrow was assessed
in 2 ways, subjectively by using microscopic examination
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and objectively by the dU test. A peripheral blood film
was examined daily.
The dU test assesses the ability of marrow cells to
manufacture fresh DNA and is used in the diagnosis of
abnormal vitamin B12 and/or folate metabolism (Metz and
others 1968, Das and others 1970, Van der Weyden 1973,
Wickramasinghe and others 1986). Deoxythymidine is one of
the 4 essential bases in DNA and marrow cells can make it
by one of two pathways;
a) Using thymidine synthase (TS) and a
tetrahydrofolate (THF) co-enzyme. This is the
main method of deoxythymidine synthesis.
Deoxyuridine + 5,10 MethyleneTHF > Deoxythymidine + Dihydrofolate
b) The salvage pathway in which thymidine kinase
converts thymidine to deoxythymidine.
Thymidine + ATP > Deoxythymidine + AMP + Pi
The marrow uses the TS pathway preferentially, but is
able to use the salvage pathway when there is a shortage
of 5,10 methylene THF (as in vitamin B12/folate
deficiency).
Incubating deoxyuridine with marrow cells results in
deoxythymidine production by TS and if radioactive 3H-
thymidine is then added, little will be converted to
deoxythymidine by the salvage pathway and so only small
amounts of the new DNA will be radioactive. If there is
insufficient 5,10 methyleneTHF present to make enough DNA
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for the cell, it produces the rest from the salvage
pathway. 3H-thymidine will be incorporated into new DNA
and its radioactivity will be increased. The greater the
deficiency of 5,10 methyleneTHF, the greater the
incorporation of radioactivity into the cells. The
percentage,
H3-thymidine in DNA with deoxyuridine added x 100%
H3-thymidine in DNA with NO deoxyuridine added
is the dU test figure and for normal marrow it is less
than 10% although each laboratory has its own limits.
Figures greater than 10% indicate a shortage of 5,10
methyleneTHF due to abnormalities in either folate or
vitamin B12 metabolism. Differentiation between the two
can be made by adding a small amount of methylcobalamin or
folic acid to the cells. With vitamin B12 deficiency,
methylcobalamin partially corrects the dU test whilst
folic acid has no effect and conversely for folate
deficiency. A correction of greater than 15% indicates a
vitamin deficiency.
In the study of Amess and others (1978), patients in
group 3 had normal marrows throughout. However those in
group 1 all had megaloblastic marrows after 24 hours which
were identical to those seen to untreated pernicious
anaemia. The dU tests were abnormal and were corrected by
methylcobalamin. After 6 days all the dU tests performed
were normal indicating that the depression was reversible.
In group 2, 3 patients had mildly megaloblastic marrows
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after 24 hours and 3 had abnormal dU tests, again all
characteristic of vitamin B12 deficiency. However because
all patients had normal vitamin B12 concentrations, it
suggested that the problem is in vitamin B12 metabolism.
Somehow exposure to N20 had caused vitamin B12 to function
abnormally.
Nitrous oxide oxidises cobalt
The work of Banks, Henderson and Pratt (1967)
suggested an explanation for this abnormality. They were
chemists investigating the effects of N20 on transition
metals and had found that in vitro, N20 could oxidise
cobalt from its monovalent to its bi and trivalent states.
2N20 + 2Co (I) + 2H20 > 2Co(III) + 2N2 + 40H~
Co(I) + Co(III) > 2Co(II)
Their work had been published in a chemical journal
not commonly read by anaesthetists and its significance
was not understood until the work of Amess and his
colleagues was published.
Cobalt is the essential co-factor of vitamin B-, 2.
Vitamin B12 is a complex molecule (Davis 1985) composed of
a central corrin ring with cobalt at its centre. At right
angles to this ring is a nucleotide 5,6 dimethyl-
benzimidazole. One nitrogen atom from this molecule is
attached to the corrin ring with the other being bonded to
the cobalt. In vitro, various compounds can bond at the
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6th position of the cobalt atom (cyanide, hydroxyl,
deoxyadenosyl or methyl groups). In humans, this vitamin
is involved in only 2 reactions.
1. Transfer of a methyl group from 5-methylTHF to
homocysteine to produce methionine, catalysed by
methionine synthase (MS). The vitamin is in its methyl-











Homocysteine + 5 methylTHF > Methionine + THF
2. Conversion of methylmalonyl CoA to succinyl CoA by
an isomerase reaction. Methyl-malonyl CoA mutase (MMCoA









Methyl-malonyl CoA > Succinyl CoA
Therefore, if the marrow depressant effect of N20 is
due to an abnormality of vitamin B12 metabolism, then it
could be secondary to inhibition of either, or both
enzymes.
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Nitrous oxide inhibits methionine synthase
Deacon and others (1978) exposed Sprague-Dawley rats
to 50% N20 for up to 24 hours and assayed the MS activity
directly by incubating rat livers with homocysteine and
5[14C]methylTHF acid. Measurement of the radioactive (14C)
methionine formed gives an indication of activity. MMCoA
mutase was assayed indirectly by measuring the formation
of methylmalonic acid in the urine because if this enzyme
is inhibited, the concentration of this compound
increases. Thirty minutes N20 exposure substantially
reduced MS activity and after 6 hours it was totally
inactive. In contrast, methylmalonic acid excretion was
not increased after 24 hours exposure even if its
catabolic pathway was stressed by an intraperitoneal
injection of proprionic acid, a precursor of methylmalonic
acid. Hence it appeared that N20 inhibited MS and not
MMCoA mutase.
Other work has shown similar results. Kondo and
others (1981) exposed Sprague-Dawley rats to 80% N20 for
up to 792 hours. MS activity was assayed as above and
MMCoA mutase activity was found by measuring the amount of
[14C]succinyl CoA formed from 2[14CH3]methylmalonyl CoA.
Fifteen minutes and 1 hour N20 exposure caused MS activity
to decrease by 55% and 70% respectively. No further
decreases occurred after this. No change in MMCoA mutase
activity was seen in the first 48 hours although it did
decrease after 384 and 792 hours (to 48 and 32% of
controls respectively). With these long exposure times,
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there was also a decrease in tissue cobalamin
concentrations suggesting a deficiency of vitamin B12
which results in inadequate manufacture of MMCoA mutase.
Methylmalonic acid excretion was measured in 5 humans
ventilated with 50% N20 for 24 hours (Rask and others
1983) . Urine was collected before, during and after
ventilation. Methylmalonic acid excretion increased by
300% during N20 exposure. However, no suitable control
group was used and the increase could have been due to an
anaesthetic or surgical cause. In addition, a relatively
non-specific calorimetric assay was used to measure
methylmalonic acid. It is probable that MMCoA mutase
inhibition is too slow to explain the clinical effects of
n2o.
Is MS inhibited by a specific effect of N20 or due to
a general anaesthetic effect?. Deacon and others (1980)
exposed rats to 100% oxygen and 0.35% halothane for 6
hours and showed only a slight decrease in MS activity.
Koblin et al (1981) showed that there was no decrease in
MS activity when mice were exposed for 4 hours to
halothane (0.69%), enflurane (1.02%) or isoflurane (0.6%).
It appears that anaesthesia itself is unable to inhibit MS
and N20 alone has this specific effect.
Species difference in MS Inhibition
Is MS of other species inhibited by N20? Koblin and
others (1981) showed that the activity of liver MS in CD-I
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mice who had been exposed to 80% N2O for 4 hours decreased
by 95%. Ethically it is more difficult to assess humans.
Kano and others (1981) studied 22 patients (7
anaesthetised without N2O and 15 with) by aspirating bone
marrow before and after anaesthesia and found that MS
activity in the N20 exposed group became abnormally low
after 4 hours with an inactivation th of 1.5 to 6 hours.
Koblin and others (1982) were able to take timed liver
samples from 14 patients undergoing laparotomy. Seven were
given 50-70% N20 and the rest acted as controls. Liver
biopsies taken at different times demonstrated a dose
dependent (time of N20 x concentration) decrease in MS
activity.
Landon and Toothill (1986) measured MS activity in
human placental tissues from 11 patients undergoing
Caesarean delivery (N20 exposure varying from 13-22
minutes) and from 20 patients undergoing vaginal delivery
(no N20 given) and found no difference. Perhaps human MS
is resistant to N20 and therefore longer exposures are
needed before inhibition occurs.
In an attempt to quantify the rate of human liver MS
inactivation, Royston and others (1988) anaesthetised 22
patients with 70% N20. Liver biopsies were taken at
variable times during the operation and the MS activity
they possessed was assayed. Batches of 6 Sprague-Dawley
rats exposed to 50% N20 in oxygen for 5, 10, 20, 40 and
80 minutes also had liver MS activity assayed. Human MS
activity varied greatly, but it tended to decline with an
increasing duration of exposure. A mean inactivation t\ of
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4 6 minutes was found compared to 5.4 minutes for rats.
Hence, it appears that N20 does inactivate MS from
different species although at different rates and humans
appear to be less susceptible to its effects. However, as
will be discussed, human individual MS activity does vary
greatly and it is possible that the inactivation t\ may be
wrong.
Inhibition of MS from different tissues
MS is found in many tissues except blood and it is
always inhibited by N20. MS activity in the brain of
Sprague-Dawley rats exposed to 50% N20 for 1 to 15 days
was almost undetectable (Deacon and others 1980) and a
similar decline was seen in the brains of CD-I mice
(Koblin and others 1981) and the kidneys of rats (Kondo
and others 1981). Kano and others (1981) showed that bone
marrow MS was inhibited by N20. MS activity in rat testis
was inhibited by exposure to 10% N20 for 1 hour (Brodsky
and others 1984). Thus it appears that MS from all tissues
is similarly affected.
MS activity
Individual MS activity appears to vary greatly both
in animals and humans. Activity is defined as the amount
of methionine formed per unit time per mass of protein.
Sprague-Dawley rats, exposed only to air had large
variations in their liver MS activity. Different values
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include 2.0 (S.E.M + 0.6) nmol methionine.hr 1.mg
protein-1 (Deacon and others 1980), 1.4 - 3.4 nmol
• — 1 • — 1
methionine.hr .mg protein (Deacon and others 1978) and
— 1 _ I
1.5 -3.2 nmol methionme.hr .mg protein (Nunn and
others 1982) . A similar wide range was seen in mice,
— 1 . — 1
ranging from 300 to 600 nmol methionme.hr .g liver .
Humans variability is equally great. Koblin and others
(1982) showed it to range from 285 to 523 nmol
methionine.hr-1.g liver-1. Royston and others (1988) found
human MS activity to range from 0.85 to 1.95 (mean 1.16,
SEM 0.2) nmol methionine.hr-1.mg protein-1. In addition,
they found great individual variation in the rate of MS
inactivation by N20. Landon and Toothill (1984) showed
the activity in 20 placentae to range from 0.8 to 2.6
— 1 — 1
(mean 1.7) nmol methionme.hr .mg protein .
Hence the rate that MS is inhibited by N20 is not
constant. The wide range of MS activity that occurs in
normal patients indicates that large numbers of patients
need to be studied for statistically relevant results.
Inhibition of MS by trace concentrations of N20
Is MS inactivated by low concentrations of N20? Kondo
and others (1981) showed that Sprague-Dawley rats exposed
to 2% N20 for 15 hours had a 30% decrease in liver MS
activity. Koblin and others (1981) studied the chronic
effects on CD-I mice of different concentrations of N20.
Exposure to less than 5% N20 for 4 hours had no effect
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whilst 10% N20 caused a 50% reduction in its activity.
Additionally rats exposed to 700 - 1,600 ppm N20 (average
1,100 ppm) for up to 22 days had their MS activity reduced
by 73% after 8 days although it became normal with longer
exposures.
Sharer and others (1983) measured the dose-effect
relationship between chronic exposure of Sprague-Dawley
rats to N20 and liver MS activity. The rats were exposed
in groups of 4 to 15 animals to 500, 1000, 2500, 5000,
10,000, 20,000 and 50,000 ppm N20 for 1 to 28 days. The
lowest N20 concentration that caused any MS inactivation
after 24 hours was 1000 ppm and for longer times it was
500 ppm. Extrapolation of these results indicate that the
minimum N20 concentration which causes any MS inhibition
over 24 hours is 840 ppm and for longer, 450 ppm. The ED50
for N20 induced MS inactivation for 24 hours was 10,400
ppm and for 2-28 days was 5,400 ppm.
Inhibition of MS by intermittent exposure to N^O
The effect that intermittent N20 exposure has on
animals has been assessed in Sprague-Dawley rats. Nunn
and others (1982) gave 2 groups 50% N20 in 50% oxygen for
three 15 minute periods each day for 4 and 21 consecutive
days. Liver MS activity in the 4 day group was 39.4% of
controls and in the others was 20.4%. N20 therefore has a
cumulative effect if used intermittently although the
duration of exposure needed for inhibition is still
unknown.
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Recovery of MS inhibition
MS recovery after inhibition is slow. Deacon and
others (1980) showed that rats exposed to 50% N20 for 6
hours had a MS activity of only 50% normal after 60 hours
and after 84 hours, 1 of 2 rats still had abnormal
activity. Kondo and others (1981) confirmed this slow
recovery by exposing rats to the same concentration of N20
for 15 hours. After 6 and 72 hours, MS activity was 29%
and 80% respectively when compared to controls. In
addition, they showed that its recovery paralleled the
reappearance of cobalamin bound to MS. Slow recovery
taking 2-4 days was seen in mice exposed to 0.8 atm N20
for 4 hours. After 24 hours, only 70% recovery occurred
(Koblin and others 1981).
Possible mechanisms of MS inhibition
Why recovery of MS activity should take so long is
still unknown. It is possible that MS inactivation is
irreversible and new enzyme must be synthesised. Addition
of exogenous vitamin B12 has little effect on MS activity
indicating that the B12 ligand is tightly bound to MS
(Coward and others 1975) . The irreversibility of this
inactivation may be due to how it occurs. Frasca and
others (1986) examined purified E. coli and partially
purified pig liver MS. N20 inactivation in vitro only
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occurred when the enzyme was in its active form. Pre¬
incubation of MS with N20 when its cobalt was in a Co(II)
inactive form did not result in inhibition because it
could easily be converted to Co(I) by a reducing system
and then was fully active. However, when cobalt was in its
Co (I) form, N20 caused irreversible inactivation. They
postulated that inactivation was not caused by oxidation
of Co(I) to Co(II) and Co(III) because this could not
explain the irreversible nature of the process. A
reduction system should have been able to convert Co(II)
back to Co(I). Possibly, Co(III) could react with an
amino group of an amino-acid to form a stable complex
although this interaction would give a Co(III) absorption
spectra when a Co(II) was seen. Frasca postulated that
during N20 inactivation, a free hydroxyl radical (OH*) was
produced;
Co(I) + N20 + H+ > Co(II) + N2 + OH"
Free radicals are atoms or molecules, existing
independently and contain one or more unpaired electrons
which mahes them highly reactive. A hydroxyl radical has 9
protons and electrons with one unpaired electron in its
outer shell. In cells, proteins, nucleic acids, membrane
lipids and supporting matrices are attacked. Proteins
containing high concentrations of sulphur containing
amino-acids are especially vulnerable to deprotonisation
by OH* (Royston 1988). Nearly 4% of the amino acids in MS
contain sulphur and many of these are near the active site
of the enzyme and when OH* is formed, it can react with
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them to produce irreversible inactivation of the enzyme
(Fig. 1).
There is further evidence that OH* is produced by the
interaction of N20 and cobalt. Koblin and others (1990)
examined MS activity in the livers, kidneys and brains of
mice exposed to N20 and studied the effects that
dimethylthiourea (DMTU) had. This is a potent hydroxy1
radical scavenger which readily penetrates cell membranes.
The mice were given either intraperitoneal injections of
DMTU or saline and then exposed to N20 for 30 minutes, 2,
4 and 8 hours. Enzyme inactivation was significantly less
in the DMTU group and this this was more noticable with
longer N20 exposure times. A second experiment showed
that there was a DMTU dose dependent effect on
inactivation. DMTU gave protection for up to 4 hours after
injection and after N20 exposure, injected DMTU slowed
the rate of recovery (Koblin and Tomerson 1990).
This series of experiments supports the concept of MS
inactivation after OH" formation. DMTU may protect MS by
reacting with any OH* formed by N20 and thereby prevent it
from reacting with amino-acids. It does not inactivate all
OH* because inactivation will eventually occur and once
this happens, DMTU has no benefial effect. This proposed
mechanism of MS inactivation can explain the species
difference in MS inactivation t\. An intrinsic cytoplasmic
hydroxyl scavenging system may exist offering varying
degrees of protection between different species.
It is possible that the marrow depression caused by
N20 may be due to the metabolism of N20 in the body to
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toxic compounds although only a small amount is actually
metabolised. Sawyer and others (1972) found that the liver
removed only 0.03 + 0.05% of N20 passing through it. In
vitro exposure of human faeces to N20 (with 5% oxygen) for
16 hours resulted in 47 nmol of N2 (SD 13) being produced
per gram wet sample. Calculations show that if a 70 kg man
breathed 75% N20 for 3 hours, only 1.0-1.3 ml N2 would be
produced from N20. The presence of oxygen inhibits any
metabolism of N20 (Hong and others 1980) and it is
possible that free radicals are formed during this
metabolism (Bosterling and others 1980). Hence some of the
clinical effects of N20 may be due to this metabolism, but
they are more likely to be caused by MS inhibition.
Summary of MS inhibition
The initial use of N20 in anaesthesia and how it was
discovered that it caused marrow depression has been
described. This effect is a result of N20 inhibiting MS in
a time and concentration dependent manner. It occurs in
all tissues and in all species tested, is irreversible,
cumulative and may only require trace concentrations of
N20. Recovery of activity is slow. Inhibition of the
enzyme may be by hydroxyl radical formation.
How does inhibition of this enzyme cause bone marrow
depression and its other possible effects? To understand
this, folate metabolism needs to be discussed because it















Figure 1. Inactivation of methionine synthase by N20 due
to formation of a hydroxyl radical.
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CHAPTER TWO




It was first realised that folic acid was an
essential vitamin in 1930 when an autolysed yeast
preparation "marmite" cured pregnant Indian women who
suffered from a macrocytic anaemia (Wills 1931).
Subsequent work identified the active factor as
pteroylglutamic acid and this was first synthesised in
1945 (Angiers 1945). Folic acid deficiency is common and
its clinical symptoms are similar to those of vitamin B12
deficiency. There is a generalised disorder of cellular
metabolism and a macrocytic megaloblastic anaemia occurs.
These two vitamins and methionine, an essential amino-
acid are biochemically closely interrelated as will be
discussed in this chapter.
Structure and activity
Folic acid can be metabolised different co-enzymes,
all which function by accepting or donating one-carbon
fragments to various compounds (Shane and Stokstad 1985).
Structurally, there are 3 distinct parts (Fig.2).
1) Pteridine moiety which binds the one carbon
fragments
2) para amino benzoic acid - joined to 1) by a
methylene bridge
3) Glutamate residues - can have any number from
1 to 10. They are linked by an alpha amino
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group to the gamma carboxyl group. The
monoglutamate is the transport form with the
polyglutamate being the active form.
Figure 2. Structure of tetrahydrofolic acid.
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The one-carbon fragments that bind to folic acid are
at different oxidative levels;
Formate -CHO bound at the N5 or N10 atom
2. Methenyl =CH- bound to the N5 and N10 atoms
3. Methylene -CH2- bound at the N5 and N10
atoms
4. Methyl -CH3 bound at the N5 atom
Folate can accept other one carbon fragments (e.g.
formimino group -CH=NH) and it is probable that the
enzymes that are involved in its metabolism are not
individual proteins, but exist as a multiple functioning
complex.
Folic acid is absorbed into the body in its
monoglutamate form and passes into the blood after
methylation (Perry and Chanarin 1970). It is activated by
being reduced at the 5,6,7 and 8 positions on its
pteridine ring to tetrahydrofolic acid (THF) by
dihydrofolic acid reductase (Burchall and Hitching 1965).
Normally, there is only a low concentration of folic acid
present because it is rapidly hydrogenated. Folate
antagonist drugs in common use have a similar structure to
the pyrimidine moiety of folic acid and are tightly bound




THF has different numbers of glutamate residues and
these affect its properties. The monoglutamate acts as
the transport form and the polyglutamate is found
intracellularly and is metabolically active (Shane and
Stokstad 1976). The monoglutamate is transported to the
cell bound mainly to albumin (Soliman and Oleson 1976) and
easily passes through cell membranes into cells where it
is conjugated with extra glutamatic residues into the
active polyglutamic form by folylpolyglutamate synthetase
(FPS).
THF (GjThplutaari.Ed--TfiF (Grpti). . r- — rTHF (G^Lu)
Polyglutamic folate cannot cross cell membranes and
accumulates - a cellular folate concentration mechanism
(Foo and Shane 1982). Conjugation is essential for cell
survival. Mutant Chinese Hamster ovarian cells containing
no conjugating enzyme required methionine, purines and
thymidine to grow. Folate intracellular concentration
decreased by 90% and no polyglutamate was produced. Wild
cells having the enzyme functioned normally and had no
special growth requirements. Hence this enzyme is vital
not only for cellular retention, but also for activation
and utilisation of folate (Taylor and others 1977). The
actual number of residues on the polyglutamate varies
between species, but appears to be from 5 to 10.
Foo and others (1982) showed that FPS has an
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increased affinity with a decreased substrate potential
for the higher conjugated folates; a type of end product
inhibition. Folate cellular concentration will only
increase up to a certain amount.
Taylor and others (1977) showed that in vitro FPS was
unaffected by vitamin B12 deficiency although rats exposed
to 50% N20 for 24 hours made no polyglutamated THF.
Addition of parenteral folic acid or 5 methylTHF did
increase its production slightly whereas 5 or 10 N
formylTHF or 5,10 methyleneTHF allowed its normal
synthesis (Perry and others 1979). Chanarin and others
(1980) suggested that formylTHF was the most active
substrate for FPS and that active vitamin B12 was needed
to formylate THF.
Other work has demonstrated that 5 methylTHF is a
poor precursor for polyglutamate formation (Mcguire and
others 1980, Cichowicz 1987). Perry and others (1980)
showed that only 21% THF was converted into a
polyglutamate form in rats. In contrast, McGuire and
others (1980) using partially purified rat liver FPS
showed much greater incorporation. Cichowicz (1985) using
purified hog liver enzyme demonstrated that THF and 10
formylTHF were equally effective as substrates. As yet,
the most effective substrate for FPS is still unknown.
Folate reactions
When converted into its active polyglutamate form,
folate can undergo a variety of reactions (Fig.3).
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a) FormylTHF
THF binds with formate at either its 5 or 10 N
position and this reaction is catalysed by formylTHF
synthetase (FTS). Formate is produced from many compounds
(e.g. catabolism of methionine, sarcosine, glycine,
serine, tryptophan, etc) and then can be oxidised to
carbon dioxide or used by THF as a source of single carbon
fragments (Friedman 1954). In rats, formate is oxidised to
C02 by THF dependent pathways (Eells and others 1982). N20
inactivation of rat methionine synthase (MS) increased FTS
activity suggesting how important this compound is to the
body (Perry and others 1980).
FormylTHF may be oxidised to C02 by formylTHF
dehydrogenase and the substrate Km in pigs liver is 8.2
(Kutzbach and Stokstadt 1971). The concentration of
celluler formylTHF is normally within this range and so a
small increase in its concentration will result in a large
increase in oxidation, a positive feedback system.
10 formylTHF is involved in the production of purines
through 2 reactions (Smith and others 1982);
a) Carbon 2 - requires 5 amino 4 imidazole
carboxamine transformylase (AICAR).
b) Carbon 8 - requires glycinamide ribonucleo¬
tide transformylase (GAR).
When rats were exposed to N20 for 5 days, the
activities of both enzymes were changed with that of liver
GAR decreasing whilst for AICAR, it increased (Deacon and
others 1983a). Their activity in rat marrow was less
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Figure 3. Tetrahydrofolate reactions. THF, tetra-
hydrofolate acid; DHF, dihydrofolic acid; DNA,
deoxyribonucleic acid; SAM, S-adenosyl methionine, SAH, S-
adenosyl homocysteine; MS, methionine synthase.
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b) MethenylTHF
FormylTHF can be reduced to 5,10 N methenylTHF by the
enzyme 5,10 N methenylTHF cyclohydrolase. Its activity in
rats exposed to 50% N20 was reduced (Perry and others
1980). Therefore, after N20 inactivates vitamin B12, the
enzymatic response is to conserve formylTHF
concentrations by increasing its synthesis and decreasing
its catabolism.
c) MethyleneTHF
MethenylTHF is reduced by 5,10 N methenylTHF
dehydrogenase to 5,10 N methyleneTHF. The activity of this
enzyme is unchanged in rats exposed to N20 (Perry and
others 1980). 5,10 N methyleneTHF is involved in
deoxythymidine monophosphate (dTMP) production because
it supplies a methyl group to deoxyuridine monophosphate
(dUMP). Thymidine synthetase (TS) catalyses this reaction
and dihydrofolic acid which is produced is reduced back to
THF by dihydrofolate reductase (O'Brien 1962). Sakamoto
and others (1975) found that purified TS from marrow
cells of patients with untreated pernicious anemia had a
ninefold increase in activity. Deacon and others (1981a)
showed a 200% increase in TS activity in N20 exposed rats
which returned to normal after the gas was removed.
However, even though TS activity is increased, the dU test
indicates that a decrease in deoxyuridine methylation
occurs suggesting a shortage of 5,10 N methyleneTHF (Amess
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and others 1978, Skacel and others 1982, Kano and others
1981, O'Sullivan and others 1981). It appears that N20
inhibits folate metabolism by altering the concentrations
of the different folate co-enzymes.
Humans have a greater dependence on vitamin
B12/folate pathway for TS synthesis of deoxythymidine than
the rat which can use the salvage pathway to produce dTMP.
Does this explain why this animal does not become
megaloblastic when exposed to N20?
d) MethylTHF
5,10 N methyleneTHF can be further reduced to 5
methylTHF by 5,10 N methyleneTHF reductase. This reaction
is thermodynamically a one way process becasue oxidation
back into 5,10 methyleneTHF is unlikely in vivo (Kutzbach
and others 1971) . S adenosyl methionine (SAM) , a non¬
competitive inhibitor of this enzyme, has a Ki=2.8 /iM for
pig liver (Kutzbach and Stokstad 1971). Normally SAM
concentrations are less than this, but when they increase,
there will be a profound inhibitory effect.
To complete the folate metabolic circle, THF is
regenerated from 5 methylTHF by methylation of
homocysteine into methionine. MS catalyses the transfer of
the methyl group (Taylor and Weissbach 1973). SAM and a
reducing system are initially needed in vitro to convert
the inactive, but stable Co(II), into the active, but
relatively unstable Co(I). Because this is the only
reaction that 5 methylTHF undergoes, it is the only way
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to regenerate THF. Patients with inherited defective MS
have liver concentrations only 30% of normal and all have
raised 5 methylTHF concentrations and clinical signs of
megaloblastic anemia.
e) Other reactions
THF is involved in the metabolism of amino-acids.
Serine is a major source of carbon units, its 3C being
reversibly transferred to THF to produce 5, 10 N
methyleneTHF and glycine.
Serine + THF > Glycine + 5,10 N methyleneTHF
There was no change in its activity in rats exposed
to 50% N20 for 15 days (Deacon and others 1980). THF is
involved in histidine catabolism by accepting a formimino
group from formiminoglutamic acid which is formed from
histidine. This produces 5 formimino-THF and glutamic acid
and is catalysed by 5 Formimino-THF transferase. The
activity of this enzyme was unaffected in rats exposed to
N20 (Perry and others 1980).
Summary
THF can accept and transfer single carbon units to a
variety of compounds. N20 has effects on the different
enzymes in its metabolic pathway (Table I) ; it fully
inhibits MS and partially inhibits GAR and 5,10 N
methenylTHF cyclohydrolase. It increases the activity of
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Formiminoglutamic acid transferase 0
+ = increase
- = decrease
0 = no effect
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Folate co-enzyme levels
Secondary to its effects on folate enzymatic
activities, N20 can change the concentrations of the
different folate co-enzymes. Lumb and others (1980) showed
a decrease in totla liver folate concentration in N20
exposed rats. Further work showed a loss of folate from
other tissues including kidney, bone marrow and brain.
Polyglutamates were affected more than monoglutamates and
both the methyl and non-methylfolates were affected.
Presumably, reductions in the rate of polyglutamation
prevented the cells from retaining folate. They also
discovered that there was a transient increase in tissue
methylTHF concentrations and that total plasma folate was
increased (Perry and others 1981). Additionally, N20
exposed rats excreted large amounts of labelled 5
methylTHF without its methyl group being removed (Lumb et
al 1982).
Rats exposed to 75% N20 for 18 hours had the folate
co-enzyme concentrations in the marrow, kidney, brain and
liver measured (Wilson and Home 1986) . MS activity
decreased by 90% in the marrow, kidney and brain and 83%
in the liver. The proportion of methylTHF to non-
methylTHF increased from 1.4 to 1.9 and there was a
decrease in the concentrations of the non-methylTHF forms.
No effect was seen on the distribution of the
mitochondrial folate co-enzymes (Home and others 1989) .
Similar changes in folate co-enzymes concentrations were
seen in embryo rats whose mothers had been exposed to N20.
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There was an increase in the methylated and a decrease in
the non-methylated forms (Hanson and Billings 1985) .
Hence, it appears that N20 inactivation of vitamin
B12 causes considerable changes in both the concentrations
and type of folate co-enzyme present. Total tissue folate
concentrations decline, mainly due to increased urine
excretion and this is probably due to cells being unable
to concentrate the monoglutamate form. Of the different
co-enzymes, only the concentration of 5 methylTHF
increases.
METHIONINE
Vitamin B12 and folate are intimately involved in
methionine metabolism. Methionine, a sulphur containing
amino-acid, is vital for protein synthesis and provides a
variety of compounds, including one carbon fragments.
Methionine turnover is about 60 mmol.day-1 of which
about 10 mmol is ingested in the diet, 45 mmol is due to
catabolism and protein synthesis and the rest used for
transmethylation reactions (Nunn and others 1985) .
Nitrous oxide effects on methionine concentrations
N20 reduces methionine concentrations. Rats exposed
to 50% N20 for 24 hours had their plasma methionine
concentration reduced by 36% (Lumb and others 1983)
although in another study it by 82% (Vina and others
41
1986) . Tissues are affected more, with liver and brain
concentrations decreasing by 55% and 54% respectively
after 24 hours (Vina and others 1986) and by 12% after 12
hours and 16% after 24 hours (Lumb and others 1983). With
shorter exposure times of 80 minutes, the plasma
concentration decrease was insignificant and in liver was
only 38% (Royston and others 1989). Humans showed no
decrease in plasma methionine concentrations during a N20
anaesthetic lasting up to 217 minutes although with an 8
hour exposure it decreased by 30% (Skacel and others
1983). Pre-operative starvation decreased methionine
concentrations (Nunn and others 1985).
Methionine metabolism
As well as protein synthesis, methionine has other
important biochemical functions. The first step in its
metabolism is the formation of a high energy compound,
SAM. This then can either be a methyl donor or participate
in the formation of polyamines.
Methionine + ATP > SAM + PP + P
The enzyme responsible is methionine adenosyl-
transferase and 3 isoenzymes have been found in the rat,
and are mainly in its liver.
I - (15%) Km met.=41 /iM
II
_ (5%) S0.5(met)=8 /i.M, inhibited by SAM,
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found extrahepatically
III - (80%) SO. 5 (met) =215 juM, activated by
SAM
The metabolic concentrations of SAM and methionine
are 50-200 /iM and 50-150 juM respectively, and hence the
reaction will occur at maximum speed outside the liver. A
negative feedback occurs when SAM concentrations increase.
The liver enzyme is less active, but it will increase when
SAM and methionine concentrations increase. Exposure of
rats to N20 for 80 minutes resulted in no changes in SAM
concentrations in plasma, liver or brain (Royston and
others 1989). This is in agreement with human data showing
no decrease in plasma SAM concentrations after anaesthesia
lasting 25 to 217 minutes (Nunn and others 1985).
Hence, in rats, even though thymidine synthesis is
impaired after 60 minutes (Deacon and others 1980), SAM
concentrations are normal. Therefore, it appears that this
compound may not have any affect on how N20 has its
effects in the short term.
SAM is the methyl donor for many methylation
reactions producing S-adenosyl homocysteine (SAH). The
methyl group may be transferred to carbon, nitrogen or
oxygen atoms (eg. synthesis of adrenaline, creatinine,
etc) . Most methyltransferases are inhibited by SAH,
although the physiological importance of this path is







dSAM + Putrescine > Spermine/Spermidine + 5MTA
Spermine/Spermidine synthase
SAM decarboxylase is activated over the physiological
range of putrescine concentrations (0-50 i so
putrescine is efficiently converted to spermine. Because
the lifespan of this enzyme is less than 2 hours, protein
turnover regulates its activity and decreased spermidine
increases protein formation. The supply of the dSAM
probably regulates polyamine formation. The only route for
further metabolism of dSAM is probably via the polyamine
pathway. Whilst the function of polyamines is still
unknown, it appears that they may be involved in the
regulation of macromolecular synthesis (Grillo 1985) and
this may be partially responsible for the decrease in DNA
synthesis - as yet this possibility has still to be
examined.
5MTA is then able to be recycled to form methionine.
This is then isomerised to 5 methylthioribulose and
converted to 1-keto 3-methiolbutyrate which can be




precursor of formate which is formed from methylthioribose
(Trackman and Abeles 1981). Hence SAM is important and
produces a variety of vital compounds. Because its
concentrations remain constant during exposure to N20,
changes in its biochemistry are probably not the cause of
N20 toxicity.
SAH can be hydrolysed to homocysteine by SAH
hydrolase, a reversible reaction with an equilibrium in
the direction of SAH formation. However, when adenosine
and homocysteine are absent, hydrolysis occurs.
Accumulation of these compounds will inhibit the formation
of homocysteine.
Homocysteine is metabolised in several ways.
1) to methionine by MS
2) to methionine by the betaine pathway
3) to cystathionine
4) to SAH
Hence, it is an important regulatory point. Its
conversion to methionine by MS has been discussed. The
betaine pathway is only found in mammalian liver and is
specific for homocystine. The Km for betaine and
homocystine for the rat and human liver are 50 and 16 and
100 and 120 /iM respectively.
Choline > Betaine + Homocysteine > Dimethyl Glycine + Methionine
B-H methyltransferase
The enzyme is inhibited in vitro by dimethyl glycine,
methionine and SAM and is induced by a methionine
deficiency and increases in homocysteine, betaine or
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choline concentrations. Therefore the enzyme acts to
remove excess substrate. This pathway may explain why rats
do not have depressed marrows on chronic exposure to N20
because methionine concentrations are maintained. However,
it will have no effect on the distribution of THF co¬
enzymes .
Alternatively, homocysteine can be catabolised by the
transsulfication pathway.
Homocysteine + Serine > Cystathionine
Cystathionine Synthase (CS)
CS Km for homocysteine and serine is 0.7 mM and 0.1-
0.4 mM respectively and SAM activates it. Approximately
27% of homocysteine in rats is metabolised by both the MS
and betaine pathways and CS removes the rest.
Methionine has a regulatory role over folate
metabolism. Isolated, methionine depleted liver cells have
normal MS activity, but cannot metabolise histidine or
formate (Krebs and others 1976). This is similar to rats
exposed to N20 with inactivated MS (Eells and others
1982). Methionine reversed this. How methionine has its
regulatory effects is unknown although it may be via SAM.
MECHANISMS OF NITROUS OXIDE TOXICITY
It is agreed that N20 causes marrow depression by
decreasing DNA synthesis because of abnormal folate
metabolism. The dU test demonstrates that dTMP production
decreases. Because this compound is usually phosphorylated
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to dTTP and incorporated into DNA, its shortage will
decrease DNA synthesis and reduce cell replication. The
abnormal dU test is caused by a decrease in 5,10 N
methyleneTHF concentration. Some 5,10 N methyleneTHF is
produced from serine, although this pathway is unimportant
in humans. There may also be a decrease in purine
production due to a reduction in 5 formylTHF
concentrations. Because purines are needed for DNA
synthesis, a decrease in their concentration will further
inhibit DNA formation. Purines are also required for RNA
formation and protein synthesis. The effect of N20 on
these compounds have not yet been fully investigated
although pregnant rats exposed to 50% N20 for 24 hours on
day 10 had a decrease in both DNA and RNA fetal content
whilst the amount of cellular purine remained normal
(Hansen and Grafton 1988). Perhaps decreased polyamine
synthesis was responsible.
However, how MS inhibition by N20 causes an abnormal
folate metabolism is uncertain. Whilst many theories have
been proposed, the two most popular are the methyl trap
and the formate starvation hypothesis.
The Methyl Trap Hypothesis
Herbert and Zalusky (1962) and Noronha and Silverman
(1962) proposed the methyl trap hypothesis. They used
experimental evidence showing that the only common link
between folate, methionine and vitamin B12 metabolism is
MS and that in vitamin B12 deficient rats and humans there
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was an increase in the amount of folate existing as 5
methylTHF. They suggested that after MS was inhibited
there would be a "trapping" of folate in its 5 methylTHF
form. Eventually most would become methylated resulting in
a functional deficit of the other co-enzymes leading to
an impairment of its reactions. Consequently there would
be a decrease in thymidine and purine biosynthesis with
decreased DNA formation.
Much evidence supports this hypothesis. Many studies
show that if vitamin B12 deficiency occurs, there is an
increase in the 5 methylTHF portion of the folate pool
(Shane and Stokstad 1985, Perry and others 1976, Wilson
and Home 1986, Home and others 1989). It is unlikely
that 5 methylTHF is metabolised by any other pathways
except through MS as thermodynamically its formation from
5,10 N methyleneTHF is so favourable. However, work has
shown that under certain conditions, 5 methylTHF can be
oxidised back into 5,10 N methyleneTHF. In vitro
lymphocytes from a patient with pernicious anemia were
shown to oxidise 5 methylTHF (Thorndike and Beck 1977),
although, unphysiological conditions were required. Fuller
(1976) reviewed the possibility of direct methylation of
biogenic amines by 5 methylTHF and he suggested that
whilst it can occur unphysiological conditions are
required. Hence, in humans there is no evidence for a
separate vitamin B12 independent pathway that can
metabolise 5 methylTHF.
Methionine prevents the clinical effects of vitamin
B12 deficiency (Noronha and Silverman 1962, Brody and
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others 1982) and this, according to the theory, is because
methionine is the precursor of SAM and increased
methionine concentrations will increase those of SAM. This
compound inhibits 5,10 N methyleneTHF reductase and this
will eventually reduce the amount of folate converted to 5
methylTHF and thereby prevent its trapping.
This explains how methionine preserves THF
concentrations, but not how it restores it when it is
already "trapped". There is evidence that the rat can
escape from the methyl trap. Rats were given a mixture of
14C 5 methylTHF and 5 methyl-3H-THF and with air the
methyl group had a half life of 2 hrs. After exposure to
N20 for 78 hours, 40% remained as methylTHF, 39% was the
polyglutamated and 20% was found on non-folate compounds
(Lumb and others 1984). Methionine has rapid effects on
folate concentrations and the inhibitory effects of SAM
may not be responsible for the rapid changes caused by
methionine.
There is other evidence which is difficult to explain
by the methyl trap hypothesis. Deacon and others (1980)
found that formylTHF could correct abnormal dU
suppression tests in vitamin B12 deficient patients whilst
THF was unable to although if the methyl trap hypothesis
is correct, it should do. THF added to marrow cells from
vitamin B12 and/or folate deficient patients was not
metabolised as expected (Deacon and others 1981). Takeri
and others (1982) examined marrows from similar patients
and found that THF partially corrected the abnormality
although not as effectively as formylTHF. However,
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formylTHF is more stable than THF and in folate deficient
cells, formylTHF was more active than THF in correcting
abnormalities. Perhaps formylTHF may enter the cell more
efficiently than THF.
The Formate Starvation Hypothesis
Chanarin and others (1980) examined rats exposed to
N20 and proposed a new theory to explain how 5 formylTHF
prevented the effects of N20 whilst THF did not. They
realised that methionine increased folate polyglutamate
concentrations in the liver (Smith and others 1974) and it
reversed the impaired synthesis in N20 exposed rats (Perry
and others 1983). SAM is equally effective at a slightly
higher concentration, although it is only partially able
to cross cell membranes (Zappia et al 1978) . Even more
effective is 5 methyl-thioadenosine (Perry and others
1983) and methionine produces formate via 5 methyl-
thioadenosine. Folate concentration decline when
methionine concentrations are low. Normally, up to 87% of
the methionine can be converted to either formate or to
C02 (Case and others 1977).
Formate is used as either a donor of one carbon
fragments or is oxidised to C02. Both these reactions
occur via folate co-enzymes (Friedman and others 1954).
Labelled formate was oxidised to C02 and this occurred
50% slower in N20 exposed rats (Eells and others 1981).
There is an increase in activity of formylTHF synthase and
a decrease in cyclohydrolase after N20 exposure
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suggesting that the body conserves formylTHF (Perry and
others 1980).
The hypothesis states that the prime defect of
cobalamin inactivation is a failure to supply methionine
due to a decrease in its production after MS inhibition.
Methionine produces formate and the main substrate for
cellular retention and activity of the folate co-enzymes
is 5 formylTHF. Therefore a decrease in formate
concentrations will cause a decrease in this folate co¬
enzyme .
Methionine in this theory would be expected to
overcome the decreased formate supply and experimentally
this is true (Skin and others 1975, Scott and others 1980,
Krebs and others 1976). Additionally, it explains the
effectiveness of folinic acid (5 N formylTHF) in
preventing megaloblastosis after N20 exposure (Amos and
others 1984) .
However, it was shown that isolated purified FPS
could use THF as a substrate equally as well as formylTHF
and only folic acid and 5 methylTHF were poor (Moran and
others 1980, Cichowic and others 1987). The methyl trap
hypothesis could explain the above data as 5 methylTHF is
a poor substrate for FPS. Additionally formylTHF may be
more stable than THF and experimental errors may have
occurred. Additionally, it is possible that formylTHF can
enter cells more rapidly than THF to produce higher
concentrations.
Further evidence indicates that there is no decrease
in plasma or brain SAM or methionine concentrations in
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rats exposed to N20 for up to 80 minutes. A decrease in
methionine concentrations was seen in the liver although
SAM concentrations remained stable. Therefore it is
unlikely that decreases in methionine and SAM
concentrations are responsible, at least in the early
stages, for the effects on DNA synthesis.
Conclusion
Folate and the co-enzymes and enzymes that are
involved in its metabolism have been described. The
effects that N20 has on these have been illustrated.
There is a decrease in total tissue folate concentrations
with a relative increase in that of 5 methylTHF compared
to the other co-enzymes. This probably results in an
general reduction in the formation of deoxythymidine and
therefore a decrease in cellular DNA synthesis. Methionine
metabolism is important for cellular activity. The
evidence for and against the methylfolate trap and the
formate starvation hypotheses tends to suggest that the




THE CLINICAL EFFECTS OF THE REACTION OF NITROUS
OXIDE WITH METHIONINE SYNTHASE
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Introduction
Methionine synthase (MS) inhibition by N20 causes a
reduction in DNA synthesis throughout the body. This may
be of no clinical significance, although it has the
potential to cause serious problems especially after
prolonged exposure. In addition, it is uncertain whether
other, more subtle effects also occur and whether they are
exacerbated by the effects of anaesthesia and surgery.
The evidence for these possibilities is presented in
this chapter by examination of the clinical and
biochemical studies performed on N20. Epidemiological
evidence will also be assessed.
Exposure to N^Q
Humans are exposed to N20 in two ways, acutely in
high concentrations usually over a short time when given
for anaesthesia or pain relief and chronically, to trace
concentrations over a longer time. Both types of exposure
may have clinical effects. Because toxicity is dose
dependent, a simple method for comparing different
exposures has been developed;
Concentration of N20 (atm) x duration of exposure (h)
An acute exposure dose is easily found if both the
concentration and duration of N20 given is known. However,
measurement of the amount of exposure to N20 that occurs
chronically is more complex because it is affected by
several factors. Many methods have been developed to
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measure it, although all have two basic criteria. The air
must be sampled and then its N20 concentration measured.
Sampling can be active or passive. Active methods involve
suctioning air into a storage or analytical system while
passive systems allow gas to diffuse into small samplers
packed with a molecular sieve. Passive methods allows N20
concentrations to be assessed over a longer time (Gray and
others 1986). Collection is either continuous or
intermittent ("grab"). Because concentrations vary over
time, grab sampling is inaccurate unless there are
multiple samples collections with the results being
averaged. Continuous sampling can be used to calculate a
time-averaged concentration and this is more accurate a
measurement for longer durations. Sampling may be from a
person's breathing space (personal sampling) or from the
work area (area sampling) with the former measuring
individually inhaled gas concentrations. In contrast, area
sampling assesses overall theatre contamination.
Unfortunately gas concentrations vary throughout theatre.
Using an infrared camera, N20 clouds could be seen in some
parts of the theatre with others having little
contamination (Allander and others 1981). Area sampling is
a poor index of a person's inhalation.
People exposed to N20 include theatre workers
(anaesthetists, surgeons, nurses, etc), dentists (and
dental assistants) and vets. Pollution in these cases
results from inadvertent leaks of anaesthetic gases from
the anaesthetic machine and from exhalation by patients.
Midwives and ambulance workers are exposed through the use
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of Entonox as an analgesic.
Levels of N^O theatre contamination
Davenport and others (1980) measured N20 and
halothane contamination over a 2 hour period in the
operating theatres, anaesthetic areas and recovery rooms
of 20 hospitals. They used active integrated area samplers
which collect theatre air at a constant flow rate by
active suction. N20 contamination varied from <10 to 3000
ppm and averaged 388.5 ppm. Because pollution in operating
areas can fluctuate, air was sampled from in front of the
anaesthetist's nose. No relationship between N20
concentrations from here and ambient air was found.
Gray and Spence (1984) analysed waste anaesthetic gas
pollution on 5 successive days in 2 operating theatres.
One contained a passive and the other an active scavenging
system. Personal pollution was measured using the Casella
evacuated canister system which was positioned on the
individual's lapel. In the passively scavenged theatre
the anaesthetists N20 exposure ranged from 40 to 700 ppm
while it was less in the actively scavenged theatre (30 to
200 ppm). Anaesthetists were exposed to greater amounts of
N20 than nurses or other theatre assistants.
Gray (1989) studied N20 exposure of anaesthetists,
anaesthetic assistants and "circulating" nurses in every
operating theatre in Glasgow. A metal tube sampler packed
with a molecular sieve that absorbs N20 passively by
diffusion was used and the gas concentrations were
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measured by gas chromatography (Gray and others 1986) . The
samplers were attached to the tunic near the subject's
breathing zone and a 1-2 week period of exposure was
measured. Anaesthetists exposure was greater than 100 ppm
for more than 50% of the time.
These concentrations can be compared with suggested
maximum values from the National Institute of Occupational
Safety and Health (NIOSH); 25 ppm N20 and 0.5 ppm
halothane. In Sweden, the recommended 8 hour time averaged
exposure is 100 ppm (Sik and others 1990) . In contrast,
the Department of Health and Social Security (DHSS)
recommendation is that the limit should be as low as
possible which allows individual Health and Safety
Executive inspectors to make a local interpretation (DHSS
1976).
Hillman and others (1981) assessed pollution of a
passively ventilated dental surgery over a 6 month period.
Sampling was active, 6-8 inches from the dentist's nose
and continuous N20 concentrations were found using an
infrared monitor. The concentrations were;
a) without scavenging 266-6281 (mean 2445) ppm
b) with scavenging 92-1228 (mean 351) ppm
Other work has found similarly high amounts of
pollution (when no scavenging is used) ranging from 350-
8500 ppm (Campbell and others 1977, Whitcher and others
1977). Blood N20 concentrations are theoretically more
accurate in assessing personal contamination and they
indicate that dental workers inhale more N20 than theatre
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workers. Hillman and others (1981) measured blood N20
concentrations in both dentists (mean 60.3, SD 31.4 jumol
. — 1
N20. litre ) and dental assistants (mean 20.3, SD 8.5 jumol
N20.litre-1) in non-scavenged rooms and found they were
considerably greater than those in anaesthetists who
worked in non-scavenged theatres (14.9 /imol
N20/litre)(Krapez and others 1980).
Munley and others (1986) studied midwife N20 exposure
over a shift in 4 maternity hospitals using personal
sampling. In 3 hospitals, mean exposure was less than 100
ppm, but in the 4 th, it was greater than 3 60 ppm and
scavenging reduced this to 150 ppm. The main reasons for
these differences appear to be different working practices
and the layout, size and ventilation of the labour suites,
lsley and others (1989) examined the duration and
frequency of Entonox administration inside ambulances. N20
concentrations were found using grab samples at one minute
intervals from the breathing zone of both the attendant
and driver whenever Entonox was used. Mean exposure time
for attendants was 11.4 (13.8) minutes to mean
concentrations of 1100 (3900) ppm with open (closed)
windows. The driver's exposure was half this and the
highest exposure of any individual was 56,000 ppm.
Hence, many types of worker are exposed to N20 with
the actual duration and concentration of exposure varying
greatly. Overall, dentists have the highest exposure,
presumably due to their particular type of anaesthetic
practice (high flows, leakage from mask, poor scavenging,
etc). Anaesthetists and other theatre workers are exposed
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to high concentrations especially in unscavenged theatres.
Human exposure and MS activity
Patients undergoing anaesthesia are exposed to N20 in
concentrations which are high enough to inhibit MS.
However there is less known about the effects of trace
concentrations. Work on animals exposed to trace
concentrations has been discussed previously, but in
summary, the ED5Q for liver MS inhibition in rats after 1
days exposure was 10,400 ppm and after 2-28 days was 5,400
ppm. The lowest N20 concentration to affect MS was 840
ppm for 1 day and 450 ppm for 48 hours (Sharer and others
1983). Koblin and others (1981) showed that exposure to
less than 50,000 ppm N20 for 4 hours had no effect on mice
MS. Extrapolation indicates that MS is 50% inactivated
after 4 hours exposure to 10% N20. Exposure to 1100 ppm
for 8 to 22 days caused a small, but significant decrease
in MS activity and recovery took 2 to 4 days. Therefore,
in rodents, MS is inhibited by exposure to trace
concentrations of N20. Is this clinically relevant to
human workers because human MS appears more resistant to
inhibition (Royston and others 1989)?
Cell division and the tissues involved
When DNA synthesis decreases, all cells in the body
are affected although those requiring large amounts of DNA
(i.e. the rapidly dividing tissues) will be the first to
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be affected. Organs and cells tested for abnormalities
after N20 exposure include the bone marrow, the immune
system, the fetus and cells involved in wound healing and
spermatogenesis.
Because N20 impairs vitamin B12 and folate
metabolism, patients with abnormalities in either of these
vitamins may be especially susceptible to N20. However, in
a study of chronic alcoholics (who tend to have a folate
deficiency) exposed to N20 for 20-60 minutes, no megalo¬
blastic changes were seen in their peripheral blood films,
although this is a crude measure of diagnosing early
marrow changes (Editorial 1987c). Two women developed
neurological complications similar to those of subacute
combined degeneration of the cord within 8 weeks of anaes¬
thesia. One had had pernicious anaemia and the other a
previous ileal resection for Crohns disease (Schilling
1986). In animals, synergy between vitamin B12 deficiency
and N20 exposure has been shown (O'Leary and others 1984).
Hence, it is possible that patients with vitamin B12
deficiency may be particularly susceptible to N20 toxicity
(eg Vegans, pernicious anaemia and malabsorption diseases,
etc). Folate deficiency is relatively common and can occur
from poor diets, pregnancy and malabsorption. Some
chemotherapeutic agents interfere with folate metabolism.
For example, methotrexate inhibits dihydrofolate reductase
and this may theoretically cause increased toxicity
(Ueland and others 1986).
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1. Cell Division
N20 is known to interfere with cell division
(Brinkley and Rao 1973). All anaesthetic drugs cause a
replicating cell to remain in mitosis by a non-specific
general action. The ED5Q of halothane's that stops the
replication of the root of the broad bean in the metaphase
of mitosis is 0.5 - 0.9% (Nunn and others 1971). Other
anaesthetic drugs caused a dose dependent reduction in
mammalian Chinese hamster cell replication by inhibiting
every phase of the cell cycle although N20 was not tested
(Sturrock and Nunn 1975) . However, 75% N20 had similar
effects to 0.5% halothane in suppressing the division of
cultured murine bone marrow cells (Nunn and others 1976),
but this is probably not a specific effect.
2. Mutagenicity and Carcinogenicity
N20 may be both mutagenic and carcinogenic due to
its effects on DNA synthesis. Because carcinogens are
always mutagens (Duncan and Brookes 1973), mutagenicity is
an essential test for any carcinogenic chemical. It is a
simpler test to perform because the standard bioassay for
carcinogenicity involves lifelong exposure of large number
of animals to the drug. The mutagenicity of N20 has been
extensively investigated using a variety of tests.
Sturroch (1977) examined the effects of halothane both
with and without N20 on Chinese Hamster lung fibroblasts
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using the 8-azaguanine assay system. Hypoxanthineguanine
phosphoribyl transferase converts guanine and hypoxanthine
to guanylic and inosinic acids. Fibroblasts are capable of
absorbing 8-azoguanine from a culture medium and if no
guanine is present, they incorporate it into their DNA and
RNA and the cell will die. However, if the cell is a
mutant lacking this enzyme, it survives because it can
make guanine in another way and a colony forms. Exposure
of these cells to 75% N20 with 1-3% halothane for 24 hours
resulted in no colony formation and hence no significant
mutation had occurred.
White and others (1979) examined the frequency of
sister chromatid exchanges (SCE) in Chinese Hamster
ovarian cells. This is a rapid in vivo assay of genetic
damage because mutagens will increase the rate of SCE
during cell division. Exposure to 1 MAC N20 for 1 hour had
no effect. Baden and others (1979) used the salmonella
microsome assay of Ames and others (1975). Two histidine
dependent strains of S.typhimurium, both of which can
revert either spontaneously or by mutagenic change to
independency, were exposed to 1-81% N20 for 8 hours in
agar. No mutagenic changes occurred and further work
(Baden and others 1981) exposing similar bacteria to high
pressures of N20 had identical results.
Baden and Kundomal (1986) exposed male Drosophilia
flies to various concentrations of N20 and halothane,
enflurane or isoflurane for 1 hour and showed that N20 was
not an enhancer of the mutagenic properties of these
volatile anaesthetics.
62
Not all tests have been negative. Exposure of
Drosophilia flies to 100% N20 for 6 minutes resulted in
increased mutagenicity (Garrett and Fuerst 1974) although
this may have been due to hypoxia. A second test has shown
N20 to be weakly mutagenic, although it used a less
reliable test which examines the colour of stamen hairs in
Tradescantia.
Overall, it appears that N20 is not a mutagen or at
worst, is a very weak one. Therefore, it is highly
unlikely that it will be a carcinogen. To examine this 2
studies have been carried out. Eger and others (1978)
exposed male and female Swiss ICR mice to 19-75% N20 for 2
hours each day at 2 day intervals during the last half of
pregnancy and for 24 times at 2-3 day intervals 5 days
after birth. The mice were killed at 9 or 15 months. There
was no evidence of an increase in the incidence of
tumours. Coate and others (1979) studied the effect of low
concentrations of halothane and N20 on male and female
Fischer rat's reticulo-endothelial systems. Exposing them
to either 1 or 10 ppm halothane with 50 or 500 ppm N20
for 7 hours a day, 5 days a week for 104 weeks caused no
increase in malignancy. Overall, there is no evidence that
N20 has any mutagenic and carcinogenic properties.
Many epidemiological studies have studied the effect
waste anaesthetic gases have on the morbidity or mortality
of exposed individuals. Unfortunately, most of the studies
have an intrinsic problem in how they are designed because
of unsuitable control groups. Unfortunately there are many
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factors in the theatre environment that could potentially
influence the health of these workers and so do these
studies reflect the effects of anaesthetic gas exposure
alone? Working in theatres can be stressful and this may
be partially responsible for any increases in spontaneous
abortions that have been seen (Fink and Cullen 1976) .
There is also an increase in exposure to other potentially
lethal agents and possible biological agents include
organisms in blood (eg hepatitis B, HIV virus). Chemical
agents unique to theatre may be toxic (methylmethacrylate)
and in some theatres there is an increase in radiation
exposure. Exclusion of these possibilities requires a
study design which uses closely parallelled control groups
who have similar work conditions, but are not exposed to
anaesthetic gases. Therefore most studies have examined
the effect of working in a theatre rather than of exposure
to anaesthetic agents as the cause of morbidity or
mortality.
There are other problems in the design of these
studies. In the exposed groups there is little or no
attempt to quantify the amounts and types of anaesthetic
gas exposure. Some individuals may have had a heavy
exposure to N20 with little inhalation of halothane whilst
others from the same group have completely different
patterns of exposure. One theatre nurse may work
exclusively in the recovery room with little anaesthetic
gas exposure and another assists the anaesthetist
throughout the operation. The groups therefore all have
different gas exposures. Additionally the amount of N20
64
present in theatre air can vary greatly.
There are problems in data collection because most
studies are retrospective and use postal surveys in which
individuals are asked to report any relevant past medical
history. This form of enquiry has many problems (Spence
1987). Recall of past medical illnesses can be inaccurate.
Some individuals are more motivated than others to respond
especially if they realise that the study affects them
personally and this can reduce the control group response
rate. For example 70% of an exposed group and 41% of the
control group responded in the 1974 ASA survey. Different
motivations may cause variations in the accuracy of recall
of problems. Verification of the response data is
difficult and it is often impossible to prove the accuracy
of the data. It is appreciated that surveys and interviews
are inaccurate when compared to data collected from
medical records (Lilienfeld and Lilienfeld 1980). However,
there have been a few studies in which registers have been
used to overcome this problem (Ericson and Kallen 1979,
1985, Hemminki and others 1985).
Hence the conclusions of these studies is
questionable. Four studies have looked at the morbidity of
cancer (Corbett and others 1973, ASA 1974, Tomlin 1979 and
Cohen 1980) and five have examined the mortality from
cancer (Bruce and others 1968, Bruce and others 1974, Doll
and Peto 1977, Lew 1979 and Neil and others 1987).
Corbett and others (1973) surveyed 621 female nurse-
anaesthetists with a response rate of 84.5% (525
responses) and found 33 malignancies in 31 nurses. The
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control group was based on statistics from the Connecticut
Tumour Registry with an expected tumour rate of
402.8/100,000 compared to 1,333/100,000 in the nurse
group. The ASA (1974) published a national study of
occupational disease in theatre personnel using a postal
survey of 49,585 exposed individuals and 23,911 non-
exposed individuals as controls. The incidence of tumour
increased only in females (from 130% to nearly 200%) and
statistically, only leukaemias and lymphomas showed a
significant increase (p=0.05). Cohen and others (1980)
looked at tumour incidence in 30,650 dentists and 30,547
female assistants. They were divided into groups who used
and did not use anaesthetic gases and then further
subdivided into groups where N20 alone (81.3%) or with
other anaesthetics (19%) was used. Therefore, the specific
effects of N20 could be found. Male dentists were
unaffected whilst female assistants had a slight, but
insignificant increase in tumour incidence.
The five surveys that have examined anaesthetist's
mortality have been mainly negative. Bruce and others
(1968) found that 17 anaesthetists had died from tumours
of the lymphoid and reticular-endothelial systems as
compared to an expected 8.9 (p=0.05) although his second
survey failed to confirm this (Bruce and others 1974).
Doll and Peto (1977) studied 20,540 male British doctors
who were older than 35 in 1951 for 20 years. Their
occupations were found from the Medical Directory in 1952
with 547 and 704 being full and part time anaesthetists
respectively. There was no increase in mortality although
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slightly more died from pancreatic cancer than was
expected. Lew (1979) examined mortality in members of the
American Society of Anesthesiologists from 1954 to 1976.
Death certificates from 610 male and 60 female
anaesthetists (out of 637 and 66 deaths respectively)
indicated no increase in the expected incidence of cancer
when compared to controls. Neil and others (1987) followed
up 3769 male anaesthetists in the UK between 1957 and 1983
and 221 died during this period. The control group
consisted of social class 1 males and the total
standardised mortality ratio (ratio of observed to
expected deaths expressed as a percentage) was 68% (95%
confidence of 59-77%) and for cancer, it was 50% (36-
67%). There was no increase in the incidence of leukaemias
or lymphomas although there was a greater incidence of
suicide (ratio 202%, with 95% CI 115-328%).
Overall, it appears that there is little
epidemiological evidence for carcinogenicity or mortality
after exposure to anaesthetic gases. Expert analysis of
these studies was performed using the relative risk (RR)
measurement to find any possible association between
exposure and disease.
RR - Rate of disease among exposed individuals
Rate of disease among unexposed individuals
The results of each study were pooled and the RR
assessed. When it is greater than 1.0 the association is
likely be true and when less, false. The higher the RR,
the greater the association. Only studies with adequate
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size and control groups were included and an overall RR
for malignancies for men was 1.07 and women 1.4. Hence it
is possible that women show an increased risk of
malignancy when working in theatres although the
association is only marginal (Buring and others 1985).
3. Bone Marrow
N20 causes bone marrow depression. Investigations
used to assess this have included examining peripheral
blood pictures, direct visualisation of bone marrow and
the dU suppression test. The evidence shows that prolonged
N20 exposure results in megaloblastic marrow changes
whilst vitamin B12 concentrations remain normal. Since
Amess and others published their study in 1978, there has
been much work which has examined this effect. The
exposure needed to cause depression, its duration, the
effect of intermittent exposure, the effect on ill people
and methods of preventing it have all been assessed.
Skacel and others (1983) anaesthetised 9 patients
with 70% N20; 5 for 24 hours, 1 for 36 hours and 3 for 4-
12 hours. The other 3 patients were controls and received
etomidate. All except one individual underwent aortic
surgery. Their peripheral blood films were assessed daily
and amino-acids and folate concentrations measured 4
hourly. Bone marrow was examined by microscope and with
the dU test pre-operatively, 24 hours later, on the 3rd or
4th day and after 1 week. Platelet numbers decreased in
all patients for 3 days. The neutrophil count initially
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increased and then decreased in the N20 group after 24
hours (especially in 2 patients, one who received 36 hours
of N20 and the other, an alcoholic who received N20 for 6
hours). All N20 exposed patients had an increase in hyper-
segmented neutrophils counts on the 5th day which
peaked at 7-9 days. After 24 hours, all 24 hour N20
exposed patients had grossly megaloblastic marrows
although they had improved after 3 days and were normal by
1 week. The marrows of control patients and the 3 who
received only a small amount of N20 were normal
throughout. Similar results were seen with the dU test.
Folate analogues were added in vitro to marrow samples and
5 formylTHF reversed the changes most effectively,
although tetrahydrofolic acid (THF) and vitamin B12 also
worked. In contrast, 5 methylTHF had only a limited
effect. Serum folate concentration increased during N20
inhalation while methionine concentration decreased in
both groups, although this was greater in the N20 group
and continued throughout the inhalational period. Vitamin
B12 concentrations were unchanged.
Hence it took at least 48 hours for marrow changes to
recover. Are these changes important or do they have no
clinical relevance? Because the bone marrow changes
affected both leucocyte numbers and morphology, they must
be important. The decrease in methionine concentrations
could have adverse effects on protein synthesis or on
methionine's other functions. One patient who appeared to
be especially sensitive to N20 was a chronic alcoholic who
was exposed to N20 for only 6 hours. Chronic ethanol
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ingestion is recognised to disrupt folate metabolism
(Barak and others 1987) and it is possible that N20
aggravates this although acute doses of ethanol had no
effect on the rate of mice MS inactivation by N20 and this
suggests no interaction between N20 and acute ethanol
intake (Tomerson and Koblin 1988).
Amos and others (1982) studied acute bone marrow
changes and abnormalities in DNA synthesis in 70 seriously
ill patients who were admitted to an intensive care unit
for at least 24 hours. Any who had received folic acid
supplements were excluded. There were 50 surgical and 20
medical (control) patients. All the surgical patients had
a 1-6 hour anaesthetic although the N20 concentrations
used were not specified.
Twenty two patients had megaloblastic marrows on
admission, 18 having had received a minimum of 2 hours N20
within the previous 24 hours. Patients who had received
N20 had a greater chance of developing bone marrow
abnormalities if illness was more severe (mean APACHE
score of 31 compared to 19 in those patients with no
changes). Sixteen N20 expsoed patients died compared to 7
of the controls. Thirty-nine out of the 42 patients who
received N20 had an abnormal dU test and its value was
proportional to the duration of N20 exposure. The dU test
correction pattern was typical of that in B12 deficiency
in 30 patients. Normal dU tests were seen in all control
patients. Eleven of the 22 patients with a megaloblastic
bone marrow on admission were still in the ICU 3 days
later. Three with a medical problem had normal marrows,
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but 4 of the other 8 surgical patients had megaloblastic
marrows when examined microscopically. All these dU tests
were abnormal. Hence, it appears that admission of
seriously ill patients to an ICU after a N20 anaesthetic
is more likely to be associated with megaloblastic marrow.
The abnormalities were not only more severe, but also
persisted for longer and in some patients became worse.
Further work by the same group (Amos and others
1985) tried to find a cause for the persistent
megaloblastic changes. They studied 48 patients admitted
to ICU for up to 15 days, 36 having had surgery (0.5-6
hours N20 exposure). N20 concentrations and APACHE scores
were given. Sixteen (33%) had megaloblastic marrows when
admitted of which 13 had been anaesthetised with N20.
After 3 days, 9 were still megaloblastic (mean exposure to
N20 [3.7 hours] was greater than in those without [3.2
hours]). All patients not exposed to N20 had normal dU
tests, but 26 patients from the exposed group had abnormal
tests and this decreased to 22 after 3 days. An additional
7 became abnormal. At admission, the abnormal dU test was
corrected by both methylcobalamin and folic acid in 10 out
of 12 samples and after 3 days in 4 out of 10. The rest
were corrected by folic acid alone. Serum folate
concentrations were low after 3 days in the N20 exposed
patients although there was increased urinary folate
excretion in the non-N20 exposed group. High doses of
folic acid (15 mg IV daily) prevented abnormal dU tests
occurring in 3 patients whereas low doses (400 ;ug IM
daily) had no effect in 5 patients.
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These results support previous findings which showed
that ill patients exposed to N20 have an increase in the
incidence of abnormal dU tests and this appears due to
folate deficiency. However, because there was no increase
in folate loss in the urine, the actual mechanism of this
deficiency is unknown.
Why severely ill patients should be more susceptible
to N20 is unknown. Perhaps it is because the illness
reduces the body's reserve to cope with abnormalities.
Other circumstantial evidence supports the possibility. A
case report described a severely ill patient who had been
stabbed and who received 7 0% N20 for 105 minutes. He
needed 31 units of blood and after 7 hours had a dU value
of 18.4%. Severely ill patients with tetanus have been
shown to have marrow depression and many have died after
N20. This is in contrast to patients who receive it for
pain relief (myocardial infarction, etc). However, caution
is needed in interpreting these results because
megaloblastic haematopoiesis has been noticed in severely
ill patients who are not exposed to N20 (Ibbotson and
others 1975).
The amount of N20 exposure needed before
megaloblastosis occurs is variable. Nunn and others (1982)
described a patient who used Entonox for physiotherapy
after an attack of acute intermittent porphyria. He was
given it for 15-20 minutes periods 3 times a day. After 24
days (total N20 exposure of 18 hours) his marrow was
megaloblastic with a dU test of 14.5% and addition of
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vitamin B12 reduced it. N20 was stopped and 7 days latter,
he had a normal marrow and dU test. N20 was recommenced at
20 minutes twice a day, but after 2 weeks his marrow was
again megaloblastic although the dU test was normal.
Recovery of marrow activity is slow, taking over 48 hours
and this intermittent chronic inhibition is interesting
because it appears that the effects are cumulative.
Attempts have been made to prevent marrow depression
occurring. Reversal of abnormal dU tests in vitamin B12 or
folate deficient patients with 5 formylTHF (folinic acid)
have been successful (Metz and others 1968, Das and others
1970, Van der Weyden 1973). Folinic acid prevents
increases in dU test results in animals (Deacon and others
1980). O'Sullivan and others (1981) studied the efficacy
of folinic acid in preventing the development of a
megablastic marrow. Thirty patients received a 1-6 hour
anaesthetic with N20 for routine surgery and a second
group of 24 patients underwent cardiac surgery. Five
received 50% N20 for 12 hours, 6 for 24 hours and 7 for 24
hours. The last group were given 20 mg folinic acid
orally, 12 and 1 hour before anaesthesia. The remaining 6
patients were anaesthetised without N20. These and the 30
patients undergoing routine surgery had no problems. In
contrast, the N20 exposed groups became abnormal with 4 of
the 5 patients who received N20 for only 12 hours having
megaloblastic marrows and mean increases in their dU test
results from 8.6% to 13.4%. All 6 patients who received
N20 for 24 hours had megaloblastic marrows with a mean dU
test increasing from 6.5% to 13.3%. It took 12 hours for
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the dU test to become normal after N20 was stopped.
Patients receiving folinic acid had no change in their dU
tests indicating that folinic acid prevented the
megaloblastic changes.
However, Skacel and others (1982) failed to show this
in 3 patients who had 4.5, 7 and 24 hour N20 anaesthetics.
All had large increases in dU test results even if
folinic acid was given IV or orally. A fourth patient was
given 30 mg folinic acid IV every 5 hours and had no
change in his dU test after 24 hours N20 exposure. Amos
and others (1984) used a variety of doses. Eleven patients
were ventilated for 24 hours with 50% N20 and each given
from 3 - 60 mg IV folinic acid. All had normal marrows
before N20 administration and only one had a raised dU
test (13.3%). Six patients received 3-36 mg folinic acid
and all had megaloblastic marrows and abnormal dU tests
postoperatively (mean 22.1% SEM 3.0%). The other 5 were
given 60 mg folinic acid in divided doses, at the
beginning and after 12 hours. Four were normal and only 1,
a seriously ill patient with a liver abscess, had a
megaloblastic marrow and an abnormal dU test. It appears
that folinic acid in high doses will prevent marrow
changes.
Folinic acid has been used to prevent marrow changes
occurring in a seriously ill patient who was repeatedly
anaesthetised with N20. An 18 year old male had a 105
minute anaesthetic with 70% N20 after being stabbed. He
needed a major transfusion and underwent another
laparotomy 7 hours later for which he received N20 in
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oxygen for 2 hours. Folinic acid (30 mg IV) was given at
induction and afterwards he received 30 mg IV daily. A
marrow sample before induction showed a dU test result of
18.4%, but when repeated 4 hours after the operation was
normal at 9.4% Hence in this patient, folinic acid both
reversed the abnormality, but also prevented it re-
occurring.
Methionine reverses neurological damage due to
prolonged N20 inhalation (Scott and Weir 1981) and it can
also correct abnormal dU tests in vitamin B12 deficient
marrow cells (Sourial and Brown 1983). Theoretically, this
compound may prevent haematological depression after N20
inhalation although it has not yet been evaluated.
Therefore, prolonged exposure to N20 causes a
megaloblastic-like marrow depression. Is this clinically
relevant to modern anaesthetic practise? The depression
is related to both the duration and concentration of N20
exposure. Exposure to 50% N20 for less than 6 hours causes
no obvious abnormality and after this, the megablastosis
becomes worse with increasing exposure (Amess and
others 1978, O'Sullivan and others 1981, Kano and others
1981 Skacel and others 1983). Prolonged intermittent
exposure can cause megaloblastosis (Nunn and others 1982)
although not all cases show this (Thomson and others
(1976), Petrovsky and Yasuni 1965, Fink 1967). Severely
ill patients may be more susceptible to N20 (Amos and
others 1982) and folinic acid in high doses can reverse
its effects (O1Sullivan and others 1981, Skacel and others
1982, Amos and others 1984). However, the importance of
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these findings is difficult to assess. As will be
discussed later, changes in marrow function are a late
indication of toxicity and it is possible that deleterious
changes could be occurring without alterations in the dU
test.
Assessment of bone marrow changes from prolonged
exposure to N20 pollution in humans has been made both
biochemically and epidemiologically. Biochemical studies
have assessed the effects of N20 upon the bone marrow of
both theatre workers and dentists. Salo and others (1984)
examined the blood of theatre workers. They studied 8 male
anaesthetists and 118 theatre nurses who worked in
scavenged theatres. An additional, 10 nurses and doctors
who worked in an unscavenged theatre were also examined.
All had normal haematological profiles except for 2
anaesthetists who had raised mean corpuscular volumes and
one who had 5 segmented neutrophils. However, this study
would only detect severe problems because abnormal
neutrophil appearance is a late effect of bone marrow
depression. Sweeney and others (1985) examined N20
pollution in dentists using a more sensitive assay. They
studied the bone marrow of 21 dentists who used N20 over a
3-11 week period. Their N20 exposure was calculated using
a personal sampler and an average exposure was 159 to 4000
ppm. Two of the dU tests were abnormal with a third being
slightly irregular. The 2 dentists with an abnormal dU
tests also had abnormal blood films with bone marrows
which appeared megaloblastic on microscopy. All 3 dentists
were exposed to high concentrations of N20 (time averaged
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exposure of 1900, 2500, and 1800 ppm) and calculation of
total exposure doses showed that they had the 1st, 3rd and
5th greatest exposures. Nunn and others (1982) found no
change in plasma methionine concentrations in
anaesthetists exposed to N20 although this is a crude
assay of MS inhibition because many factors can influence
it.
These biochemical studies suggest that theatre
workers are not adversely affected by N20 pollution.
However, 2 of the studies were too insensitive to detect
any subtle changes. The 3rd study which examined dentists'
bone marrows was positive in 3 individuals. Dentists tend
to be exposed to greater amounts of N20 and it is possible
that high concentrations are necessary before toxicity
occurs.
There is evidence that N20 can depress bone marrow
other than by direct inhibition of cellular division. It
may change the micro-environment of haemopoietic cells.
Mice inhaled 50% N20 for 7 days and then were totally
irradiated. Bone marrow cells were injected and the
amount that fixed in the animals' bone marrow and spleen
were measured. There were no differences in implantation
rates in the bone marrow between N20 exposed and control
mice, but a 60% reduction occurred for the spleen (Suzuki
and others 1989). N20 had a greater effect in reducing the
spleen stem cells numbers when compared to the bone marrow
(Kondo and others 1987) . Therefore, does N20 have effects
on the spleen micro-environment in mice resulting in




Spermatogenesis involves cellular replication and
because this requires large amounts of fresh DNA, it my
therefore be especially vulnerable to N20. Kripke and
others (1976) examined 135 young male rats exposed to 20%
N20 either continuously or for 8 hours a day. Tests
performed after 1-35 days of exposure showed that
testicular weight was decreased after 28 days exposure.
Histologically, there was damage to the spermatogenic
cells and suppression of spermatogenesis although the
supporting cells were completely normal. The smallest
exposure which caused this was 2 days both in the
intermittent and continuously exposed groups. After 14
days all rats showed some abnormalities, although it was
less in the intermittently exposed rats. Recovery took 6
days. Hence N20 does reversibly decrease spermatogenesis
in a dose dependent manner. Because testosterone
concentrations remained constant, N20 appears to act
directly on dividing cells.
Rat testis contains MS and this is inhibited by N20.
After 1 hour exposure to 10 or 50% N20, MS activity
decreased by 29 and 63%. Full recovery took 24-48 hours in
the 10% group and 72 hours in the others. Therefore it is
likely from the above study that N20 has its effects via
MS inactivation.
Coate and others (1979) examined young rats using
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trace concentrations of N20 (50 and 500 ppm) and halothane
(1 and 10 ppm) . They were exposed for 7 hours daily, 5
days a week for up to 52 weeks. Increases in chromosomal
damage was seen in both bone marrow and sperm cells. It is
interesting that these changes occurred in both groups
even though rat MS was not affected by concentrations of
less than 450 ppm (Sharer and others 1983). Could there be
another factor impairing spermatogenesis?
Other studies have not shown these abnormal effects.
Mazze and others (1983) exposed male mice to 0.5%, 5% or
50% N20 for 4 hours daily, 5 days a week. After 14 weeks
there was no change in their testes. Land and others
(1981) found no increase in abnormal sperm when mice were
exposed to 8% or 80% N20 for a similar time. Therefore, it
appears that N20 in animals causes a reduction in sperm
numbers, but has little effect on sperm morphology.
Are humans affected by N20 in trace concentrations
(or combined with other anaesthetic agents)? Wryobek and
others (1981) examined semen samples from 46 anaesthetists
who had been exposed to N20 for at least one year. No
abnormalities in sperm concentration or morphology were
seen. The operating rooms used scavenging eguipment and
N20 concentration varied from 5-300 ppm. Studies on
personnel exposed to greater concentrations have yet to be
performed.
Overall, it appears that while N20 causes abnormal
spermatogenesis in rats, it has little effect on
morphology. Anaesthetists showed no obvious effect,
although personnel exposed to higher concentrations have
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not been assessed. Individuals undergoing anaesthesia are
unlikely to be affected in a meaningful manner because the
changes appear to be reversible.
5. Fetal Development
Conception and fetal development require large
amounts of DNA and it is possible that N20 may interfere
in three ways. It may decrease conception rate, increase
spontaneous abortions or may cause developmental
abnormalities. Pregnant women are exposed to N20 either at
work or during a co-incidental anaesthetic. Animal studies
have examined the possibility that N20 can cause
increased teratogenicity although interpretation of these
results is difficult. Most studies have used small numbers
of animals reducing the power of these experiments and
extrapolation to other species is impossible because the
relative susceptibilities of each animal to N20 is hard to
predict (Cohen 1980). However the experiments do give
useful information on any potential problems and their
possible causes.
There are many teratogenic mechanisms (mutation,
interference with cell division, lack of energy or
precursors for development, enzyme inhibition, cell
membrane changes). N20 was shown to be potentially
fetotoxic and teratogenic in 1967 when pregnant rats
inhaling 50% N20 had an increase in fetal resorption,
mortality and visceral and skeletal abnormalities (Fink
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and others 1967). Bussard and others (1974) found similar
results when hamsters were exposed to 60% N20 and 0.6%
halothane. This is specifically caused by N20 rather than
a general toxicity of anaesthesia because xenon, a gas
with similar properties to N20, caused no teratogenicity
in similar doses (Lane and others 1980) . Further work has
been carried out to find when teratogenicity is most
likely in pregnancy and how much exposure is needed.
Shephard and Fink (1968) exposed pregnant rats to 24
hours continuous 50% N20 from day 5 to 11 of pregnancy and
the incidence of skeletal abnormalities was maximal on day
11, but it increased from days 5-8. Hence, it appears
that N20 has different effects at different times during
rat pregnancy.
There is a trace concentration below which no
teratogenicity occurs. Pregnant rats were exposed to 100,
1000, or 15,000 ppm N20 either continuously or for 8 hours
a day on days 8-13, 10-13, 12-19, 14-19 or 10-19 of
pregnancy. Intermittent exposure had no effect except
during days 10-13 when the fetal death rate increased. In
the continuous group, 1,000 and 15,000 ppm exposure for 24
hours caused increased fetal death rates with decreased
implantations in contrast to 100 ppm which had no effect
(Corbett and others 1973) . Exposure of rats to 250 or 500
ppm N20 throughout pregnancy had no effect whilst 1000 ppm
caused a difference in the litter size, freguency of fetal
resorption and fetal weight (Vieira and others 1980).
Hence, in rats, it appears that concentrations greater
than 500 ppm are reguired for teratogenesis. This dose is
81
similar to the lowest concentration that inhibits rat
liver MS activity (450 ppm - Sharer and others 1983). In
intermittently exposed rats the threshold was above 1,000
ppm (Vieira and others 1983).
However, not all studies show N20 to be teratogenic.
Pope and others (1978) exposed Sprague Dawley rats for 8
hours daily throughout pregnancy to either a graded
concentration of halothane (0.16-0.32%), N20 (1-80%) or a
N20:halothane mixture (10% and 0.16%). There was some
fetal growth retardation (3-21% decrease in weight), but
no increase in fetal loss or skeletal abnormalities. Mazze
and others (1982) exposed Swiss ICR mice to 0.5%, 5% or
50% N20 for 4 hours daily from day 6 to 15 of pregnancy.
The 154 female mice studied produced a total of 1,7 61
fetuses and there was no increase in fetal resorption or
skeletal abnormalities.
Why N20 is not always teratogenic is still unknown.
The two negative studies used intermittent exposures and
recovery may have occurred during the rest periods
although MS activity takes days to recover (Deacon and
others 1978). N20 was given throughout pregnancy and there
may have been sufficient time for alternative pathways of
folate metabolism to be induced. Rats have a betaine
pathway which converts homocysteine to methionine and this
requies several days days before it is induced (Lumb and
others 1983). Davidson and others (1988) grew thymidine
kinase negative mutant mouse leukemic lymphoma cells
without methionine and then exposed them to 76% N20 or N2
for 30 minutes. Cell growth was identical although there
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was no MS activity in the N20 cells. Because these cells
are incapable of making deoxythymidine from thymidine it
suggests that alternative methods of methylating
deoxyuridine MS exist. Rat exposure to N20 in early
pregnancy may allow induction of this pathway and no
teratogenicity will occur.
The mechanism of N20 teratogenicity is still unknown.
Maternal and fetal MS was inhibited in a dose dependent
manner although it was slower in the fetal enzyme probably
because of the time taken for N20 equilibration between
maternal and fetal blood (Baden and others 1984). In vitro
N20 inactivation of fetal MS was similar to that of
maternal MS (Baden and others 1987). Is the teratogenicity
a consequence of abnormal folate and DNA metabolism? N20
does decrease cellular proliferation in mice fetuses
exposed briefly to N20 (Rodier and others 1986) . However
there is evidence that other mechanisms may be
responsible. If isoflurane (0.35%) and N20 (50%) are given
to rats the effects are substantially reduced (Fujinaga
and others 1987a), but fentanyl alone had no effect (Mazze
and others 1987). If teratogenesis is mediated via folate
inhibition, folinic acid should protect the animal
although there was no change (Keeling and others 1986,
Fujinaga and others 1987B). N20 causes a high adrenergic
tone and increases plasma noradrenaline concentrations
(Smith and others 1970) and this may reduce uterine blood
flow and compromise the fetus. Because both isoflurane and
halothane prevent a high adrenergic tone and cause
arterial dilation, it is possible that they can reduce the
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vasoconstrictor effects of N20. However, in a culture
system 100 10 day old rat embryos exposed to 75% N20 had a
reduced DNA content compared to controls and 7 rats
developed abnormally (Fujinaga 1988). Exposure of rat
fetuses to 75% N20 on day 9 in the same system increased
abnormalities (Baden and Fujinaga 1991). This whole embryo
culture system avoids maternal influences and allows the
direct effects of N20 on the fetus to be assessed. Are the
effects of N20 multifactorial?
There have been several epidemiological studies which
have examined the effects of anaesthesia and surgery in
pregnant women because it is possible that anaesthesia
during early pregnancy may cause an increase in
spontaneous abortions. There was an incidence of 8.5% and
9.3% respectively in fetal death and congenital
abnormalities in 147 women who had had surgery in the
first trimester (controls were 2.0 and 6.0%
respectively)(Schnider 1965). A postal review of dentists
and dental assistants showed that of 187 pregnant women
who had been operated on during the first trimester and
100 in the second, 9.6 and 2.6% respectively had aborted.
Control values for these 2 groups were 5.1 and 1.4%
(Brodsky and others 1980). A review of 175 pregnancies
during which an anaesthetic (20 - 30 minutes) was given
for the insertion of a Shirodkar suture (mostly between
14-16 weeks) was unable to show any teratogenicity
(Aldridge and Tunstall 1986). Slater (1970) described a
patient who gave birth to a normal boy, even though she
received 17 anaesthetics during her pregnancy. A
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retrospective study reviewed 53 infants who had neural
tube defects and 97 with other major congenital
abnormalities. Only 1 mother had received an anaesthetic.
The anaesthetic histories of 471 mothers showed that 72 of
then had received a total of 76 anaesthetics, 70 before
their last menstrual period and 6 during pregnancy. No
abnormalities were found although 2 miscarried (Konieczko
and others 1987).
Other studies have examined larger numbers of women
and found a similar high rate of miscarriage after
anaesthesia in the first trimester. Duncan and others
(1986) assessed more than 1,000,000 people who lived in
Manitoba from 1971 to 1978 and found 2,565 women who had
undergone surgery during pregnancy. Each woman was matched
to a control. In the surgical group, there was a 1.68%
incidence of congenital anomalies and a 7.1% abortion rate
compared to controls of 1.52 and 6.5% respectively. The
type and timing of the anaesthetic had no effect on
congenital anomalies although general anaesthesia
increased the number of abortions significantly (risk
ratio=1.58). Whilst the evidence is still not definitive,
it does appear that surgery can increase the incidence of
abortions. Is this due to N20 or to other factors (eg.
volatile anaesthetics).
Does N20 have an effect on fertilisation? Ninety-
eight patients received either N20 and isoflurane or
isoflurane alone for laparoscopic retrieval of oocytes and
both groups had the same successful fertilisation rates
suggesting that N20 has little effect. This is expected
85
because oocyte retrieval is a relatively quick procedure
and N20 exposure is only brief. However, prolonged N20
exposures may interfere with fertilisation and the
implantation rate? Should N20 be used in women attempting
to have a family?
Does N20 have an effect on fetuses when used for
Caesarean section late in pregnancy? Fetal MS is
inactivated in N20 exposed rats (Baden and others 1984,
1986). However, a similar experiment would be impossible
to do in human fetuses. Landon and Toothill (1986)
examined MS activity in placentae collected either after
Caesarean section (with a N20 exposure of 13 to 22
minutes) or after normal vaginal delivery and found no
difference in MS activity.
Overall, the evidence indicates that short N20
anaesthetics for pregnant women are probably safe after
the first trimester although they may cause an increase in
first trimester abortions. The embryo culture system
indicates that N20 directly affects the fetus. It may be
advisable to avoid N20 as an anaesthetic for women in the
1st trimester of pregnancy. Whether N20 should be used in
women attempting to become pregnant has not yet been
established.
Fetotoxicity and teratogenicity may occur in exposed
female workers (Askrog and Harvald 1970, Cohen and others
1980, Erikson and others 1979, 1985 Tomlin 1979, ASA 1974,
Corbett and others 1974, Knill-Jones and others 1972).
Initial studies showed there was an increase in
spontaneous abortions in these women although the study
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sizes were small and controls were inadequate. Buring and
others (1985) pooled the results of 6 studies to calculate
the RR for women. For spontaneous abortion the RR was
1.30 (95% CI 1.2-1.4) and for congenital abnormalities it
was 1.20 (95% CI 1.0-1.4). Nurses were less affected than
doctors. It is possible that this small increase in RR may-
have been a result of bias in the studies. Cohen and
others (1980) assessed the effect of N20 upon pregnant
women and showed a dose dependent increase in spontaneous
abortions of up to 105% above control values for the
chairside assistants. Also, there was a small increase
(50%) in congenital abnormalities among children of the
same chairside assistants. However, this was not dose
dependent.
In Sweden a Medical Birth Registry, started in 1973,
holds information on pre-natal care, delivery and post¬
natal examinations for 99% of pregnancies. Similarly, a
registry for nurses for abortions (spontaneous and
induced) exist. Using these registries, Ericson and Kallen
(1979) studied 494 pregnancies from 1973-1975 in women who
had worked for at least 50% of their pregnancy in
theatres. The data was accurate and verifiable because
there were no responder problems. No abnormalities were
seen except for a shorter gestation period. Similar work
on the same registries over a longer period (1973-1978)
involved 1323 theatre nurse. Controls were 1382 medical
ward nurses and results were similar (Ericson and Kallen
1985). The Nurse Registry allowed a case-control within-
group study. Twenty five theatre nurses whose children had
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died perinatally or had severe congenital malformations
were chosen. Controls were 50 nurses from the same group
who had had a normal childbirth. Questionnaires sent to
these 75 women (74 replies) showed no difference.
Hence, it appears from these epidemiological studies
that the toxic effect of exposure to N20 pollution is not
as significant as was once thought with the only possible
abnormality being a slight increase in spontaneous
abortions in pregnant females.
6.Infection
It is possible that N20 may affect the immune system.
Normal human lymphocytes exposed to N20 for a short period
had a reduced methylcobalamin synthesis, a reaction that
is vitamin B12 dependent (Linnel and others 1978).
Prolonged exposure to N20 causes a peripheral leukopenia
due to marrow depression from inhibition of DNA synthesis
and several deaths have resulted from this (Lassen 1956).
Is it possible that N20 could have more subtle effects?
Leukocytes (neutrophils, monocytes and lymphocytes) fight
infection by either phagocytosing and killing bacteria
or by producing antibodies. For the proper fuctioning of
the immune system sufficient leukocytes must be made and
then mobilised from the body's stores. They must be able
to undergo chemotaxis to the bacteria, kill and then
phagocytose them.
Depression of chemotaxis leads to an increase in
susceptibility to infection. Nunn and others (1982)
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investigated the motility of human neutrophils in vitro.
Neutrophils were exposed to 80% N20 in oxygen and their
chemotactic response towards casein found. Compared to
controls, this decreased by 22% and this may explain why a
leukopenia develops after 24 hour N20 exposure even though
there are sufficient body stores to last 72 hours (Skacel
and others 1983). Fresh neutrophils are unable to be
mobilised into the blood and because their life span is
brief, a deficiency will soon develop. However, neutrophil
exposure to volatile anaesthetics for 24 hours caused a
similar depression. One MAC isoflurane, enflurane,
halothane and methoxyflurane reduced motility by 8, 32,
50, and 58% respectively compared to a reduction of 53%
with 0.76 MAC N20. (Moudgil and others 1984) . Is the
depression a general effect of anaesthesia rather than a
specific effect of N20 on MS?
In vivo experiments have given a different result.
Seven volunteers had blood sampled before and 20 minutes
after inhaling 60% nitrogen and again 20 minutes after
inhaling 60% N20. This was inhaled for 60 minutes and 20
minutes later a final sample was taken. All the samples
were tested for polymorphonuclear (PMN) chemotaxis, PMN
random motion and white blood cell and PMN concentrations.
N20 increased the PMN chemotactic index, but had no effect
on any of the others (Hill and others 1978) . Alpha
adrenergic agonists enhance chemotaxis whilst beta
agonists reduce it (Hill and others 1976). Exposure to
N20 increases the concentration of plasma noradrenaline by
40% (Eisele and Smith 1972) and this may be responsible
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for the stimulating effects of N20 in vivo as compared to
its inhibitory effects in vitro. Hence, even if N20 in
vitro causes a decrease in motility and chemotaxis, then
is it clinically relevant?
Phagocytosis appears unaffected. In vitro exposure of
human leukocytes to either 0.5%, 2.5% or 80% N20 for 30
minutes didn't affect the phagocytosis of latex particles
(Cullen 1974). Welch and Zaccaria (1982) looked at the
effects of N20 on the oxidative activity of human
neutrophils. Neutrophils can generate reactive oxygen
species (superoxides and peroxides) which kill bacteria.
Eighty percent N20 had no effect on their generation.
Nitroblue tetrazolium was reduced in a normal manner by
leukocytes exposed to 80% N20 for 30 minutes indicating
normal oxidative activity (Cullen 1974).
N20 can cause an in vitro dose dependent reduction in
killer cell cytotoxicity although halothane or enflurane
have greater effects. Withdrawal of N20 reverses this
effect (Woods and Griffith 1986). In conclusion, even
though the effects of N20 are not consistent, there
appears to be a slight effect on the immune system. There
is a reduction in cell production and a decrease in blood
leukocyte concentrations, a decrease in the ability to
mobilise and undergo chemotaxis although this may not
occur in vivo. Phagocytosis and the ability to kill
bacteria is unaffected. Some of these effects may be due
to a direct effect of anaesthesia and surgery rather than
a specific N20 effect. The incidence of post-operative
wound infections increase with increasing surgical
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duration and therefore increasing duration of exposure to
N20 (Cuse and Foord 1973) although there are many other
explanations for this. A blinded study which would examine
the effect that N20 has on wound infection is the obvious
study to be undertaken, although this is a large
undertaking. The clinical consequences of N20 exposure on
the immune system have yet to be established.
7. Wound Healing
A further possibilty is that N20 may interfere with
wound healing because fibroblasts must replicate and
produce new proteins for adequate healing. Shah and others
(1978) made a 3 cm linear incision in 90 rats; 30 of which
were exposed to air, 30 to 20% continuous N20 and 30 to
20% N20 8 hours each day. Ten rats were killed on days 3,
7 or 10. Eighty-seven of the 90 rats had normal wound
healing, both grossly and histologically and N20 had no
effect. Algie and others (1985) exposed 24 female rats
who had received a 4 cm incision in the paravertebral area
to either air or continuous 3% N20. Fifteen to 18 days
later they were killed and the force required to break the
wound was found to be the same in both groups. A second
batch of 40 rats were exposed to either Entonox or 50%
nitrogen in oxygen. On the 8th day they were killed. No
statistical difference was seen in the force required to
break the scars between the 2 groups. A similar result was
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seen by Parbrook (1967).
Hence, it seems unlikely that N20 impairs wound
healing significantly, although there is a possibility
that it may cause minor problems which may increase the
effects of other complications (poor nutrition, obesity,
poor surgery, etc). A full study of this, similar to that
for infections is a large undertaking.
8. Neuropathy
Chronic N20 exposure can cause a neuropathy in
humans. This is an effect unique to N20, although possibly
not related to MS inactivation. The condition was first
seen in 1959 when 2 patients, both with chronic myeloid
leukemia, were treated by inhalation of N20. Both became
euphoric and then depressed. Eventually they became very
tired and lapsed into a coma (Lassen and Kristensen 1959) .
In 1978, Layzer and others described 3 patients who
had abused N20 whilst Sahenk and others (1978) described
a student who had inhaled N20 from a whipped cream
dispenser. All had similar neurological disorders and
nerve biopsies showed a peripheral neuropathy. Layzer
(1978) described 15 men (aged 22-50 years), 14 of who were
dentists and the other a dental technician. All had been
exposed to N20 for between 3 months to 12 years, 13 had
self administered it and the cause in the other 2 was
faulty equipment. The commonest presenting symptom was a
numbness and/or tingling in the hands and feet which
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ascended up the limbs. Lhermitte1s sign was positive in
12. Other common symptoms included impotence (in 7),
abnormal bowel movements (in 4) and depression or memory
loss (in 7). Ten had retired from work. Later symptoms
suggested the development of a distal sensiro-motor
polyneuropathy involving the long motor/sensory tracts of
the spinal cord. The EMG showed a denervation pattern in 6
cases and a reduced motor nerve conduction in 10. The CSF,
myelography and vitamin B12 concentrations were normal.
There was an immediate improvement on stopping N20
inhalation in one patient whilst the others took weeks
although none fully recovered.
The condition appeared to be caused by N20 because no
other abnormality or toxic factor was present and vitamin
B12 concentrations were normal. The neurological picture
was unusual and distinctive and it improved on withdrawing
N20. The syndrome was similar to that in patients with
pernicious anaemia, subacute combined degeneration of the
cord (SACD).
Two factors have hampered study into this neuropathy.
Human work is difficult because the syndrome is rare and
only a few suitable animal models exist (e.g. rats when
exposed to N20 do not develop any neuropathy (Dyck and
others 1980)). Two animal models that have been used are
the fruit bat (Van der Westhuysen and others 1980) and
the primate (Dinn and others 1978). Fruit bats develop a
neuropathy after only a few weeks exposure whilst primates
take up to 10 or more weeks. Although both animals are
expensive to buy and difficult to look after they have
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been used as models for SACD.
N20 inactivates B12 and because this vitamin is found
in only 2 enzymes, it is probable that the neuropathy is
due to inactivation of either enzyme. MS is rapidly
inactivated by a direct effect whilst MMCoA mutase is
inhibited indirectly and this takes longer (Kondo and
others 1981). Accumulation of both methyl-malonic acid
and homocysteine in the urine of patients with pernicious
anaemia is seen indicating that both enzymes are inhibited
in this condition (Lindenbraum and others 1988) . Whatever
the reason for the neuropathy, it must explain why these
patients often have no haematological abnormalities
(Lindenbaum and others 1988).
1. Inactivation of methyl malonyl CoA mutase
(Frenkel and others 1973a 1973b). Folic acid
supplementation in vitamin B12 deficienct patients worsens
the condition (Will and others 1959). MMCoA mutase
catalyses the conversion of the branched chain fatty acid,
methyl-malonic acid to succinic acid and is required for
catabolising proprionic acid, a 3 carbon fatty acid.
Proprionyl CoA + C02 > Methylmalonyl CoA
When this enzyme is inhibited there is an
accumulation of both odd chain and branched fatty acids
which may then be incorporated into the myelin around
axons and cause them to function abnormally. Frenkel
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(1973) found both C15 and C17 fatty acids in the sural
nerves of patients with pernicious anaemia. Because both
inactivation of MMCoA mutase and incorporation of abnormal
fatty acids into the myelin is slow it would explain why
the neuropathy takes a long time to develop.
However, not all children with a hereditary
deficiency of MMCoA mutase have neurological abnormalities
similar to those of SACD (Morrow and others 1969).
Additionally, Scott and others (1981) demonstrated the
protective effects of methionine on N2O inactivated
vitamin B12 deficient monkeys. MMCoA mutase is not
involved in methionine metabolism and so it is difficult
to explain why methionine protects the animals by this
theory.
2) Inactivation of methionine synthase (Jacobsen
and others 1973). This will decrease the formation of
methionine, a vital precursor of S-adenosyl methionine
(SAM) a compound required for methylation reactions. If
methylation is reduced, it may cause a neuropathy.
Cycloleucine inhibits transmethylation reactions of SAM
and if fed to rats causes a demyelination syndrome similar
to vitamin B^2 deficiency (Small and others 1980).
Further work was performed on monkeys (Scott and
others 1981). Two groups were exposed to 15% N20
continuously for 10-12 weeks with the diet of one group
supplemented by 2 g methionine daily. Throughout treatment
the supplemented monkeys remained normal. However, in the
non-supplemented group, all the monkeys became ataxic
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after 10 weeks and their condition then worsened
considerably over the next 3 weeks. At autopsy the
classical changes of SACD in the spinal cord and the
peripheral nerves were seen. Hence, it appears that
methionine prevents these degenerative changes from
occurring supporting the theory that it is the
inactivation of methionine synthase by N20 that causes the
neuropathy.
SAM concentrations in the brains of rats exposed to
70% N20 for 24 hours were significantly reduced (Vina and
others 1986) . However, this was not seen in fruit bats
(Van der Westhuyzen and others 1983) and the reasons for
this remain unknown.
An interesting theory was proposed by Weir and others
(1988). They exposed pigs to 15% N20 for 3, 5 and 9 weeks
and half of them received extra methionine. Those exposed
to N20 without methionine developed ataxia and severe
spinal damage was seen at pathology. Brain and liver MS
activity was reduced. Their spinal cords showed an
increase in SAH concentrations, but SAM concentrations
remained normal (SAM:SAH ratio inverted). The supplemented
group also had a similar increase in SAH concentrations,
but SAM concentrations increased as well (SAM:SAH ratio
normal). From these results, it appears that SAM
concentrations are not responsible for the neuropathy.
This change in methylation ratio (from 15 to 0.8) can
inhibit the transmethylation enzymes (Schatz 1977) and
this may lead to a failure of methylation. Interestingly,
the ratio change in rats is not as dramatic (from 2.7 to
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1.4) which may explain why rats do not develop the
neuropathy.
Scott and Weir (1981) proposed that it was the methyl
folate trap that was responsible for the neuropathy. They
suggested that the trap is a normal physiological process
whereby cells are able to overcome periods of methionine
deficiency which occur during episodes of starvation. It
maintains SAM concentrations to ensure vital
transmethylation reactions can occur. Methionine
concentration is maintained by 2 processes. Firstly, when
it is low, so is SAM concentration as well. This results
in an increase in 5-methylTHF concentrations because no
SAM inhibition of the reduction of 5,10 methylene-THF
occurs. This prevents folate from entering the
purine/pyrimidine cycle because all folate is in the 5-
methyl form. DNA formation and therefore cell division is
inhibited. This will conserve methionine. Secondly, for
folate to be retained by a cell, the transport form, 5-
methylTHF, a monoglutamate, should be converted to a
polyglutamate. Folate must be in its unmethylated form
before polyglutamation can occur and if folate remains as
5-methylTHF, it will not be retained by the cells and a
relative lack of cellular folate will occur. This will
decrease cell turnover.
In this type of neuropathy, the theory suggests that
the cell interprets vitamin B12 inactivation incorrectly.
It sees it as methionine shortage and responds
inappropriately by trapping all folate as 5 methyl-THF.
This will aggravate the decreased supply of methionine and
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SAM concentrations will decrease.
As yet, its pathogenesis is still unknown. Whatever
the cause, it is rare and prolonged exposure to high
concentrations of N20 are needed. In humans, it only
occurs in either self-administered cases or in people who
are exposed to high concentrations by accidental
malfunctioning of anaesthetic machines.
Assessment of the effects of chronic exposure to
trace concentrations of N20 was made in dentists. Nineteen
were examined and they were placed in either a low (no
exposure or less than 5 litres. hour-1. week-1) or high
exposure group (greater than 5). Neurologically, there was
no difference between these groups. However, only a few
subjects were studied and because the effect occurs
rarely, it could have been missed.
Brodsky and others (1981) examined approximately
30,000 subjects half of whom used inhalational anaesthesia
and half who didn't (Cohen and others 1980). Neurological
complaints were assessed including symptoms of tingling,
numbness and muscle weakness. Exposure to N20 was
classified as none, light (less than 2,999 hours/10 years)
and heavy (greater or equal to 3,000 hours/10 years).
There was an increase in neurological complaints in both
male dentists and female chairside assistants. The overall
incidence of complaints was small (less than 2%) . Even
with the limitations of this study, it appears that
occupational exposure to N20 may be detrimental to health.
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Summary
N20 has the potential to cause multiple effects in
humans when exposed either acutely or chronically.




ASSESSMENT OF THE TOXICITY OF NITROUS OXIDE
Rationale for the study
100
Assessment of the Toxicity of Nitrous Oxide
How can the biochemical and clinical toxic effects
which N20 may have on humans be measured? The use of
experimental animal models has allowed us to theorise how
these effects may occur, but we are unable to extrapolate
the results to man. There is a species difference in the
rate that methionine synthase (MS) is inhibited by N20
with human MS being relatively resistant. In addition,
animals develop different clinical problems after
exposure when compared to man. Only a few species have
similar neurological symptoms to man after chronic N20
exposure and we are the only species to suffer from
megaloblastic anaemia. Animal studies will give little
indication of the possible consequences of N20 exposure.
Therefore, to assess the clinical consequences of
exposure, man must be studied and 2 different techniques,
epidemiological and biochemical, have been used. The many
epidemiological studies examining N20 exposure in both
patients and staff have not been able to provide
definitive answers. Biochemical assays are of two types
and both require tissue samples. One techniques measures
human MS activity and the other assesses bone marrow for
megablastosis. Unfortunately, because MS is not found in
blood, invasive tissue samples are needed with the liver
and bone marrow being the favourite organs. Because
invasive sampling has potentially devastating
consequences, only a small number of patients have been
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examined. In addition, the large variations that exist
between human MS activity has made calculation of the
average inactivation th difficult. For example, whilst
mean human MS th of inactivation by 70% N20 is 46 minutes,
its 95% confidence limits are 30 - 99 minutes (Royston and
others 1988). Another problem in assessing the clinical
importance of MS inactivation is how much MS must be
inhibited before any relevant clinical signs or symptoms
appear? It is possible that no detrimental effects will
occur even if most of the MS in the body is inhibited.
The extent of bone marrow megablastosis can be
assessed both by microscopy or by using the dU test. Again
an invasive marrow aspirate from either the sternum or the
iliac crest is needed and consequently, only a few
patients have been tested. A positive test indicates that
an effect detrimental to the patient has occurred.
However, other diseases can cause megaloblastosis and
therefore this test's specificity is poor. It is unable to
detect whether N20 has toxic effects prior to
megablastosis occurring and so suffers from a reduced
sensitivity. Other problems occur with microscopy because
of its subjective nature including the missing of minor
changes and making comparison between samples difficult.
The dU test is more objective and gives a quantitative
assessment of marrow depression. However, it is a
difficult assay to set up and each laboratory has its own
normal range making comparisons between studies difficult.
Normal values are often arbitrary with some laboratories
having a 10% dU limit. If the result is 9.9%, does this
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indicate pre-clinical toxicity or is the marrow normal?
Toxicity is not all or non, but a spectrum.
Because the main biochemical methods used to assess
N20 toxicity have only been able to examine small numbers
of patients, their results must be treated with caution.
Other biochemical assays have been used which are less
invasive although are also equally unsatisfactory.
Measurement of plasma methionine and S-adenosyl
methionine concentrations have already been discussed.
Short term anaesthesia (25 - 217 minutes) caused no change
to either although pre-operative starvation did decrease
methionine concentration (Nunn and others 1986). In
contrast, prolonged exposure (8 - 24 hours) reduced
methionine concentration to 15-25% of control values
(Skacel and others 1983). Anaesthetists exposed to N20
had normal concentrations (Nunn and others 1982). However,
other factors are important in methionine metabolism
including the individual's diet and the stress of surgery
and it is difficult to know the significance of this
reduction.
When MS is inhibited, plasma homocysteine
concentration may increase because it cannot be converted
to methionine. Bevan and others (1982) examined the urine
of 41 patients undergoing N20 anaesthesia (1 to 18 hour
duration) by collecting a sample voided after surgery. A
simple nitroprusside colorimetric test was used to measure
homocysteine. This reacts with disulphides formed from
the reaction of homocysteine and cyanide to give a magenta
colour with a positive test occurring if there is more
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than 0.12 juM.ml-1 homocysteine present. No colour change
occurred in any of the samples indicating no
homocystinuria. However, this test is relatively
insensitive and readily gives a false negative result. In
addition, homocysteine is metabolised in a variety of
other ways. Recently, a radioactive assay system for
accurately measuring plasma homocysteine concentration has
been descibed and this may allow the effects of long term
N20 exposure on homocystinuria to be studied (Cho and Hall
1988) .
Rask and others (1983) studied the effects of N20
upon methylmalonylCoA (MMCoA) mutase by looking at the
urinary excretion of methyl malonic acid in 5 patients who
had received 50% N20. Urine was collected for three 24
hours periods, before, during and after the operation.
Control values were found using haematology nurses. A dU
test performed after N20 ventilation was abnormal. Urinary
methyl malonic acid excretion increased 3 fold during N20
exposure becoming normal after N20 was stopped. However,
the control and exposed subjects were not comparable and
the increases in excretion could have been due to the
stress of the operation (open heart surgery) or to the
anaesthetic. MMCoA mutase was shown by Kondo and others
(1983) to be inhibited by N20 although only after
prolonged exposure (16 days). Therefore it is unlikely
that N20 affects this enzyme during a relatively short
anaesthetic.
Overall, the assays used to measure possible N20
toxicity are unsatisfactory being either clinically
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irrelevant, having an inadequate specificity or
sensitivity or requiring invasive sampling. As yet no
completely suitable assay system has been developed and
this is the rational for these series of experiments. It
is an attempt to find a repeatable, quantifiable and
meaningful method of assaying N20 toxicity in a variety of
exposed groups.
Because folate metabolism is the link between MS
inhibition and clinical toxicity, its concentration may
be used as an indicator of N20 toxicity. This should be
more sensitive at diagnosing clinical toxicity than bone
marrow tests because an abnormality in folate metabolism
will occur before the marrow is depressed. It may also be
of more clinical relevance than MS activity because folate
affects many different metabolic processes and any
abnormalities may indicate a derangement of bodily
function.
















How can folate metabolism be measured? Animal work
has shown the effects that N20 has on the concentration of
each folate co-enzyme. Total plasma folate concentration
measured in man progressively increases with increasing
N20 exposure (Skacel and others 1983). However, cellular
folate status is more important than plasma concentrations
and because tissue samples are too invasive for freguent
use another method of assessing cellular folate metabolism
is reguired.
Various tests have been used. Therapeutic trials with
oral folate were found to be too time consuming and it was
difficult to calculate an absolute folate deficiency
(Marshall and Jandl 1960). The plasma clearance and
urinary excretion of tritiated folic acid ( H-Folic acid)
allows folate deficiency to be diagnosed within 3 hours
although the test is relatively crude and too insensitive
to detect minor abnormalities (Sheehy and others 1962).
Other tests used include measuring the concentration of
urinary amino-imidazolecarboximine. Folate is essential
for converting this to AICAR and when there is a folate
abnormality it accumulates and is excreted in the urine
(Johns and Bertino 1965).
Another method of assessing folate metabolism is the
formiminoglutamic acid urine excretion test. This test
assesses the ability of the body to metabolise histidine,
a process which requires an intact folate metabolic
pathway. This test is able to indicate the functional
state of cellular folate metabolism with an increase in
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urinary formiminoglutamic acid excretion indicating an
abnormality in folate metabolism.
The Formiminoglutamic Acid Urine Excretion Test
In the late 1950's there was much research into
developing a suitable assay system to assess folic acid
deficiency. Measuring plasma folic acid blood
concentrations was time consuming and gave confusing
results because each laboratory used its own control
values (Stokstad 1943, Schweigert and others 1947, Usdin
and others 1956, Chanarin 1958). Another method was to
measure gastrointestinal absorption of folic acid
(Chanarin and others 1958). However, it became apparent
that the only reliable diagnostic test was a clinical
trial whereby the patient was given folic acid and his
clinical progress charted. This was a laborious and time
consuming process.
However previous work suggested there might be
another possible assay system to measure folic acid
deficiency in vivo. Bakerman and others (1951) noticed
that rats deficient in folic acid excreted large amounts
of a glutamic acid precursor in the urine which if heated
allowed a bacteria, Lactobacillus arabinosus, to grow.
Further work showed that this urinary compound was
formiminoglutamic acid (Silverman and others 1952, Tabor
and others 1953, Borek and others 1953, Seegmiller and
others 1954, Broquist and Luhby 1959).
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Formiminoglutamic acid (FIGlu) is a small, water
soluble molecule (mol. weight 183). Structurally, it
consists of a glutamic acid moiety with a formimino group










FIGlu excretion was proportional to the severity of
folic acid deficiency. Tabor and others (1953) used 15N-
histidine to show that 55% of body histidine was converted
to glutamic acid with the nitrogen on the amino group of
FIGlu coming from the imidazole ring of histidine. This
catabolism occurred in both bacteria and liver extracts.
An intermediate in the pathway was urocanic acid and
further work discovered the histidine catabolic pathway
(Slavik and others 1954, Tabor and Mehler 1954, Sagers
and others 1956, Tabor and Rabonowitz 1956, Miller and
Waelsch 1956, 1957).
histidinase Urocanase imidazolone-proprionate hydrolase
HISTIDINE > UROCANIC ACID > 4-IMIDAZOLE,5-PROPRION IC ACID > FORMIMINOGLUTAMIC ACID
It was noticed that THF was necessary to convert
FIGlu into glutamic acid by accepting its formimino group
in both mammals and bacteria. The enzyme FIGlu transferase
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Histidine, an amino acid, is essential for infants
(Snyderman and others 1963 ) , but not adults (Rose and
others 1951) . It is catabolised in a variety of ways
(Stifel and Herman 1971) although the most important
pathway is to FIGlu. Others include;
1) Decarboxylation to histamine, then oxidation to
imidazoleacetic acid.
2)Transamination to imidazolepyruvic acid, which
is reduced to imidazoleacetic acid. This is the
second major pathway of degradation.
3) Methylation to 1 or 3-methyl histidine.
4) Condensation of histidine or methyl histidine
with B-alanine to form carnosine or anserine
respectively.
It was considered that measurement of urinary FIGlu
excretion would be able to quantify the folic acid
metabolic state in humans because shortage of THF causes a
buildup of FIGlu. Being water soluble, this compound is
excreted in the urine. Initial evidence supported this
view. Leukaemic children prescribed a folic acid
antagonist had an increased urinary excretion of
glutamate activity which decreased when the antagonist was
stopped (Broquist 1956). Luhby (1957) showed a similar
increase in a pregnant lady with macrocytic anaemia that
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decreased with folic acid therapy. Further work confirmed
these observations (Luhby and others 1958) and that the
increase in glutamate activity was caused by an increase
in FIGlu concentrations (Broquist and Luhby 1959) .
In early studies of folic acid deficient people it
was common to see very low urinary FIGlu excretion even if
a haematological response had occurred after folic acid
supplementation. This was possibly because of a shortage
of histidine in the body. To overcome this, metabolic
loading with oral histidine was tried. Patients swallowed
histidine monochloride in large doses. Because the average
daily histidine intake is 0.5-2.0 gm (Orr and Watt 1957),
greater amounts will allow any dietary variations to be
ignored. With 15 gm oral histidine given daily for 48-72
— 1
hours, normal patients excreted less than 0.15 ^mol.ml
FIGlu compared to those with a folic acid deficiency.
These patients had a 3 to 1000 fold increase in excretion.
The urine was collected over 24 hours (Luhby and others
1958 , 1959b) .
Hence, it appeared that histidine loading made the
test more sensitive. Various regimes were tried using
different amounts given either once or in divided doses.
With no loading folic acid deficiency can only be
diagnosed if urinary FIGlu concentration is greater than
0.05 jumol.ml-1 (Luhby 1960). Doses of 15 gm daily in 3
divided doses 4 hours apart was the most specific method
of assessment although it was accompanied by a high
incidence of nausea and vomiting. (Luhby and Cooperman
1964). Doses greater than 25 gm in normal subjects for
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several days resulted in abnormally high FIGlu excretion
presumably due to an overloading of the catabolic pathway
(Luhby and Cooperman 1959) . Doses of 10 to 20 gm allowed
folic acid deficiency to be diagnosed when there was
little or no megaloblastosis present in the marrow (Luhby
and others 1958, Luhby and others 1959).
After histidine ingestion any FIGlu produced is
mostly excreted within 8 hours. It takes 2 hours before it
appears in the urine with a peak excretion at 6 hours.
Only small amounts are excreted after this (Kohn and
others 1961, Chanarin and others 1962, Knowles 1962,
Knowles and others 1961). Therefore, the most efficient
collection period is 8 hours after loading. Histidine
monochloride when dissolved in water has an unpleasant
taste, similar to that of stagnant water. It is also
poorly soluble with its crystals dissolving slowly
(Chanarin and others 1963). The best method to give it is
in warm water or orange juice.
Chanarin and others (1963) and Davis and Kelly
(1963) showed that urocanic acid was often excreted in
large quantities in the urine in addition to FIGlu.
However there appears to be little correlation between
folate deficiency and urocanic acid excretion (Knowles
1961). Perhaps the raised urocanic acid excretion found by
these investigators was due to a buildup in the metabolic
pathway of histidine. Alternately there could be a
decrease in liver urocanase activity due to an inhibitory
feedback mechanism by FIGlu (Baldridge 1958). Thirdly, it
could be an artifact of the enzymatic assay used to
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measure FIGlu because histidinase is often present in the
enzyme preparation and this enzyme could metabolise any
histidine present in the urine.
The clinical application of this test was not used
immediately because measuring urinary FIGlu is difficult.
There are now 4 main measurement techniques, all of
varying complexity and sensitivity. They are
microbiological, electrophoretic, enzymatical and
chemical.
1)Microbiological Assay
When Lactobacillus arabinosus is grown in a synthetic
broth containing all required growth factors except
glutamic acid, any growth occurring is related to the
amount of glutamate (glutamic acid or glutamine) added
(Henderson and others 1948). FIGlu causes no growth
unless heated because it then decomposes to glutamic acid
(Silverman and others 1952). Hence the urinary
concentration of FIGlu can be found by measuring growth
when heated urine is added. Heated urine is added to the
broth and L.arabinosus growth is measured using the
turbidity of the solution. Normally, urine contains 400%
more glutamine than glutamic acid and when this is heated,
it degrades to pyrollidone carboxylic acid. This does not
support growth and hence the ratio of glutamate activity
of heated to unheated urine (H/U) is usually about 0.3.
However, if FIGlu is present this ratio increases and
values greater than 0.9 are considered significant
(Broquist and others 1959). Controls have been found
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using this assay on normal patients and on two folic acid
deficient patients, a child with acute leukaemia treated
with anti-folate drug and a pregnant women with macrocytic
anaemia. Both had an increase in the H\U ratio.
To perform the assay, urine is sterilised by
filtration and two aliquot taken, one being heated. They
are added to samples of the broth and growth assessed.
Standards can be found using known amounts of glutamic
acid. The test is reasonably specific and reproducible, is
moderately easy to perform, although it is an indirect
assay. Its sensitivity is moderate being able to measure
FIGlu concentrations of 10 /ig.ml-1. Disadvantages include
the time taken to complete the assay (96 hours) and colour
in the urine can influence the test, although activated
charcoal will remove most of the colour compounds.
Additionally, with a low urine glutamine content, high H/U
ratios can be found even when FIGlu concentrations are
low.
A modification of this test by Davis and Onesti
(1960) gives a greater sensitivity but it still requires 6
days to complete. They allowed L.arabinosus to grow for a
day with the addition of unheated urine to extract all the
glutamate activity. The bacteria were removed by
centrifugation, the sample reheated and re-assayed. The
sensitivity is about 5-10 /xg.ml-1.
2) Paper Chromatography
FIGlu moves faster than glutamic acid or glutamine in
a descending solvent front paper chromatography. Tabor and
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others (1954) took 18 hours to estimate FIGlu content
with chromatography. FIGlu has no free amide groups but if
exposed to ammonia vapour, the formimino group is
displaced and ninhydrin can colour exposed ammonia
radicals. This allows FIGlu to be differentiated from
glutamic acid by comparing two samples. However it has a
poor sensitivity of 20-50 ngm.ml-1 (Luhby and others
1959) .
Other types of chromatography have been developed.
High voltage electrophoresis uses 6000 volts with a
current of 80 milliamperes to give a sensitivity of 10
jLtgm.ml-1 (Knowles and others 1960) . However, it is
expensive, requiring specially constructed apparatus. In
1962, Knowles and Prankerd using a loading dose of 20 gm
histidine showed that in 18 patients with both a presumed
deranged folic acid metabolism and a vitamin B12
deficiency, only 11 had an increased urinary FIGlu
excretion and with vitamin B12 treatment all but 1 of
these returned to normal.
Conventional electrophoresis uses a lower voltage of
200-500 volts (Kohn and others 1961a, 1961b). Folic acid
and vitamin B12 deficient patients were given a loading
dose of 15 gm histidine and urine was collected for 5
hours. All folic acid deficient patients had increased
FIGlu excretion. Similarly, 4 out of 15 vitamin B12
deficient patients also showed an increase. Because FIGlu
separation from glutamic acid can be incomplete,
conventional electrophoresis with an elution assay has
been developed. FIGlu was converted to glutamic acid using
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alkaline hydrolysis after electrophoresis and this is
stainable by ninhydrin (Zalusky and Herbert 1962). Two
samples, one having been hydrolysed, are assayed and the
colours compared. Using this, patients were loaded with 20
gm oral histidine and their urine was collected over 12
hours in 2 ml concentrated HCL. Six controls excreted a
mean of 19 mg of FIGlu compared to 561 mg in 8 patients
with folic acid deficiency and 288 mg in 7 patients with
vitamin B12 deficiency.
Knowles (1962) examined patients with steatorrhoea by
giving them a 20 gm histidine loading dose. Using both
high and conventional voltage electrophoresis, he showed
that the high voltage technique was superior in detecting
raised FIGlu excretions and confirmed that minor folic
acid deficiency occurs with this disease. Additionally, he
showed that FIGlu appears in the urine within 2 hours and
peaks at 5-6 hours and is hardly present after 12 hours.
3) Enzvmic Assay
If urine is incubated with THF and a semi-purified
liver concentrate, 2 enzymes, THF transferase and
cyclodeaminase, will convert FIGlu to 5,10-MethenylTHF
(Tabor and Rabinovitz 1956). This undergoes spontaneous
non-enzymatic conversion to 10-FormylTHF. Acidification
converts it back to 5,10-MethenylTHF.
FIGlu Transferase
FIGlu + THF > Glutamic acid + 5 FormiminoTHF
Cyclodeaminase
5 FormimnoTHF > 5,10-MethenylTHF + NH3
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5,10-MethenylTHF + OH < > 10-FormylTHF + H+
Because 5,10-MethenylTHF has a peak absorption at 350
m/x, its concentration can be found spectrophotometrically
using standard solutions (Tabor and Wyngarden 1958). This
method is sensitive taking only a relatively short time.
However, production of the enzymes is both time consuming
and difficult. The solution is often impure containing
contaminants including histidinase and urocanase which
will metabolise any urocanic acid or histidine. Therefore
urinary FIGlu measurements will tend to be greater than
the true amount. Carter and others (1961) investigated
FIGlu excretion in patients with hepatic cirrhosis
collecting 24 hour urine samples for 5 days. The urine was
stored in 20 ml concentrated HCL. Subjects received no
histidine on day 1, 15 gm in 3 doses on day 2, nothing on
day 3 and 15 gm with 20 mg folic acid on days 4 and 5.
Those with hepatic cirrhosis had raised FIGlu excretion
which was unresponsive to folic acid.
Modifications of this assay have been described.
Silverman and others (1958) used it combined with a
microbiological assay. They enzymatically converted FIGlu
to 10-FormylTHF and then ascorbic acid changed this to 5N-
FormylTHF. This was measured using a microbiological assay
performed simultaneously on both heated and unheated urine
and FIGlu concentrations were calculated by subtracting
the two results. However the test is time consuming
taking over 36 hours and it has a poor specificity
especially if the enzyme preparation is impure. However it
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has a good sensitivity of 1-5 /zm.ml .
Chanarin and Bennett (1963) further modified this
technique by measuring the amount of 5,10-N MethenylTHF
that had been converted from 10-N FormylTHF by
acidification. Two assays were done on heated and unheated
urine. The test can be performed in a day, but it is only
20% as accurate as the method of Tabor and Wyngarden and
has the same problems as the Silverman assay.
4)Chemical Assay
Two methods have been used. Alkaline ferricyanide-
nitroprusside turns red with reducing agents. Whilst
FIGlu will reduce it (Tabor and Wyngarden 1958), so will
many other urinary compounds (histidine, ascorbic acid,
etc) and so it has a poor specificity. Its main advantage
is speed because the reaction is rapid and the colour
intensity can be found immediately. Naphthoquinone-4-
sulphonate turns reddish-brown with imino compounds.
Again, it has a poor specificity because it can also react
with amino acids. Because it reacts with FIGlu it can be
used instead of ninhydrin to identify FIGlu in a
chromatography assay.
In conclusion, the most sensitive method of
measuring FIGlu is enzymatic, although it can be
inaccurate especially if the enzyme preparation is impure.
FIGlu is unstable in urine with a pH greater than 5 (Luhby
and others 1959) and it rapidly decomposes to glutamic
acid at room temperature and even at -20 °C can only be
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kept for a short time. However at pH's of 2 or less it
remains stable even at room temperature for months.
Addition of 1ml concentrated HC1 per 100 ml urine will
reduce the pH to below 2 and therefore preserve FIGlu
(Chanarin and Bennett 1962, Carter and others 1961,
Zalusky and Herbert 1962).
There is no definitive test procedure. One
recommended method is to give 15 gm oral histidine
monochloride, and collect all urine for the next 8 hours.
The patient empties his bladder before ingestion and urine
is then collected in 5 ml concentrated hydrochloric acid
(British Medical Journal 1969).
FIGlu excretion in 94 healthy people without
histidine loading was measured using the modified
enzymatic method of Tabor and Wyngarden (Rosenauerova-
Ostra and others 1976) . Sex had an insignificant effect
but short term calorie restriction did decrease FIGlu
excretion. Age had a small difference, with the 40 - 50
age group excreting slightly more FIGlu than either
younger or older subjects.
Other diseases may increase FIGlu excretion. Liver
disease (Carter and others 1961, Nigro 1967) and
sarcoidosis increase it, probably due to a reduction in
formimino-transferase enzyme concentration (Kohn and
others 1961b). Patients with iron deficient anaemia also
have raised excretion (Chanarin and others 1962).
What is the significance of this test? Examples have
been given demonstrating its usefulness in detecting a
functional deficiency of folate (Kohn and others 1961,
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Chanarin and others 1962) . This test does not assess
total folate deficiency, only that of one co-enzyme,
THF. When folate concentrations are normal, but urinary
FIGlu excretion is increased, the test suggests an
abnormality of folate metabolism associated with
insufficient THF.
This test may be used to investigate the toxic
effects of N20 on vitamin B12 • N2° wiH decrease THF
concentrations and so increase urinary FIGlu excretion.
This test is different to the other assays because it
examines the intermediate phase between MS inhibition and
marrow depression. It is therefore more sensitive than
marrow or blood examination and because folate metabolism
is important, abnormalities in it are more clinically
relevant than MS inhibition. Therefore, this test has both
increased sensitivity and clinical relevance to the toxic
effect of N20. A further advantage is that it is
relatively non-invasive, requiring only the ingestion of
an amino-acid and the collection of urine.
The assay has previously been used to investigate N20
toxicity in 3 studies. Rats were exposed to 50% N20 in
oxygen for 24 hours and their urine collected. Prior to
exposure, one group was given 250 nmol L-methionine in 0.5
ml saline and the other group saline alone. Two extra
control groups exposed only to air excreted no FIGlu. The
methionine N20 exposed rats excreted a mean of 3 6.5 (SE
6.7) jitmol FIGlu compared to 52.2 (SE 7.5) /xmol in the N20
saline group (Deacon and others 1983). Therefore, rats
exposed N20 have an increased FIGlu excretion even if no
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histidine is given. Methionine decreased the amount
excreted as was expected (Silverman and Pitney 1958,
Herbert and Sullivan 1963).
A recent study examined FIGlu excretion in rats of
different ages (Koblin and Tomerson 1990). The urine of
young, middle aged and old rats exposed to 60% N20 for 6
hours was collected. All had increased FIGlu excretion on
the day after exposure, returning to normal on the second
day. The older the rat, the greater the excretion.
It is possible that N20 could affect FIGlu
transferase enzyme and this could cause increases in FIGlu
excretion although exposure of rats to 50% N20 for 10 days
had no effect on its activity (Perry and others 1980)
suggesting that increases in FIGlu occurs due to an effect
on folate metabolism.
Hawkins and others (1987) assessed FIGlu excretion
in 6 healthy volunteers anaesthetised with 70% N20 in
oxygen at 2 atmospheres (a total of 2.2 - 4.9 atm. hours
N20 exposure which is equivalent to 70% N20 for 3.1 to 7.0
hours). They were given a histidine load daily for 2 days
before and several days after exposure and urine was
collected every 8 hours. FIGlu was converted to glutamate
and this was assayed enzymatically. Two subjects had an
increase in FIGlu excretion after exposure. The study did
not state the sensitivity of the method used to measure
FIGlu or the dosage of histidine given. In addition, it is
difficult to extrapolate this result to a clinical
situation because it is possible that the added stress of
surgery may have a cumulative effect on N20 toxicity.
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Cancer and folate deficiency
Folate deficiency is associated with malignant
disease (Chanarin 1979) for several reasons including poor
dietary intake and increased folate utilisation by
malignant cells (Saleh and others 1982). Another reason
may be impaired synthesis of folate enzymes (Davis 1986).
The serum folic acid activity in patients with both
leukaemia and cancer has been found using the L.casei
_ 1
assay. In controls it is 2.5 to 7.5 (mean 4.6) jug. ml
whilst in malignant tumours is 1.1 to 8.5 (mean 2.3)
— 1 • — 1
jug. ml and m leukaemias 0.8 to 7.0 (mean 2.7) jug. ml .
Overall, it is significantly lower in patients with
malignancies (Rama Rao and others 1965). Therefore it
appears that cancer has a deleterious effect on folate
activity. Measurement of serum and red blood cell folate
concentrations indicated they were normal in patients with
localised cancer, but low if there was metastatic disease
(Magnus 1982).
Does this abnormal folate activity cause an increased
excretion of FIGlu? Seventy patients with neoplastic
disease were loaded with 20 gm oral histidine and all
urine produced for 8 hours collected. FIGlu concentrations
were found by converting it to glutamate by heat and using
electrophoresis. Controls excreted 0-30 (mean 10.5, SD
9.8) jumol whilst patients with malignancy excreted up to
25 times more with 49% excreting concentrations greater
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than 30 iimol (mean 66, SD 118) . Ten patients had cancer of
the lung and of these, 5 had raised excretions. One had
cancer of the oesophagus and a raised excretion (Carey and
others 1964). A similar increase in FIGlu excretion was
seen in patients with carcinoma (Noeypatimanond and others
1966). It therefore appears that many patients with
malignancy have raised FIGlu excretion and have
abnormalities of folate metabolism.
Are patients more susceptible to N20 if they have a
malignancy? It is possible because N20 effects on the
folate pathway may be additive. The uptake and utilisation
of the various folate co-enzymes by tumour cells is
similar to that of rapidly replicating cells. Therefore
individuals with cancer exposed to N20 may have similar
effects to patients with rapidly growing tissues (pregnant
women, young children, patients recovering from trauma,
etc) . These groups of patients are ethically more
difficult to study and it may be possible to extrapolate
results from cancer patients to them. This maybe a simple
method of assessing the possible dangers of N20 on these
types of individuals.
Thesis experiments
This thesis uses the FIGlu test to examine the
possible toxicity of N20 inhalation that may occur in a
variety of situations. A suitable FIGlu assay system has
been developed with a standardised histidine loading and
urine collection system. Five groups have been examined;
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1. Normal subjects, not exposed to N20
2. Subjects receiving a N20 anaesthetic for limb
surgery
3. Subjects not receiving a N20 anaesthetic for
limb surgery
4. Subjects with oesophageal and bronchial
carcinoma receiving a N20 anaesthetic
5. Anaesthetists exposed chronically to N20
pollution.
The first group was studied in order to find normal
excretion values and to compare these to other studies.
The second group examines the effects of N20 anaesthesia
upon patients to see if there is a possible undetected
toxic action. Group 3 acted as controls for group 2 to
ensure that surgery itself had no effect. Group 4 was
studied in order to examine a high risk group and see if
there was an increase in excretion greater than that seen
in normal risk patients. Finally, group 5 was used to
assess the risk to anaesthetists who were exposed to N20
in their everyday work.
From these experiments, it was hoped to obtain a
better understanding of the possible toxicity of N20 on
the vitamin B12/folate metabolic pathway in a variety of





Each of the studies described in this thesis has
received full approval from the local Anaesthetic Ethics
Committee. All subjects gave full informed consent and all
were told of their right to withdraw.
The description of the methods used is in three
sections. Firstly, the assay system developed for
measuring urinary FIGlu concentration in the urine will be
described. The second section will explain how the
formiminoglutamic acid (FIGlu) urine excretion test was
performed and the third part will define the experiments
on the different subject groups.
THE FIGlu URINE EXCRETION TEST
A. ASSAY SYSTEM
The most accurate and simplest method of measuring
urinary FIGlu is the spectrophotometric enzymatic method
of Tabor and Wyngarden (1958) because all the other
techniques have problems. Some take too long to complete,
some require expensive equipment and others are
insufficiently sensitive to detect small amounts of FIGlu.
The enzymatic method has been modified because pure
enzymatic solutions are now commercially available. Tabor
and Wyngarden in their description of the enzymatic method
obtained the FIGlu converting enzymes from purification of
homogenised hog liver. However, this method is
complicated, time consuming and produces an impure
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preperation with many contaminants which include urocanase
and histidinase. These decrease the overall assay
specificity because any histidine or urocanic acid that is
present will be converted to FIGlu and then measured.
Therefore, a pure enzyme preperation was used in these
experiments. Other chemicals required included THF and
FIGlu.
1. Enzymes. The two converting enzymes, FIGlu
transferase and formiminoTHF cyclodeaminase can be bought
in pure form (Sigma Chemicals). The enzymes are stored as
crystals and when needed were dissolved in a buffer
solution (1 M K2HP04, pH=7.2). The activity of this
solution can be changed by altering either enzyme
concentration or the duration of the reaction. The
standard reaction rate used in the experiments was that
obtained when 100 jul of enzymatic solution reacted with
the standard reagents described below to give an optical
density reading of 0.8 - 1.2 when a known FIGlu
— 1
concentration of 0.1 /imol.ml was added. The enzymatic
concentration giving this absorbency was found to be 25
_ 1
,
IU.100 ml if the reaction time was for 4 hours.
2. Tetrahydrofolic acid. A tetrahydrofolic acid (THF)
solution was obtained by dissolving 88 mg of pure THF
(Sigma Chemicals) in 18 ml 1.1 M mercaptoethanol (to
prevent THF being oxidised) and 2 ml 0.2 N potassium
hydroxide. This solution has a concentration of 4.4 mg or
— 1 . . .
approximately 7-10 jumol.ml THF. It retains its activity
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for over a year if frozen at -20°C in the dark. THF assay
reagent was made by adding 10 ml of this THF solution to
10 ml of buffer (1 M K2HP04, pH=7.2) and 35 ml of
distilled water. This volume is sufficient for 100 tests.
3. Formiminoglutamic acid. FIGlu (Sigma Company) was
made up into 8 different concentrations in distilled
water. Five were used as standard concentrations to draw a
standard concentration/optical density curve. The other 3
were made into pools for testing the reproducibility of
the different assay batches. The solution is highly stable
if frozen at -20°C. The 5 concentrations used for the
standard curve were 0.02, 0.05, 0.1, 0.15 and 0.2
_ "I
jiimol.ml .
4. Urine samples were prepared for the assay by
thawing batches overnight, fully mixing each sample by
agitation and then centrifuging them at 6,000 rpm for 10
minutes to precipitate any solid material. The supernatant
was pipetted off.
5. Assay system. Each sample was assayed in duplicate
and the mean absorbency found. If the difference in
absorbency of any 2 samples was greater than 10% they were
re-assayed. Each sample (including standards, pools and
urine) was assayed twice, once with enzyme added (sample)
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and once with distilled water added (control). Subtracting
the absorbancy values allowed for any differences in
sample absorbency due to urine, etc. All samples were
placed in 3 ml test tubes. In addition to all these
samples, the absorbency for the enzyme (enzyme control)
was found using enzyme blanks (no test sample added). Each



















Total volume 900 900 900 900
The samples were agitated to ensure good mixing and
left in a warm (25°C) dark place for 4 hours. Then, 300 /i 1
of 10% perchloric acid was added to stop the reaction and
the samples left for a further 2 hours, completely mixed
and the absorbency of each sample found using an
ultraviolet spectrophotometer at an absorbency of 350 jum.
Quartz curvettes were used for the samples. Calculation of
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the concentration of FIGlu present in each sample was as
follows.
1. Add each duplicate sample and divide by 2
2. Calculate enzyme blank absorbency;
Enzyme sample - enzyme control
3. Subtract 2 from all other values
4. Subtract for each standard and urine sample;
Sample - control
5. Plot standard curve for the 5 known FIGlu
concentrations
6. Read other values off curve
The total FIGlu excretion for each urine sample was
found by multiplying the concentration of the FIGlu
(jumol.ml-1 urine) by the volume of urine collected (ml).
The linearity of the assay extended beyond the
working range required, and the absorbency of a standard
FIGlu solution agreed well with the calculated target
value. The within-assay and between-assay coefficients of
variation were 8% and 10% respectively.
B. THE FIGLU EXCRETION TEST
1. Histidine
Histidine was obtained in a pure crystalline form as
histidine monochloride. One gram contains 0.74 gm
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L.histidine. The oral histidine loading dose used was 10
gm histidine monochloride (= 7.4 gm histidine).
Because it is sparingly soluble in cold water and
requires stirring to fully dissolve it, warm water was
used. However, it has a particularly unpleasant taste
although dissolving it in 50 ml orange juice masked this.
The subjects swallowed it in one mouthful immediately
after it had dissolved. The hospital subjects swallowed
the histidine in the morning. All subjects received oral
histidine on each consecutive day of the study.
2. Urine collections
Urine was collected in large (2 litre) plastic
containers to which 5 ml concentrated hydrochloric acid
had been added. The bladder was emptied after histidine
ingestion and any urine produced over the next 8 hours was
collected with the bladder being emptied at this time. The
volume of each specimen was measured and aliquots taken
and stored at -30° C for analysis later.
EXPERIMENTAL DESIGN
There were 5 sets of experiments on 5 different
groups of subjects. All subjects were aged between 18 and
65 and all were ASA grade I and II. None had any evidence
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of hepatic or renal disease. All had full biochemical and
haematological testing which included urea and
electrolytes, liver function tests, blood proteins,
creatinine, haemoglobin, platelet and leukocyte counts
with a blood picture, folate (plasma and red blood cell)
and vitamin B12 concentrations. The 5 groups were;
1. Ten volunteers who were not exposed to N20 were
studied over 5 consecutive days. None had been exposed to
N20 for at least 1 month. This was the control group and
normal FIGlu excretion for this experimental system was
established.
2. Fifty subjects undergoing general anaesthesia for
at least 60 minutes for limb surgery. These subjects were
studied over 6 days. The initial FIGlu excretion was found
on the day before surgery and continued on the day of
surgery and for the next 4 days. Full haematological
investigations were carried out on the 1st and 4th post¬
operative days. Twenty mg temazepam was given orally as
pre-medication 1 hour before induction, which was with
. — 1
approximately 4 mg.kg thiopentone and 70 mg
suxamethonium for tracheal intubation. Anaesthesia was
maintained with 70% N20 in oxygen, enflurane being given
as reguired. The duration of N20 inhalation was noted.
Papaveretum (10-20 mg) was given intravenously and also
used intramuscularly in the same dosage for post-operative
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pain relief.
3. Five subjects receiving no N20 for limb surgery
of at least 60 minutes duration. They were studied in a
similar manner as the subjects in group II, except instead
of a general anaesthetic they received either a
subarachnoid or epidural anaesthetic with 0.5% bupivacaine
heavy or 0.5% bupivacaine plain respectively. Intra¬
operative sedation was with midazolam as required.
Postoperative pain relief and investigation was as for
group II.
4. Twenty subjects, 10 with oesophageal cancer (Group
4a) and 10 with bronchial cancer (group 4b) were studied.
Both the timing and dose of histidine given were the same
as for Group II. The method used for anaesthesia was
standardised and consisted of a premedication of temazepam
— 1
20 mg with thiopentone 4 mg.kg , suxamethonium 70 mg for
induction. Anaesthesia was maintained using N20 in oxygen,
enflurane, morphine 10 mg and an atracurium infusion of
— 1 . .
0.5 mg.hour . Up to 70% N20 was given depending upon the
patient's arterial oxygenation. Total N20 exposure
(calculated as hours of 70% N20) was noted. Postoperative
pain relief was provided by a morphine infusion of
— 1 ...
1 mg.hour with an extra 2.5 mg IM as needed. Histidine
was given daily down the nasogastric tube. Subjects
undergoing thoracotomy for lung carcinoma received a
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similar anaesthetic.
5. Ten anaesthetists exposed to N2O pollution during
their normal work were studied. All were male, aged 24 to
31 and had worked as full time anaesthetists for at least
6 months. They were all healthy. They were studied over 7
consecutive days which included a normal working week and
a weekend when they were not in theatre. The mean
concentration of each anaesthetist's daily exposure to N20
was found using personal passive diffusive samplers. These
allow N20 to enter but not leave and they provide a time
weighted average exposure (Gray 1989) when worn on the
lapel throughout theatre exposure. At the start of the
list, they were uncapped and then recapped at the end. The
time that they were open for was recorded. Measurement of






Subject data for age, weight and sex for group 1 are
shown in table II. The mean age of group 1 was less than
that of the other groups (Students unpaired t test)(Table
VI). All 10 control subjects who had had no N20 exposure
had normal biochemical and haematological results. The
mean red blood cell and plasma folate concentrations were
452.6 and 4.3 ng.ml-1 (SD 168 and 1.2 ng.ml-1)
respectively. The mean vitamin B12 concentration was 557
pg.ml-1 (SD 170 pg.ml-1). All were within normal limits.
All the control subjects excreted formiminoglutamic
acid (FIGlu) on each of the 5 days (Table VII, Fig.5). The
total mean excretion for all 5 days (50 samples) was
26.99 jumol (SD 21.95, 95% CI 20.8-33.3). However,
excretion varied greatly ranging from 0.33 to 74.32 jumol.
The mean daily total excretion of FIGlu for all the
subjects was similar on each of the 5 days (ANOVA) .
Because no cumulative effect was seen, it indicates that
the histidine loading dose used in these experiments did
not saturate the catabolic system when given for 5 days
(Table XVII). The total mean excretion of each individual




Sixty six patients who received a N20 anaesthetic for
limb surgery were studied. Sixteen were withdrawn from
the trial; 9 due to severe nausea postoperatively
preventing histidine ingestion, 4 due to errors in urine
collection, 1 due to early hospital discharge, 1 because
the patient required re-operation and 1 due to failure to
prescribe histidine correctly. Subject data is in table
III. The subjects wre older than the control group 1
subjects (Students unpaired t test, p<0.001, Table VI).
The other groups are comparable to group 2.
The 50 subjects who completed the trial had the
following operations; 17 total hip, 11 elbow and 15 knee
replacements, 5 ankle and foot operations and 2 removal of
infected plates. Duration of N20 inhalation was from 54 to
312 minutes with a mean of 132.3 minutes (SD=56.5)(Fig.6).
Pre-operative biochemical and haematological
screening was normal for all patients except in one
individual who had a low vitamin B12 concentration (194
jumol with normal > than 220) . Blood samples on the 1st and
4th postoperative days were all normal with no evidence of
marrow depression. All urine samples contained FIGlu
(Table VIII-XIII, Fig 7). On the preoperative and
operative days (days 1 and 2) all patients except for a
different individual on each day excreted FIGlu within the
control range (Tables VIII and Villi) . Mean FIGlu
excretion for these two days was 24.8 (SD 22.3, 95% CI
18.4-31.1) and 28.9 (SD 23.6, 95% CI 22.2-35.6) jumol
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respectively (Table XVII). These concentrations are
similar to those found from control group 1.
FIGlu excretion was increased on the first
postoperative day (day 3) with 22 patients excreting more
than 69.8 jumol (i.e. the mean + 2SD those of the control
group) (Table X) . There was a statistical difference
between amounts excreted on this day and those in the
control group 1 (unpaired Students t test p<0.0001). The
range of FIGlu excretion was great with a mean of 78.21
(SD 67.38, 95% CI 52.7-103.7) M^ol (Table XVII). There was
a decrease in the number of high FIGlu excretors on the
next day (day 4) with 12 individuals excreting more than
70 nmol (Table XI). There was still a statistical
difference between this and control values (p<0.0001 with
t test). Mean excretion was 61.52 (SD 50.98, 95% CI 42.2-
80.8) jumol (Table XVII).
FIGlu excretion returned to that for the pre¬
operative controls on the following two days (days 5 and
6) with 3 and no subjects respectively excreting more than
70 jumol (Tables XII and XIII) . The means (SD, 95% CI) were
25.49 (21.11, 22.4-37.2) and 29.80 (18.92, 24.1- 39.5)
/jmol (Table XVII) .
The patients who excreted FIGlu in greater amounts
were exposed to N20 (mean 158.6, SD 64.6 minutes) for
longer than normal patients (mean 113.3, SD 44.7
minutes)(Students unpaired t test, p<0.008). No patient
exposed to 70% N20 for less than 90 minutes had an
increase in FIGlu excretion whilst all exposed for more
than 211 minutes had increased excretions. For inbetween
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exposures, a similar number of individuals had raised and
normal excretions (Fig 8).
The patient with a low vitamin B12 concentration had
normal FIGlu excretion throughout. The 22 subjects with a
FIGlu excretion of greater than 70 jumol on day 3 had
similar plasma and red blood cell folate and vitamin B12
concentrations when compared to the lower group.
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Group 3.
The local anaesthetic group had 3 total hip and 2
knee replacements. Subject data is in table IV; they were
older than the control group 1 (Students unpaired t test,
p<0.001) but were similar to the other groups. All had
normal biochemical and haematological results. Surgical
duration was similar to that of group 2 and it lasted for
a mean of 111.4 minutes (SD=33.1).
Again all excreted FIGlu daily (Table XIV, Fig 9).
Excretion on the 1st day was similar to the control group
1 subjects and it stayed within this range over the next 5
days (t test comparison to control excretions)(Table
XVII). There was no statistical increase in excretion on
any of the study days including day 3 and 4 (ANOVA).
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Group 4.
Twenty patients were studied. Ten in group 4a
underwent operations for lung tumour (7 adenocarcinoma and
3 with oat cell carcinoma) and 10 in group 4b underwent
resection for oesophageal tumour. There were no
withdrawals from the trial and all had a thoracotomy.
Patient data is in Table V. The ages were greater than
group 1 (Table XVII) but were comparable to the other
groups. Weights were slightly less than other groups, but
not statistically significant. Preoperative haematology,
plasma folate, red blood cell folate and vitamin B12
concentrations were all normal. Biochemistry was normal in
group 4a whilst in group 4b, there was a non-significant
reduction in the concentration of total plasma proteins
(0.71gm.ml-1) and albumin (0.34gm.ml-1).
All excreted FIGlu on each of the 6 days (Tables XV
and XVI) . Excretion of FIGlu for each of these 2 groups
was similar on each day (Students unpaired t test) (Fig.
10, 11). Whilst mean total excretion (41.8, SD 26.2, 95%
CI 29.5-54.0) for both groups on day 1 was raised when
compared to group 1, it was not statistically significant
(Table XVII). Similar excretions were seen on day 2. In a
similar manner to group 2, there was an increase in
excretion on the next 2 days the mean being 60.4 (SD 43.8,
95% CI 40.0-81.0) and 53.1 (SD 35.1, 95% CI 36.7-69.6)
respectively. There is no statistical significance in
these increases. On day 3, 4 individual (2 in both groups)
excreted significantly more (mean + 2SD) than on day 1.
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Similarly for day 4 with 4 individuals, 3 being the same
as for day 3 (1 in group 4a and 3 in group 4b) . The
excretion returned to day 1 levels on day 5 and day 6
(mean, SD and 95% CI respectively 36.8,22.7, 26.2-47.4 and
37.1,21.5, 27.0- 47.2).
The duration and concentration of N20 exposure varied
with the operations. Oesophageal surgery took longer than
lung surgery with a calculated exposure to 70% N20 of 154
(SD 42) minutes when compared to 96 (SD 32) minutes for
lung surgery. Three patients undergoing lung surgery
received small amounts of N20 (12, 18 and 24 minutes of
70% N20). All had normal excretion on each of the 6 days.
All of the 3 individuals with greatly increased FIGlu
excretions were exposed to N20 for longer periods (172,
164 and 173 minutes).
141
Group 5.
All anaesthetists had normal biochemical and
haematological values. Table XIX shows the time weighted
exposure of each of the anaesthetists for each day of the
working week. The mean exposure of each individual ranged
from 53.4 to 159.2 ppm. Four had no exposure to N20 on one
day of the experiment due to work with only local anaes¬
thesia or due to a study day.
Fig. 12 and Table XVIII shows the amount of FIGlu
excreted in the urine by each anaesthetist for each of the
7 days. The mean daily FIGlu excretion of all the
anaesthetists for each of the 7 days is similar to that of
the control group. There was no significant difference in
any of the days mean total excretion (ANOVA) . The
anaesthetists all excreted similar quantities of FIGlu
compared to each other.
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Figure 5. Formiminoglutamic acid excretion (jumol)in




Figure 6. Duration (minutes) of inhalation of 70% nitrous





Figure 7. Formiminoglutamic acid excretion (/xmol) in 50
surgical patients (group 2) over 6 consecutive days
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Figure 8. Raised (>70/mol) and normal (<70/xmol>
formiminoglutamic acid excretion related to duration of
70% nitrous oxide.













60-90 91-120 121-150151-180181-210 >211
Minutes
146
Figure 9. Formiminoglutamic acid excretion (jumol) in 5
surgical patients not exposed to nitrous oxide (group 3)














Figure 10. Formiminoglutamic acid excretion (jumol) in 10
patients undergoing thoractomy for lung carcinoma (group
























Figure 11. Patients undergoing thoracotomy for oesophageal



















Figure 12. Formiminoglutamic acid excretion (^mol) in 10
anaesthetists over 7 consecutive days.
Days
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Table II. Group 1. Age (years), weight (Kg) and Sex.
N=10
Age; 41 34 25 35 28 26 27 29 30 26
weight; 82 64 63 75 64 68 87 73 79 58
Sex; Male - 7
Female - 3
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44 23 62 58 51 47
65 62 58 42 64 63
48 62 37 54 61 65
44 47 64 58 62 28
56 62 64 47 52 62
42 62 74 75 74 84
68 82 68 72 64 59
61 74 54 49 76 74
Male - 24
Female - 26
48 54 60 62 27 47 48
47 28 64 55 52 47 51
62 38 57 49 65 62 64
51 56 38 64 57
82 64 76 92 64 64 84
48 57 74 61 86 92 74
82 74 65 49 91 57 74
67 73 69 70 65





54 47 74 78 78




Table V. Group 4. Age (years), weight (Kg) and sex.
Group 4a, n=10
Age; 55 48 65 63 61 59 53 64 57 60
Weight; 85 74 54 58 47 58 67 63 69 54
Sex; Male - 5
Female - 5
Group 4b, n=10
Age; 57 50 61 63 61 55 63 56 49 63
Weight; 75 64 49 54 58 52 65 73 71 49
Sex; Male - 4
Female - 6
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Table VI. Combined subject data for groups 1, 2, 3 and 4.
Mean (SD).
Group Age(years) Weight(Kg) Sex
Group 1 30.1 (7.5)* 71.5 (9.7) 7 male
n=10 3 female
Group 2 51.7 (11.8) 69.0 (12.7) 24 male
n=50 26 female
Group 3 56.2 (5.1) 73.6 (9.7) 2 male
n=5 3 female
Group 4a 58.5 (5.3) 62.9 (11.2) 5 male
n=10 5 female
Group 4b 57.8 (5.3) 61.0 (10.0) 4 male
n=10 6 female
*
significant at p<0.001 against the other groups
(unpaired t test).
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Table VII. Urine excretion (ml), FIGlu concentration
(jumol .ml-1) and 8 hourly total FIGlu excretion for each
subject (jLtmol) for each of the 5 days tested for Group 1
subj ects.
Subject 1
Day 1 2 3 4 5
Urine volume 701 1117 1036 1048 891
FIGlu conc. 0.079 0.037 0.049 0.050 0.073
Total FIGlu 55.4 41.3 50.8 52.4 65.0
Subject 2
Day 1 2 3 4 5
Urine volume 1187 753 946 729 668
FIGlu conc. 0.033 0.073 0.045 0.045 0.052
Total FIGlu 39.2 55.0 42.6 32.8 34.7
Subject 3
Day 1 2 3 4 5
Urine volume 420 350 410 390 420
FIGlu conc. 0.041 0.091 0.041 0.032 0.005
Total FIGlu 17.2 31.8 16.9 7.14 1.26
Subject 4
Day 1 2 3 4 5
Urine volume 410 480 330 420 360
FIGlu conc. 0.130 0.004 0.001 0.124 0.045
Total FIGlu 53.3 1.92 0.33 52.8 16.2
Subject 5
Day 1 2 3 4 5
Urine volume 365 300 525 410 360
FIGlu conc. 0.016 0.096 0.026 0.023 0.002
Total FIGlu 5.84 28.8 13.6 9.43 0.72
Subject 6
Day 1 2 3 4 5
Urine volume 280 340 380 400 320
FIGlu conc. 0.067 0.003 0.023 0.079 0.082
Total FIGlu 18.76 1.02 8.74 31.6 23.04
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Subject 7
Day 1 2 3 4 5
Urine volume 841 971 1303 925 991
FIGlu conc. 0.073 0.063 0.029 0.077 0.075
Total FIGlu 61.4 70.9 37.8 71.2 74.3
Subject 8
Day 1 2 3 4 5
Urine volume 315 450 380 370 360
FIGlu conc. 0.005 0.024 0.048 0.047 0.059
Total FIGlu 1.57 10.8 18.24 17.39 21.24
Subject 9
Day 1 2 3 4 5
Urine volume 520 610 410 370 280
FIGlu conc. 0.002 0.019 0.015 0.145 0.043
Total FIGlu 1.04 11.59 6.15 53.65 12.04
Subject 10
Day 1 2 3 4 5
Urine volume 245 192 325 285 180
FIGlu conc. 0.011 0.076 0.036 0.087 0.106
Total FIGlu 2.69 14.59 11.7 24.79 19.08
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Table VIII. Urine volume (ml) over 8 hours following
histidine ingestion, FIGlu concentration (/xmol.ml-1) and
total FIGlu (jumol) excreted for day 1 for all 50 patients
undergoing limb surgery under a N20 anaesthetic.
Subject Urine FIGlu Total Subject Urine FIGlu Total
Volume Cone FIGlu Volume Cone FIGlu
1 426 0. 112 47 .71 26 318 0.240 79.36
2 306 0.032 9 .79 27 512 0 . Ill 56.80
3 312 0. 048 14 . 97 28 315 0 . 016 4 .96
4 198 0. 016 3 . 17 29 223 0.284 63 .24
5 138 0. 012 1. 66 30 325 0. 003 0. 88
6 740 0. 004 2.96 31 111 0. 047 5.20
7 471 0. 056 26.38 32 210 0. 094 19 .82
8 108 0. 057 6. 05 33 317 0. 026 8 .40
9 317 0. 092 29 . 16 34 126 0. 217 27 . 28
10 412 0 . 108 44 . 50 35 843 0 . 017 14 . 40
11 306 0 . 088 26.93 36 226 0 . 015 3.36
12 196 0 . 164 32 . 14 37 326 0. 055 18 . 08
13 174 0. 160 27 . 84 38 306 0. 132 40.42
14 89 0. 092 8 . 19 39 212 0. 087 18 . 36
15 194 0. 080 15. 52 40 164 0 . 010 1. 69
16 472 0. 143 67 .80 41 412 0. 013 5.25
17 208 0.311 64 . 89 42 141 0. 175 24 .72
18 762 0. 052 39 . 6 43 106 0.223 23 . 69
19 374 0. 124 46 . 37 44 224 0. 085 19 . 08
20 744 0. 095 71. 00 45 227 0 . Ill 25. 09
21 611 0. 084 51.32 46 416 0.006 2 . 69
22 326 0 . 008 2 . 61 47 196 0 . 042 8 . 32
23 260 0. 032 8 . 32 48 128 0.024 3 . 13
24 511 0 . 140 71.40 49 191 0 . 052 10. 24
25 218 0. 008 1. 68 50 162 0. 193 31.36
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Table IX. Urine volume (ml) over 8 hours following
histidine ingestion, FIGlu concentration (jumol.ml-1) and
total FIGlu (nmol) excreted for day 2 for all 50 patients
undergoing limb surgery under a N2O anaesthetic.
Subject Urine FIGlu Total Subject Urine FIGlu Total
Volume Cone FIGlu Volume Cone FIGlu
1 328 0.215 70.32 26 143 0 . 083 11.90
2 282 0 . 135 38 . 07 27 140 0 . 117 16 .45
3 479 0 . 121 57 .48 28 83 0 . 455 37 .80
4 154 0. 020 3 . 68 29 148 0 . 074 11. 00
5 147 0. 012 1.84 30 217 0.030 16 .80
6 470 0. 007 3 . 52 31 168 0 . 062 10 . 50
7 174 0. 012 2 . 17 32 427 0.033 16 .80
8 94 0 . 013 1. 17 33 103 0 . 469 48.30
9 328 0 . 028 9 . 19 34 84 0 . 178 14 .96
10 317 0. 165 52 ,51 35 227 0 . 093 21.03
11 412 0. 172 71. 07 36 174 0. 163 28 . 60
12 208 0.235 48 . 89 37 212 0.099 23 .92
13 264 0. 091 23.76 38 74 0 .458 33 . 92
14 186 0 . 213 39.99 39 88 0 .151 13 .32
15 382 0 . 057 21.96 40 186 0.056 10. 34
16 196 0. 117 23 . 03 41 74 0.515 38 . 13
17 342 0 . 117 40 . 18 42 45 0.493 22 .20
18 840 0 . 082 69 . 30 43 186 0 . 075 13 . 95
19 294 0 . 107 31.61 44 173 0 . 228 39 . 52
20 144 0 . 177 25 . 56 45 218 0 . 089 19 .44
21 297 0 . 060 17 . 82 46 109 0 . 630 68 . 67
22 106 0 . 102 10.86 47 241 0 . 120 28 . 88
23 410 0.310 127.10 48 102 0.413 42 . 17
24 246 0. 090 22 .20 49 148 0. 161 23.92
25 105 0 .250 26.25 50 94 0 . 081 7 . 65
159
Table X. Urine volume (ml) over 8 hours following
. —1
histidine ingestion, FIGlu concentration (jumol.ml ) and
total FIGlu (/zmol) excreted for day 3 for all 50 patients
undergoing limb surgery under a N20 anaesthetic.
Subject Urine FIGlu Total Subject Urine FIGlu Total
Volume Cone FIGlu Volume Cone FIGlu
1 414 0.221 91.94 26 327 0 . 015 52 .22
2 194 0 . 045 8 . 69 27 423 0 . 028 11. 97
3 319 0 .454 144 . 92 28 420 0 . 157 65 .85
4 254 0. 525 133.32 29 346 0 . 291 100.92
5 268 0.061 16 . 29 30 326 0 . 247 80 . 51
6 860 0. 022 19.26 31 186 0 . 529 98.31
7 102 0 .012 2 . 17 32 303 0.230 69 . 70
8 72 0 . 019 1.38 33 227 0. 150 34 . 16
9 416 0 .272 113.15 34 90 0 . 563 50 . 68
10 404 0 .251 102.50 35 475 0 . 089 42.35
11 916 0 . 262 240.36 36 194 1.706 330.88
12 416 0 . 368 153.01 37 172 0 .295 50.80
13 574 0 . 144 82 . 65 38 174 0.221 38 . 52
14 204 0 . 394 80.29 39 65 1.456 94 . 65
15 411 0. 195 80.23 40 94 0 . 008 0.83
16 308 0 . 086 26.61 41 274 0 . 086 23.46
17 172 0 .358 61. 64 42 189 0.296 56. 11
18 183 0. 196 35.77 43 224 0 . 170 38 . 12
19 790 0 .237 187.10 44 124 0. 682 84 . 58
20 822 0. 163 134.12 45 74 0 . 418 30.95
21 394 0 . 037 14.74 46 222 1. 151 255.62
22 924 0. 150 138.97 47 322 0. 034 10.89
23 328 0.300 98, 66 48 74 1.382 102.30
24 486 0. 129 60 . 35 49 82 0 . 893 69 . 61
25 198 0 . 183 36.28 50 152 0.349 53 . 04
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Table XI. Urine volume (ml) over 8 hours following
— 1histidine ingestion, FIGlu concentration (/xmol.ml ) and
total FIGlu (/xmol) excreted for day 4 for all 50 patients
undergoing limb surgery under a N20 anaesthetic.
Subject Urine FIGlu Total Subject Urine FIGlu Total
Volume Cone FIGlu Volume Cone FIGlu
1 528 0. 210 110.89 26 418 0 . 150 62 .73
2 324 0. 161 66.98 27 318 0 . 168 53 . 55
3 142 0. 468 66. 46 28 519 0.036 18 . 60
4 238 0 .384 91.39 29 323 0. 090 29 . 07
5 1119 0.033 36.93 30 273 0.226 61.74
6 116 0. 015 1.74 31 342 0 .189 64 .80
7 198 0. 174 34 . 45 32 264 0. 149 39 .36
8 66 0. 174 11.48 33 215 0. 301 64 .74
9 712 0. 177 126.02 34 226 0.217 49 .20
10 312 0.243 75.82 35 346 0 . 197 68 . 48
11 728 0.261 190.10 36 241 0 .292 70 . 38
12 560 0 .259 144.52 37 253 0 . 159 39.76
13 602 0 . 107 64 .75 38 106 0. 007 0.72
14 192 0 . 300 57 . 60 39 108 0 . 009 0 .95
15 206 0.039 8 . 03 40 126 0 .234 29 .48
16 604 0 . 171 103.28 41 406 0 . 056 22 . 68
17 962 0 .234 255.11 42 126 1. 025 129.10
18 96 0 . 147 14 . 11 43 162 0 . 089 14 . 36
19 872 0 . 174 151.80 44 106 0. 312 33 . 05
20 741 0. 063 46. 68 45 88 0. 181 15. 90
21 526 0. 168 88 . 37 46 104 0 . 056 5.81
22 1044 0. 177 184.82 47 108 0.511 55 . 20
23 174 0 .252 43 . 84 48 62 0.826 51. 19
24 343 0 . 161 55. 08 49 224 0 . 071 16 . 00
25 254 0. 106 27 . 00 50 184 0 . 265 48.81
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Table XII. Urine volume (ml) over 8 hours following
• — 1histidine ingestion, FIGlu concentration (/umol.ml ) and
total FIGlu (^tmol) excreted for day 5 for all 50 patients
undergoing limb surgery under a N20 anaesthetic.
Subject Urine FIGlu Total Subject Urine FIGlu Total
Volume Cone FIGlu Volume Cone FIGlu
1 142 0. 051 7 . 24 26 264 0. 102 26.91
2 416 0. 065 21.22 27 189 0. 114 21.60
3 78 0 . 117 9. 13 28 261 0 . 028 7 . 27
4 147 0. 216 31.78 29 419 0.035 14 . 82
5 570 0. 012 11.11 30 259 0. 031 8 . 16
6 108 0. 079 8 . 95 31 264 0. 173 45.75
7 412 0. 101 41.41 32 156 0. 365 56.94
8 194 0. 101 19.50 33 324 0 . 085 27 .45
9 890 0. 114 101.46 34 104 0 . 614 63 . 89
10 74 0. 084 6.22 35 295 0. 073 21. 68
11 308 0. 153 47 . 12 36 238 0 . 190 45.24
12 512 0. 069 56. 06 37 128 0 . 189 24 .22
13 192 0. 028 5.47 38 212 0. 026 5.50
14 104 0.045 4 . 68 39 121 0.247 29 . 89
15 316 0.048 15. 17 40 205 0. 036 7 . 07
16 344 0. 150 5. 16 41 282 0. 050 14 . 10
17 382 0 . 029 10.89 42 104 0.301 31.30
18 348 0. 145 50 . 63 43 108 0. 052 5 . 62
19 174 0 . 150 26 .10 44 214 0. 035 7 .45
20 367 0. 180 6. 61 45 221 0 . 081 17 . 97
21 109 0. 099 10.79 46 392 0. 079 31.16
22 374 0. 049 18 . 51 47 74 0 . 659 48 . 78
23 478 0. 108 51. 62 48 109 0 . 196 21.21
24 357 0. 059 21.00 49 278 0 . 043 12 . 01
25 328 0 . 100 32 . 55 50 372 0. 159 59 .20
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Table XIII. Urine volume (ml) over 8 hours following
histidine ingestion, FIGlu concentration (/xmol.ml-1) and
total FIGlu (^mol) excreted for day 6 for all 50 patients
undergoing limb surgery under a N20 anaesthetic.
Subject Urine FIGlu Total Subject Urine FIGlu Total
Volume Cone FIGlu Volume Cone FIGlu
1 624 0 . 032 20. 15 26 294 0. 045 13 .22
2 172 0 . 029 19 . 16 27 160 0 . 086 13 . 89
3 296 0.201 59 . 62 28 295 0 . 128 37.70
4 236 0. 009 2 . 07 29 274 0 . 132 36 . 37
5 490 0. 018 8 . 84 30 324 0 . 107 34 . 58
6 241 0. 076 18 . 32 31 294 0 . 134 39 . 52
7 378 0 . 078 29 .45 32 228 0 . 116 26.45
8 108 0 . 072 7 . 64 33 174 0 . 136 23 .83
9 116 0 . 137 15.86 34 88 0 . 189 16 . 62
10 118 0. 146 17 .26 35 764 0 . 024 18 .39
11 246 0.135 33 . 18 36 96 0.481 46.21
12 248 0.215 53 .25 37 286 0 . 001 0.36
13 174 0. 095 16. 91 38 78 0 . 352 27 .48
14 203 0. 098 19 .86 39 243 0 . 011 2 . 67
15 417 0 . 084 34.86 40 151 0 . 073 11. 04
16 292 0. 066 19 . 18 41 174 0.030 5 . 16
17 106 0. 192 20.34 42 228 0 . 090 20 . 49
18 266 0. 133 35.38 43 142 0 . 305 43.32
19 628 0. 148 93 . 07 44 196 0. 107 21. 04
20 411 0. 148 60.91 45 106 0. 112 11.92
21 874 0 . 152 131.50 46 561 0 . 003 1.41
22 511 0 . 061 31. 17 47 194 0.407 78 . 88
23 829 0. 102 85.01 48 246 0. 221 54 . 55
24 421 0. 008 3 . 19 49 416 0.033 13 .80
25 210 0. 070 14 . 06 50 263 0. 213 56.01
163
Table XIV. Urine volume (ml) over 8 hours following
histidine ingestion, FIGlu concentration (/imol.ml-1) and
total FIGlu (jumol) excreted for day 6 for all 50 patients
undergoing limb surgery without any exposure to N20.
Patient 1
Day 1 2 3 4 5 6
Urine volume 206 172 278 143 374 262
FIGlu conc. 0.050 0.060 0.016 0.428 0.038 0.077
Total FIGlu 10.39 10.37 4.48 61.20 14.14 20.24
Patient 2
Day 1 2 3 4 5 6
Urine volume 428 184 122 196 204 310
FIGlu conc. 0.006 0.018 0.308 0.003 0.022 0.075
Total FIGlu 2.52 3.33 37.52 0.68 4.59 23.13
Patient 3
Day 1 2 3 4 5 6
Urine volume 362 244 176 184 183 224
FIGlu conc. 0.023 0.011 0.003 0.112 0.052 0.050
Total FIGlu 8.38 2.70 0.46 20.57 9.72 11.24
Patient 4
Day 1 2 3 4 5 6
Urine volume 247 96 106 84 126 156
FIGlu conc. 0.051 0.240 0.225 0.200 0.062 0.105
Total FIGlu 12.65 23.02 23.87 16.82 7.85 16.44
Patient 5
Day 1 2 3 4 5 6
Urine volume 108 74 114 252 184 162
FIGlu conc. 0.060 0.018 0.072 0.021 0.002 0.095
Total FIGlu 6.49 1.31 8.23 5.38 0.42 15.42
Table XV. Urine volume (ml) over 8 hours following
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histidine ingestion, FIGlu concentration (/imol.ml 1) and
total FIGlu (jumol) excreted for all 6 days 6 for all 10


























Day 1 2 3 4 5 6
Urine volume 543 165 270 145 562 732
FIGlu conc. 0.148 0.112 0.294 0.527 0.063 0.049
Total FIGlu 80.44 18.60 79.50 76.45 35.76 35.58
Patient 3
Day 1 2 3 4 5 6
Urine volume 298 90 124 325 272 197
FIGlu conc. 0.038 0.448 0.454 0.143 0.166 0.221























Day 1 2 3 4 5 6
Urine volume 378 321 312 645 239 340
FIGlu conc. 0.122 0.037 0.036 0.010 0.049 0.011





































































Table XVI. Urine volume (ml) over 8 hours following
. . . — 1
histidine ingestion, FIGlu concentration (/jmol.ml ) and
total FIGlu (/imol) excreted for all 6 days 6 for all 10
patients undergoing thoracotomy for oesophageal carcinoma.
Patient 1
Day 1 2 3 4 5 6
Urine volume 124 243 295 179 325 204
FIGlu conc. 0.351 0.096 0.153 0.132 0.106 0.169
Total FIGlu 43.62 23.54 45.32 23.68 34.59 34.50
Patient 2
Day 1 2 3 4 5 6
Urine volume 90 78 216 328 281 295
FIGlu conc. 0.873 0.607 0.325 0.281 0.080 0.228






2 3 4 5 6
253 450 348 240 370
0.211 0.324 0.281 0.281 0.007
53.54 146.21 98.43 67.54 2.63
Patient 4
Day 1 2 3 4 5 6
Urine volume 146 452 327 683 496 257
FIGlu conc. 0.076 0.032 0.233 0.098 0.017 0.177
Total FIGlu 11.20 14.75 76.54 67.54 5.87 45.63
Patient 5
Day 1 2 3 4 5 6
Urine volume 354 642 342 784 684 356
FIGlu conc. 0.212 0.117 0.033 0.004 0.013 0.209




Day 1 2 3 4 5 6
Urine volume 625 348 624 851 254 573
FIGlu conc. 0.054 0.260 0.054 0.067 0.308 0.026
Total FIGlu 33.65 90.54 34.21 56.78 78.43 14.74
Patient 7
Day 1 2 3 4 5 6
Urine volume 365 257 356 852 80 106
FIGlu conc. 0.112 0.029 0.161 0.040 0.842 0.378
Total FIGlu 41.13 7.54 57.64 34.75 67.43 40.11
Patient 8
Day 1 2 3 4 5 6
Urine volume 90 172 140 350 285 284
FIGlu conc. 0.262 0.201 0.161 0.133 0.085 0.124
Total FIGlu 23.64 34.67 22.65 46.71 24.54 35.43
Patient 9
Day 1 2 3 4 5 6
Urine volume 274 739 194 375 108 384
FIGlu conc. 0.021 0.088 0.347 0.257 0.604 0.033






2 3 4 5 6
860 475 382 639 274
0.053 0.018 0.030 0.029 0.061
45.73 8.96 11.64 18.64 16.85
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Table XVII. Mean, SD excretion of FIGlu on each of the






















Table XVIII. Urine volume (ml) over 8 hours following
. —1
histidme ingestion, FIGlu concentration (/xmol.ml ) and
total FIGlu (^mol) excreted for 7 consecutive days in 10






1 2 3 4 5 6 7
840 615 105 660 560 480 780
0.008 0.072 0.060 0.026 0.048 0.050 0.040




















0.094 0.013 0.060 0.040 0.046 0.063 0.062




















0.041 0.031 0.006 0.014 0.027 0.025 0.028






1 2 3 4 5 6 7
660 680 710 630 670 420 590
0.041 0.031 0.006 0.014 0.027 0.025 0.028


















0.025 0.017 0.001 0.001 0.009 0.015








1 2 3 4 5 6 7
420 650 380 280 140 280 310
0.053 0.037 0.064 0.071 0.070 0.052 0.047


















0.044 0.034 0.042 0.040 0.039 0.018




















0.061 0.052 0.011 0.038 0.009 0.023 0.028




















0.017 0.020 0.017 0.022 0.025 0.053 0.021




















0.027 0.021 0.034 0.027 0.021 0.027 0.017
17.01 13.96 32.30 14.04 9.24 17.28 9.01
171
Table XIX. Time weighted mean (SD) and range of exposure
to N20 (ppm) for each anaesthetist.
Anaesthetist Mean SD Range
1 135.6 112.3 47 — 325
2 115. 2 85.7 22 - 229
3 119.8 134 . 0 32 - 356
4 60. 8 66. 5 0 - 139
5 94 . 8 77 . 4 0 - 193
6 85.2 86.1 14 - 226
7 159.2 184.3 0 - 413
8 53.4 45.5 0 - 107
9 109 . 8 166.7 12 - 407






This series of experiments has examined the effect of
acute and chronic N20 exposure on human folate metabolism
using the formiminoglutamic acid (FIGlu) excretion test.
Overall, it appears that acute N20 exposure can cause a
dose related increase in FIGlu excretion for 2 days. Brief
exposure (<90 minutes) resulted in no increase whilst
intermediate exposure (91-210 minutes) caused an increase
in 50% of subjects. Prolonged exposure (>211 minutes)
resulted in all subjects having an increase. Subjects with
cancer had similar results. In contrast, anaesthetists
exposed chronically to trace amounts of N20 showed no
effect. From these findings, it has been possible to show
that folate metabolism becomes abnormal in people exposed
to high concentrations of N20 sooner than was previously
thought. Conversely, and reassuringly, theatre pollution
by N20 appears to have little effect on the FIGlu
excretion of anaesthetists.
Discussion
The FIGlu excretion test was used to assess folate
metabolism for two reasons. Firstly, it is a non-invasive
test requiring only histidine ingestion and urine
collection. Secondly, this test has already been validated
as being a good method of assessing cellular folate
metabolism. Cellular folate metabolism was examined
because it is the link between methionine synthase (MS),
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the enzyme inhibited by N20, and DNA synthesis.
How valid is this test when the subjects are
undergoing surgery? Can the results be extrapolated to
assess N20 toxicity? FIGlu excretion depends on several
factors including the histidine dose, its absorption into
the body, the volume of urine produced and the time it is
collected for, the amount of cellular tetrahydrofolic acid
(THF) present and the guantity of histidine catabolised to
FIGlu.
Most previous studies have used 15 g oral histidine
loading doses while in this series of experiments, 10 g
was used. This dosage was chosen for several reasons.
Firstly, histidine monochloride is expensive and difficult
to obtain and therefore a lower dose was more economical.
Secondly, it has been shown that any loading dose from 10
20 g is equally effective in diagnosing marginal
folate/vitamin B12 abnormalities (Luhby and others 1958,
1959). Thirdly, the larger the dose, the greater the
incidence of nausea and vomiting. This is the most common
post-operative complaint of anaesthesia (Cohen and others
1986) and increasing its incidence by giving large
histidine doses is both unacceptable to the patient and
will reduce the total amount absorbed. Even with this low
dose, 9 patients still had severe nausea and withdrew from
the study. Fourthly, there was the possibility that large
doses would result in accumulation of histidine
overwhelming its catabolic pathway. No cumulative effect
on urinary FIGlu concentration by continuous daily
administration of 10 g histidine in the control subjects
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was seen. However, it is possible that the 10 g dose may
have allowed subjects with borderline abnormal folate
metabolism to remain undetected which will have reduced
the sensitivity of the test although its specificity
should be maintained.
Absorption of histidine from the gastrointestinal
tract may have been decreased as surgery inhibits proper
gut function. However, histidine was given in a small
volume at least 2 hours before the operation and most
should have been absorbed. The operations were peripheral,
and disturbance of gut function would have been minimal.
All subjects were eating and drinking on the first post¬
operative day indicating that all histidine given after
this was absorbed. The subjects undergoing thoracotomy or
laparotomy are more likely to have suffered from decreased
absorption. Whilst histidine was placed down a nasogastric
tube, aspiration produced only small amounts of gastric
fluid and so it appears that most of the histidine was
absorbed. If absorption was reduced, the overall effect
would have been to decrease the effective loading dose and
therefore reduce the sensitivity of the test.
Urine output for all the subjects was maintained as
customary for these operations and none became oliguric.
Collection was over 8 hours. Many previous studies have
measured urocanic acid excretion in the belief that it
increases the test's sensitivity. This compound is an
intermediate in FIGlu production.
Urocanase
Histidine > Urocanic acid > FIGlu
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It is often excreted together with FIGlu,
occasionally in large amounts and has been measured both
alone and together with FIGlu as a total histidine
derivative. Chanarin (1963) showed it to be present in 88%
of urine samples when 15 g oral histidine was given and in
42% of these it was the main histidine derivative. Davis
and Kelly (1964) assayed 25 control subjects (loading dose
15 g oral histidine) and 8 excreted urocanic acid. Out of
31 patients with a vitamin B12 deficiency, 21 and 25 had
raised FIGlu and urocanic acid excretions respectively.
However, urocanic acid excretion is associated with many
different conditions (e.g. liver disease, protein
malnutrition, thyrotoxicosis, certain malignancies and TB)
and this makes it a less specific test for folate/vitamin
B12 abnormalities (Todays Tests 1969). The assay system
used in these studies specifically measures FIGlu and
causes no catabolism of urocanic acid. It is possible that
some of the subjects had raised urocanic acid, but normal
FIGlu excretions. However, as other reasons may have
caused this, it was decided to use the more specific
assay.
Therefore the FIGlu excretion test was designed to
specifically measure urinary FIGlu and to use a histidine
loading dose that was acceptable to the patient whilst
being large enough to diagnose abnormalities. It is
unlikely that the operations had much effect on either
absorption of histidine or excretion of FIGlu. It is
possible, however, that a few subjects with an abnormal
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folate metabolism were not detected and the test may have
a reduced sensitivity in these circumstances.
The FIGlu excretion of the control subjects varied
widely (range 0.33 to 74.3 ijlmol) . It is difficult to
compare this to other studies as many different assay
systems, loading doses and urine collection times have
been used although the results of this study are in
approximate agreement with many of the other studies
(Table XX).
Histidine Collection FIGlu Urine
loading dose Time excretion
g hours jumol
Range Mean
Carey et al 20 4 0-110 40
1964
Electrophoresis
Davis et al 15 8 0-95 44
1963
Enzymatic
Luhby et al 15 24 0-29 3.5
1959
Enzymatic
Chanarin et al 15 8 5-98 52
1962
Enzymatic
Table XX. FIGlu excretion determined in other studies in
normal groups.
The mean age of the control group is significantly
lower than those of the other groups. On group who used no
loading dose and an enzymatic assay found that there was a
slight increase in FIGlu excretion in the 40-50 year olds
as compared to other ages (Rosenauerova-Ostra and others
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1976). Koblin and Tomerson (1990) found that age had an
]effect with older rats excreting more FIGlu after N20
exposure. However, no loading dose was used and it is
possible that older rats have a different metabolic rate
in respect to protein and histidine catabolism. In
addition, vitamin B12 concentrations were not measured and
it is possible that they are reduced in the older rat. The
control group was comparable to the other groups in all
other aspects. All subjects acted as their own controls on
the pre-operative day and these were similar to the 10
control subjects although those patients with tumours had
a non significant increase in excretion.
None of the subjects undergoing surgery showed any
evidence of marrow depression in their blood films. This
was expected as any changes are indicative of severe and
prolonged marrow depression. It thus appears that exposure
to N20 for up to 6 hours has no gross effect on bone
marrow. FIGlu excretion was increased on the first and
second post-operative days for group 2 subjects indicating
either a cellular deficiency of THF or a surgical effect
although group 3 subjects were unaffected. One possible
explanation could be that the raised excretion was due to
the stress response of surgery. Central nerve blockade
prevents this during surgery of the lower limb (Pflug and
Halter 1981, Stefansson and others 1982). However,
blockade was brief, lasting only a couple of hours and the
stress response would occur after this in both epidural
(Gordon and others 1973) and spinal anaesthesia (Moller
and others 1985). It would be expected that nerve blockade
179
would be unlikely to prevent the increase in FIGlu
excretion on the next 2 days.
The other possibility is that it could be related to
the general anaesthetic drugs, thiopentone or enflurane,
although they have not been implicated in folate
metabolism previously. Therefore, it appears that N20
exposure causes an abnormality in the functional THF
pathway in 50% of subjects exposed to N20 for more than
90 minutes and this lasts for up to 48 hours. This agrees
with the time taken for MS recovery (Deacon and others
1980, Kondo and others 1981, Koblin and others 1981).
Of interest is the increase in excretion that
occurred in patients exposed to N20 for only a relatively
short time. Work has shown that the inhibitory th for MS
by 70% N20 is 46 minutes (95% CI 30-99 minutes) (Royston
and others 1988) and this would indicate that
approximately 2-8% of MS would still be active after 159
N20 minutes exposure. However, some increases were seen in
patients with shorter exposure times (down to 90 minutes).
How is it possible that these individuals had a raised
excretion as theoretically there would still be 25% MS
activity present?
A second interesting observation is the finding that
whilst those subjects exposed to N20 for a long time (>211
minutes) all excreted raised FIGlu and those exposed for a
brief time (<90 minutes) had no increase, the subjects who
had an intermediate exposure had a 50% probability of
raised excretion which was not related to duration.
Hawkins and others (1987) showed an increase in excretion
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in 2/6 subjects who were exposed to hyperbaric N20. Even
though it is difficult to compare these findings, it is in
agreement with the present studies. Why should some
subjects be more susceptible to the effects of N20?
Various possibilities may explain these apparent
anomalies. Firstly, MS activity shows great individual
variation and there may exist people with intrinsically
low MS activity. Such individuals may be especially
vulnerable to N20 as only a small amount of MS inhibition
would cause an overall significant decrease in activity.
Secondly, the amount of MS that has to inhibited
before clinical effects occur is unknown. Presumably, less
inhibition is needed to cause folate abnormalities than
for clinical effects. It is possible that there is great
individual variation in the relationship between the
amount of MS inhibited and folate status. Some people who
are resistant to N20 may only develop abnormal folate
metabolism if most of their MS is inhibited whilst others
who are less resistant will show changes in metabolism
when small amounts of MS are inactivated. Presumably these
individuals will also demonstrate more obvious clinical
effects at an a earlier stage. Why this should be is
unknown.
Thirdly, it may be that individuals have different
susceptibilities to MS inactivation with some being more
sensitive and others more resistant. This may be related
to the intrinsic amount of MS present, but also may be
related to how MS is inhibited. If, as suggested, it is
due to formation of a hydroxyl radical (Koblin and
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Tomerson 1990), then cells may have a protective mechanism
whose efficiency could vary greatly. This would explain
the interspecies difference in MS inhibition as different
animals may possess different amounts of the scavenging
system.
If this mechanism exists, 2 possibilities could be
considered. Firstly, there may be a group of humans who
are especially sensitive to MS inactivation and who will
demonstrate clinical effects more readily. Ill patients
may be more prone to the toxic effects of N20 (Amos and
others 1982) and it could be possible that gross physical
illness may, in some way, interfere with the scavenging
system. If individuals have other abnormalities causing
increased sensitivity to N20 (decreased folate, vitamin
B12, etc), then they may be especially sensitive. One
possibilty for this apparent difference in
susceptibilities could be because glutathione (GSH) is the
scavenging system. It can scavenge hydroxyl radicals and
is present in high concentrations in cells and is readily
oxidised.
OH*
2GSH > GSSG + NADPH + H+ > 2GSH + NADP+
The oxidised glutathione (GSSG) is reduced back to
GSH by glutathionine reductase. Normally there is a high
GSH:GSSG ratio in the cells as oxidised GSSG can inhibit
sulphur containing enzymes;
Enzyme-SH + GSSG > Enzyme-S-SG + GSH
However, it is possible that with large
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concentrations of hydroxyl radicals, the rate that GSSG is
reduced back to GSH is too slow to prevent a decrease in
GSH:GSSG resulting in damage to the active site of MS by
both GSSG and OH" . If the cellular concentrations of GSH
are low, then MS inhibition may occur sooner. Alternative
scavenging systems include uric acid (Ames 1981).
The second possibility is that there may be a better
method of protecting a patient from N20 toxicity than
using folinic acid. After MS is inhibited, folinic acid
acts as an escape mechanism for DNA synthesis. However, it
is better if the hydroxyl radical is scavenged before MS
is inhibited. This method has been used successfully in
mice given dimethylthiourea (Koblin and Tomerson 1990).
Other, less toxic, compounds exist that can scavenge
hydroxyl radicals (Halliwell and Gutteridge 1985). For
example, vitamin C reacts rapidly with OH*
Ascorbate + OH" > Semihydroascorbate
2Semihydroascorbate > Ascorbate + dehydroascorbate
The dehydroascorbate breaks down in a complicated
fashion to form oxalic and threonic acids. Therefore high
cellular concentrations of vitamin C may protect MS. Many
other compounds can react with the hydroxyl radical (e.g.
glucose, bicarbonate ,etc - Anbar and Neta 1967) and these
could also be used. This remains to be investigated.
It was interesting to note that one patient who had a
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low vitamin B12 concentration excreted normal amounts of
FIGlu. It has been suggested that these individuals are
more prone to N20 effects although there is little
evidence for this in man. Unfortunately other possible
groups that may be more susceptible were not studied.
One group that is likely to have abnormal folate
metabolism was studied. Tumour cells have an increased
requirement for folate in a similar manner to that of
rapidly proliferating tissue (Rama Rao 1964). FIGlu
excretion in subjects with cancer was very similar to that
seen in non-cancerous subjects. Pre-operative excretion
was slightly raised as compared to normal controls.
Interestingly, 3 of the patients undergoing lung resection
received only a small amount of 70% N20 (12, 18 and 24
minutes) and all these had normal FIGlu excretion,
further evidence that the stress of surgery is not
responsible for raising FIGlu excretion. Excretion in the
other subjects was similar to that in group 2 patients
with approximately 50% showing a raised excretion. The
duration of 70% N20 exposure was 96 (SD 32) minutes, less
than of the non-tumourous patients indicating that even
though the increased excretion was similar, exposure was
less. Possibily these patients are more susceptible, but
this needs further study.
Patients undergoing oesophagectomy for oesophageal
cancer are often malnourished with a vitamin deficiency
although there was no evidence of this in these patients.
FIGlu excretion was similar to the lung tumour group,
although N20 exposure was longer (mean 154 (SD 42)
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minutes).
It appears therefore that patients with cancer may
have an increase in FIGlu excretion when compared to
normal patients undergoing N20 anaesthesia and therefore
it is possible that cancer may increase the effects of N20
on folate metabolism. Extrapolation from this result to
other groups with rapidly growing tissues (pregnant women,
young children, etc) whilst possible, must be done with
care. However, the effect appears at worst to be minor.
Daily urinary excretion of FIGlu by anaesthetists
exposed to N20 pollution is similar to that of normal
unexposed subjects, indicating that the chronic exposure
to N20 of anaesthetists had no effect on folate metabolism
and this is in agreement with other studies (Salo and
others 1984, Nunn and others 1982) . The amount of N20
pollution varied widely and was greatly reduced by
scavenging. Most anaesthetists work in scavenged theatres
and had exposures to N20 that are consistent with these
other studies (Davenport and others 1980, Gray 1989).
This result, taken in context with the other
biochemical studies and with the epidemiological evidence
is reassuring for anaesthetists and other theatre workers.
Chronic exposure to low concentrations of N20 appears not
to be a health hazard except for a possible detrimental
effect on fetal development. However, there is still a
lack of evidence about the safety of N20 when worse
pollution occurs (e.g. dental surgeries) and it is
possible that the effect may become toxic. At what
concentration of N20 contamination danger occurs is
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unknown. The target exposure concentration set by the
United States National Institute for Occupational Safety
and Health is 25 ppm. These targets were almost always
superseded in this study and it appears that this
concentration may be unnecessarily low. A greater higher
exposure concentration appears to be not only safe, but
also more realistically obtainable.
Increase in FIGlu excretion due to abnormal folate
metabolism is an indicator that the effects of N20 are
more profound at a lower exposure dose than have been
previously reported. However, it is still impossible from
these observations to make deductions about the direct
clinical effects of N20.
In conclusion, several possible conclusions may be
made from these results.
1. This test may be used to investigate N20 toxicity
by examination of folate metabolism. The test will tend to
underestimate abnormalities.
2. It appears that people may be more susceptible to
N20 than has been previously thought. Folate metabolism
is affected in a dose dependent manner. Some individuals
appear to be more susceptible than others and possible
reasons are discussed. Whether the derangement in folate
metabolism is of clinical significance is still unknown
3. Tumour patients may be more susceptible to N20,
with effects occurring at lower concentrations. This may
have relevance to other groups with rapidly growing
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tissues.
4. Occupational exposure to the N20 pollution
concentrations studied (approximately 100 ppm) have no
effect on folate metabolism.
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CHAPTER EIGHT
NITROUS OXIDE IN MODERN ANAESTHESIA
A PERSONAL VIEW
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Both acute and chronic nitrous oxide (N20) exposure
interfere with vitamin B12 and> consequently can result
in a reduction in DNA synthesis. Chronic exposure can
cause a neurological disease with similar symptoms to
those of vitamin B12 deficiency. These are biochemical
toxic effects unique to N20. However, N20 causes other
complications which influence morbidity and mortality
after surgery (Table XX) . Nunn has suggested that N20
would not receive a product certificate if it was
introduced into anaesthesia as a new drug because of these
problems (Nunn 1987). Some anaesthetists have even
suggested banning its use altogether in anaesthesia
because of these side effects (Eger 1985).
However, this solution is drastic because there are
undoubted advantages in its use. It is a popular drug
having been used since 1844 in countless millions of
anaesthetics. For example an estimated 1 x 109 litres were
used in 1988 by British anaesthetists alone (Editorial
1989). If it was banned, most anaesthetists would have to
make significant modifications to their practice.
General anaesthesia is considered to comprise of 3
components, narcosis, reflex suppression (analgesia) and
muscle relaxation. Anaesthesia involves one or all of
these and anaesthetic drugs vary in which they affect.
N20 can cause narcosis and analgesia, but no muscle re¬
laxation and so this area will not be discussed further.
If N20 was banned, techniques which give an equivalent
amount of narcosis and reflex suppression would be need to
be developed. Three methods are available, to use more
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volatile anaesthetics, to use intravenous techniques or to
use local anaesthesia.
Whilst local anaesthesia is common, it has several
disadvantages including a slow onset time which can delay-
surgery, a greater failure rate than general anaesthesia,
and is disliked by some patients. Anaesthetists often use
local anaesthesia alone or as part of a "balanced
anaesthetic technique". However, regional anaesthesia will
not be discussed further because it is not universally
applicable to all operations.
To clinically assess an anaesthetic drug, 2 factors
are important. Firstly, how effective an anaesthetic is
it? Because surgical stimuli vary greatly, so must
anaesthetic depth. Inadequate narcosis or reflex
suppression (light anaesthesia) may cause awareness and
recall, operating conditions will be poor and potentially
dangerous physiological responses can occur (hypertension,
tachycardia, etc). In contrast, with deep anaesthesia,
recovery may be prolonged and dangerous cardiorespiratory
depression may occur. An anaesthetic drug (or combination)
should be able to anaesthetise patients to a suitable
depth and then be able to vary this quickly.
The second factor concerns the incidence of side
effects that a drug has. A good drug has only a few minor
ones. Therefore the most suitable anaesthetic drug (or
technique) is one that gives effective anaesthesia with
few side effects. An ideal anaesthetic drug should have
many characteristics (Editorial 1990). It should be easily
and inexpensively prepared in its pure form, stable
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without preservatives with a long shelf life, be non¬
flammable or explosive, potent to allow high
concentrations of oxygen to be used, possess a low
blood/gas partition coefficient to allow a fast induction
and emergence and flexibility in adjusting anaesthetic
depth, pleasant to inhale, have no effects on the
cardiovascular and respiratory systems, should depress
specific areas of the central nervous system causing
anaesthesia, but no stimulation, undergo no bio¬
transformation and lastly, have no organ toxicity.
Assessment of the role N20 has in anaesthesia must
consider these 2 areas. In this chapter, the advantages
and disadvantages of N20 will first be discussed and then
they will be compared to those of the above techniques.
The first reported death from N20 inhalation was
published in 1873. Miss Ida Wyndham died during a N20
anaesthetic for the unsuccessful removal of an upper molar
tooth, probably due to asphyxia (Lancet 1873). Since then,
there have been many other fatalities from the use of N20,
some of which will be detailed later in this chapter.
Nitrous oxide is manufactured by heating ammonium
nitrate (Wynne 1985).
NH4N03 > N20 + 2H20 + 58. 6kJ
Older manufacturing plants use solid ammonium nitrate
heated to 245° - 270°C whilst modern ones use 83% aqueous
ammonium nitrate which is cheaply obtained as a byproduct
of ammonia manufacture. The reaction is exothermic and
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requires strict control to prevent the temperature rising
because ammonium nitrate explodes when too hot. There have
been 25 major explosions related to N20 manufacture which
have injured or killed over 5,000 people in the last 100
years (Wynne 1985). High temperatures also increase N20
contamination by the higher oxides of nitrogen. Other
impurities may be present including carbon monoxide,
chlorine and ammonia. These are formed as a result of side
reactions occurring during manufacture.
5NH4N03 > 4N2 + 9H20 + 2NH03 + 157.OkJ
2NH4N03 > 2NO + N2 + 4H20 + 54.4 kJ
2NH4N03 > 2N2 + 02 + 4H20 + 145.5kJ
Then 2NO + 02 > 2N02
These impurities are removed by passing the gas
through water, caustic soda, sulphuric acid and alkaline
potassium permanganate. However, problems have occurred in
the purification process. In 1966 there were 2 deaths from
N20 contamination by nitric oxide. Met-haemaglobinaemia,
pulmonary oedema and circulatory collapse occurred
(Clutton-Brook 1966) and investigations revealed that N20
contamination was relatively common and probably had been
responsible for a considerable mortality in the past
(Editorial 1967) . Modern regulations allow N20 to be
contaminated by up to 1 ppm nitrogen dioxide, 1 ppm
halogens, 10 ppm carbon monoxide, 300 ppm carbon dioxide
and 25 ppm ammonia (U.S. Pharmacopoeia). Stringent
manufacturing safeguards and checks make it unlikely that
dangerous contamination can now occur although this
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potential will always exist.
N20 delivery to the patient can cause problems with
too much, too little, or the wrong gas being inhaled. N20
is supplied to theatres either in cylinders or piped from
a central depot. Cylinder use has obvious problems because
they are cumbersome and dirty and can empty quickly
causing the patient's anaesthetic depth to lighten, or if
the fresh gas flow decreases, can cause rebreathing with
C02 accumulation. Even though modern cylinders use a pin
index system, wrong ones may still be fixed to the N20
port.
Equally, there are problems in using piped N20.
Different pipes carrying other gases may be abnormally
connected with the wrong gas being delivered to the
theatre. A new emergency treatment room with outpatient
operating theatre facilities was built in Canada. After
having been used for 5 months, a young girl died from
asphyxia during an operation and the cause was found to be
a misconnection of the oxygen and N20 pipelines during
installation. A subsequent inquiry suggested that this
problem had been involved in the deaths of another 2 2
patients (Pelton 1978).
Whilst safeguards have been developed preventing
this, whenever a hypoxic gas is connected to an
anaesthetic machine it may be accidently given instead of
oxygen with disastrous consequences. Modern safeguards
(coloured cylinders, pipelines, pin index system, oxygen
analysers, etc) have reduced the possibility, although
mistakes can always be made. For example there have been
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several documented cases of cylinders being attached to
the wrong pin index (Goebel 1980). Rotameters may be
accidently set to give a hypoxic gas mixture although
modern anaesthetic machines are designed to prevent this
(Quantiflex rotameters, etc). However, the only foolproof
method of preventing the wrong gas being given is not to
have any hypoxic gas (N20 and carbon dioxide) on the
anaesthetic machine.
Once formed, it is a stable gas with a long shelf
life and an atmospheric lifetime of about 150 years
(Editorial 1990). It is expensive. For example, in 1975,
it cost as much to use as halothane (Barton and Nunn
1975) . Less is needed with closed circuit anaesthesia
although this technigue again requires expensive equipment
and exposes patients to new hazards.
It is non-flammable or explosive, but if heated will
decompose into nitrogen and oxygen (450°C) and this
mixture strongly enhances combustion of other compounds
(Mushin and Jones 1984).
There is concern that environmental pollution from
industrial wastes can affect the ozone layer or could
increase the "greenhouse" effect. N20 has been implicated
because of its long atmospheric life. It is a significant
"greenhouse" gas and its atmospheric concentration is
increasing. From 1979 to 1982 there was an annual increase
of ~0.8 ppb (0.25% yearly) (Khalil and Rasmussen) . N20 has
a similar molecular potency to C02 in causing the
"greenhouse effect". However, many other N20 sources exist
including microbial nitrification and denitrification of
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fertilisers and anaesthesia's contribution (estimated at 1
x 109 litres in 1988) is small when compared to these
sources (3-10% of microbial nitrification alone - Logan
1989) .
N20 has no direct ozone effect although it can be
oxidised to nitric oxide which then enters the NOx
catalytic cycle. This works in the same way as chlorine in
causing ozone depletion. The oxides of nitrogen are only
removed when they react with other radicals and hence can
inflict great damage on the ozone layer (Brown and others
1989) .
The potential health hazard of exposure to trace
concentrations of N20 from theatre pollution has been
previously discussed. In addition, it may also cause
behavioural problems although most studies show no or only
a small effect. Cook and others (1978) exposed 29 healthy
males to up to 0.4% N20 and found no change in the digit
span test (memory) or the choice reaction time
(attention) . Halothane (20 ppm) and N20 (500 ppm)
combinations had no effect. Whilst sub-anaesthetic
concentrations have a behavioural effect, 20-30% N20 is
needed (Rice 1983). Twenty two anaesthetists (time
averaged exposure to N20 was 58 ppm and to halothane was
1.4 ppm) had normal mood and cognitive test results after
working in theatre (Stollery and others 1988). Therefore,
at normal theatre concentrations, N20 appears to have
little behavioural effect.
It is a weak anaesthetic having a high minimum
alveolar concentration (MAC) of 104% (SE + 10%) . To find
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its MAC, volunteers were anaesthetised with only N20 in a
pressure chamber and movement to an electrical stimulus
assessed (Hornbein and others 1982). In normal
anaesthesia, lower concentrations are given and therefore
other anaesthetics are needed to prevent light
anaesthesia. If given alone (usually in concentrations of
50 - 70%), the patient will be poorly anaesthetised and
awareness may occur. For amnesia, 65-86% nitrous oxide is
required. When 42 patients were given 70% N20 and curare,
3 were aware (Taub and Eisenberg 1975). Inhaling only 70%
N20 will always cause some awareness.
In contrast to its weak anaesthetic actions, it is a
powerful analgesic with 20% N20 being as effective as 15
mg subcutaneous morphine (Chapman and others 1943).
Analgesia is dose related (Dundee and others 1962) and
may be partially due to interaction with the endorphin
receptor system. N20 decreased the pain of a tight
tourniquet and intravenous 4-8 mg naloxone partially
reversed this (Yang and other 1980). Other studies have
shown similar results although high doses of naloxone are
required suggesting that the N20-endorphin receptor
interaction is complicated and other effects may be
important (Finck 1985).
Its analgesic effects are used in childbirth and
relief of acute pain. Portable cylinders are readily
available which contain Entonox, a mixture of oxygen and
nitrous oxide (50:50). Analgesia is not instantaneous and
Entonox must be inhaled for some time. For instance, it
takes 45 seconds before analgesia becomes satisfactory in
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the first stage of labour. Forty six percent of mothers
had effective analgesia when using it although another 30%
had no relief (Holdcroft and Morgan 1974). Other uses for
Entonox include pain relief post-operatively (Parbrook
1967), for painful minor procedures (Baskett and Bennett
1971) and in ambulances (Stewart 1983). Storing Entonox is
a problem because it is normally a gas mixture (Poynting
Effect), but when cooled below -7°C, the N20 liquefies. If
it is now used, only oxygen will be inhaled giving no
analgesia. As the oxygen is used up, further inhalation
will result in an increase in N20 intake and hypoxia may
occur. Therefore, it needs to be stored in areas where the
temperature does not fall. If liquefication occurs,
leaving it at room temperature for 2 hours reverses the
changes.
When used at anaesthetic concentrations, it has few
effects on either the cardiovascular or the respiratory
systems although there is concern over possible ischaemic
and arrhythmogenic effects. All anaesthetic drugs
decrease tidal volume and increase respiratory rate and
N20 is no exception, although the respiratory rate
increases enough to prevent decreases in minute alveolar
ventilation (at 1.55 atmospheres (atm), the respiratory
rate was 47.4 + 2.5 breaths.minute-1 (Hornbein and others
1982)). It reduces the ventilatory response to hypercapnia
and hypoxia and at 0.1 MAC these decreased by 45% and 42%
respectively. This is similar to the other anaesthetics
(Knill and Clement 1982).
N20 can cause a tight chest and may make assisted
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ventilation more difficult. When 70% N20 and morphine (2
mg.kg-1) were given, there was an increase in the rigidity
of the abdominal wall and a decrease in chest compliance
(Freund and others 1973) . Whilst morphine may have been
responsible, a similar rigidity was seen when only 1.55
atm N20 was inhaled (Hornbein and others 1982).
N20 may increase the incidence of post-operative
chest complications. Gawley and Dundee (1981) studied 85
patients undergoing non-emergency upper abdominal
operations anaesthetised with either 66% N20 and a
volatile anaesthetic or with a volatile anaesthetic alone
(but the gases were humidified) . The N20 group had more
respiratory complications and lower arterial oxygen
saturations. This, however, may have been due to
humidification of the gases. Another study compared post¬
operative seguelae in upper abdominal operations in 48
patients anaesthetised with either 30% oxygen in nitrogen
or N20 and showed no difference (Logan and others 1977).
Lampe and others (1990) studied 270 patients receiving
hip replacements. They used an isoflurane-vecuronium
anaesthesia with either 100% 02 or 60% N20. Ventilation
was controlled and the gases humidified. Fentanyl was
given as needed with both groups receiving similar doses.
Pulse oximetry measured arterial oxygen saturation pre-
operatively, intra-operatively, 60, 120 minutes post¬
operatively and on days 1, 2, 3 and 5 after 5 minutes of
breathing room air. Intra-operative saturation was lower
in the N20 group (93.3%+2.8% v 96.0%+5.2%). Immediate and
later post-operative saturations were the same for both
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groups. Similar findings occurred on days 1 to 5. Because
oxygen can cause absorption collapse, nitrogen may have
been a more suitable control gas. However, from these
studies, it appears that N20 has little deleterious post¬
operative effects although a larger study is still needed.
In addition, there may be a subgroup of patients with
existing respiratory abnormalities who may be more
susceptible.
It has little effect on the cardiovascular system
when compared to the volatile anaesthetics. It depresses
cardiac muscle contractility slightly. Eighty percent N20
reduced it in dog myocardial perfusates by 25% (Motomura
and others 1984). Because it causes sympathetic
stimulation, this depression is usually of no clinical
relevance because blood pressure is usually maintained
(Eisele and Smith 1972). Its cardiovascular stability
gives N20 a great advantage over the other volatile
anaesthetics which all depress either the myocardium or
the peripheral circulation. However, patients who already
are maximally sympathetically stimulated may become
hypotensive when given N20 (e.g. shocked patients).
Pulmonary artery pressure and vascular resistance
are not normally changed unless pulmonary hypertension is
already present when large increases in resistance and
pressure can occur (Schulte-Sasse and others 1982).
However, in another study when 70% N20 was given to 10
patients with pulmonary hypertension, there was a decrease
in pulmonary arterial pressure suggesting that pulmonary
vascular resistance had not increased (Konstadt and others
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1990) . More work is needed on this subject.
There has been concern that N20 may adversely affect
patients with ischaemic heart disease. Philbin and others
(1985) used a canine model with a critical stenosis of the
left anterior descending coronary artery. Increased
dysfunction of the supplied myocardium occurred when 60%
N20 was given. Other work has shown similar cardiac
dysfunctions at N20 concentrations of 40% although the
effect was small (Leone and others 1988). The clinical
relevance of this is still unknown. Patients undergoing
carotid endarterectomy (high incidence of coronary artery
disease) were given isoflurane-fentanyl-vecuronium with
either 100% 02 or 60% N20 in 02 and the incidence of
cardiac ischaemia was found using 12 lead ECG and
trans-oesophageal echocardiography (TEE). Seventy patients
were studied, randomly allocated to either group; both had
a similar degree of previous myocardial infarction (20%)
and ischaemia (10%). Intra-operative cardiovascular drug
usage was similar. Twenty one patients in both groups had
one or more haemodynamic events (30% change in baseline
systolic pressure) and there was no difference in intra¬
operative ischaemia or TEE abnormalities. Other studies
have found similar clinical findings. Slavik and others
(1988) studied 7 patients undergoing bypass for coronary
artery disease using TEE and gave, in 10 minute sequences,
100% 02, 70% N20 in 02, 70% N2 in 02 and 100% 02. No
abnormal wall motion was seen. Mitchell and others (1989)
examined 70 patients undergoing coronary artery grafting
using a crossover design with either 60% N20 or N2 in 02.
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N20 had no effect on TEE determined ischaemia. Therefore
it appears that there is little clinical effect although
larger studies are needed.
N20 may possibly be arrhythmogenic because it can
activate the sympathetic nervous system and increase
plasma catecholamine concentrations (Roizen and others
1987). One hundred patients undergoing trans-sphenoidal
hypophysectomy received either 100% 02 or 60% N20 in 02.
Adrenaline, 1:200,000 in 0.5% lignocaine was given (mean
— 1
dose 2.6 /ug.kg ) and the ECG was monitored for 15
r
minutes. N20 increased the number of premature ventricular
beats although this was not statistically significant. In
addition, isorhythmic AV dissociation was increased by
50%. It appears therefore that N20 does increase
arrhythmias - more work is needed to assess the clinical
dangers (if any) of this.
In conclusion, N20 has little effect on the
respiratory system apart from a possible increase in
post-operative complications. It has a small cardio-
depressant effect, but because it causes sympathetic
stimulation, blood pressure is maintained. Arrhythmias
may be a problem and its use in patients with myocardial
ischaemia is still controversial.
Its blood/gas partition coefficient (0.46) is the
lowest of all the common inhalational anaesthetics and
therefore, it is the least soluble in blood. This,
theoretically, will allow a rapid induction. Its alveolar
concentration will rapidly approach that of the inspired
air long before other anaesthetics because only a little
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is removed by blood. The concentration effect also
increases the speed of induction. Smith and others (1974)
anaesthetised 2 volunteers with the same amount of N20
(approximately 1 atm) at different pressures of 2 atm
(50% N20) and 1.2 atm (85% N20) . Induction was faster
when 85% N20 was used. The second gas effect is enhanced
by N20 (Epstein and others 1964). All these effects
combined with its lack of odour and its non irritability
to the respiratory tract makes N20 an excellent induction
drug.
Recovery is equally rapid because N20 is quickly
exhaled from the lungs. There is the possibility that
hypoxia could develop during recovery because N20 will
dilute the other alveolar gases including oxygen
(diffusion hypoxia). It however appears that this is only
of minor clinical importance in most patients because it
is mild and short lived (Frumin and Edelist 1969). If
there is anxiety about hypoxia at this stage, oxygen
prevents it.
N20 readily diffuses into body spaces that contain
air. Diffusion is related to the partial pressures of the
gases between the different media (Fick's Law). When one
of these media is a fluid then diffusion is related to the
solubility of the gas in the liquid. The more soluble the
gas, the greater its diffusing capability. N20 is more
soluble in blood than nitrogen (blood/gas coefficient
0.015) by a factor of 25. Gas in body spaces is in
equilibria with that dissolved in blood and therefore
normally, spaces will contain nitrogen, oxygen and carbon
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dioxide. If N20 is inhaled in oxygen with no rebreathing,
nitrogen will be exhaled and eventually all will be
removed from the lungs, blood, tissues and body spaces and
replaced with N20. Because more N20 is in solution, it
will diffuse faster into the body spaces than nitrogen can
diffuse out and so there will be an increase in the amount
of gas present. If N20 continues to be inhaled, eventually
all nitrogen will be removed and the total amount of gas
present in the spaces will be the same as before. The
converse will happen when N20 is withdrawn.
This increase in the amount of gas present in the
space before eguilibrium can have two consequences. If the
space is compliant there will be an increase in its volume
which is theoretically equal to (Eger and Saidman 1965);
FiNgO in alveolar
f1.0-FiN20)
Therefore inhalation of 70% N20 can cause an increase
in volume of a compliant body space of up to 233%
However, if the space is non-compliant, there will be an
increase in its gas pressure. Increases in pressure are
related to the partial pressure of N20 in the alveolae and
can have significant clinical effects.
Compliant spaces include the stomach and intestines,
a pneumothorax, a pneumo-peritoneum, surgical emphysema
and air emboli. Normally, the intestines contain only
small quantities of air and so 70% N20 would only have a
minor effect on volume. However, during intestinal
obstruction, the quantity increases greatly and in this
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situation, N20 expansion may make abdominal closure
difficult or increase intra-abdominal pressure.
Fortunately, the rate that the volume increases is slow
because loops of intestines from a dog exposed to 70% N20
took 100 minutes to double in size (Eger and Saidman
1965). N20 appears to have no effect on post-operative
motility or gasto-intestinal function (Giuffre and Gross
1986) . However, recent work has different results
(Scheinin and others 1990) because 40 patients undergoing
colonic surgery were anaesthetised with either isoflurane
and air or isoflurane and N20 (70%) . Subjects in air group
had less gas in their small bowels and the operating
conditions were superior. Bowel function returned earlier
as measured by passage of flatus and faeces and overall,
they had a shorter hospital stay. However, air was placed
in the stomach at the start of the anaesthetic and this
could have had a significant effect. Further investigation
is needed to determine the importance of this result.
Lung spaces can expand and squash remaining intact
tissue when N20 is inhaled. Experimentally, in dogs
breathing 70% N20, a pneumothorax doubled and then tripled
in size in 10 and 30 minutes respectively (Eger and
Saidman 1965). This change is quicker than that occurring
in the gut and its possible consequences are more severe.
Air embolism is common in both open heart and
neurosurgery. Air emboli size increases with N20 and may
become life threatening or lodge in vital arteries (e.g.
brain) causing strokes. Inhalation of 72 - 76% N20 reduced
the amount of IV gas required to kill rabbits by up to
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340% (Munson and Merrick 1966) . Pigs had increased
cardiovascular problems after cardiac bypass when given
N20 probably due to an expansion of air emboli (Tuman and
others 1987). Therefore, its use is contraindicated in
operations were air emboli may occur.
The cuff on an endotracheal tube may expand with an
increase in mucosal pressure thereby increasing the
incidence of sore throat or pressure necrosis. This occurs
in a time dependent manner although it is most profound
over the first 60 minutes (Mehta 1981) . The effect can be
avoided by using a variety of technigues including
expanding the cuff with water or N20, using a valve to
allow excess gas to bleed off or to manually check the
cuff pressure.
Non-compliant spaces include the middle ear and nasal
sinuses, a pneumo-encephalos and the eye. Operations on
the middle ear are particularly prone to the diffusive
effects of N20 (Perreault and others 1982). Bulging of the
drum can be seen which may result in rupture, graft
displacement, stapes displacement, haematotympanum and
hearing loss. Withdrawing N20 30 minutes before graft
placement prevents this happening.
It can diffuse into any air spaces in the cranium
possibly resulting in harmful pressure increases (Saidman
and Eger 1965) . These air spaces may be as result of
trauma, investigative procedures (ventriculography,
pneumo-encephalography) or treatment (CSF shunt, posterior
fossa surgery) . When there is a possibility of a closed
airspace in the cranium, N20 should not be used.
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Gas is often injected into the eye (usually sulphur
hexaflouride) after surgery for retinal detachment in
order to tamponade the retina and N20 can cause a
considerable increase in intraocular pressures and it is
recommended that it be stopped 15 minutes before injection
(Stinson and Donlon 1982). There appears to be little
effect in surgical emphysema (Poulton and others 1982),
but it is possible that increases in the size of the
balloon in flotation catheters could distend the pulmonary
artery although an in vivo study showed no effect (du
Bouley and Nahrwold 1982).
Hence, N20 may cause considerable morbidity or
mortality as a result of its low solubility. The effects
are predictable and in high risk cases N20 should not be
used. However, these spaces may be present without the
anaesthetist being aware of them.
N20 may cause nausea and vomiting for several
reasons. It diffuses into the gut causing distension,
into the middle ear causing an increased pressure, it can
interact with the endogenous opioid receptor systems and
it activates the sympathetic nervous system (Melnick and
Johnston 1987). All 7 volunteers anaesthetised with N20 at
1.55 atm had post-anaesthetic nausea and vomiting
suggesting that it has emetic properties (Hornbein and
others 1982). Many clinical trials examining this have
been performed (Table XXI).
Alexander and others (1984) studied 74 women
undergoing laparoscopy and showed an increase in the
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incidence of nausea and vomiting in those receiving 70%
N20 and fentanyl as compared to patients who received
Table XXI. The Emetic potential of nitrous oxide.





















































isoflurane alone or with fentanyl. Melnick and Johnston
(1987) found that in 60 women undergoing minor
gynaecological surgery, 60% N20 with isoflurane caused an
increase in the incidence of nausea and vomiting (25%).
No narcotics were used and the operations did not involve
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the gastrointestinal system. Lonie and Harper (1986)
showed that the incidence of vomiting in 87 patients
undergoing laparoscopy decreased from 49% to 17% when no
N20 was given.
However, other work has failed to demonstrate this.
Muir and others (1987) showed N20 had no effect on nausea
and vomiting in 780 patients undergoing non-abdominal
surgery although the patients were older than in previous
studies. Kortilla and others (1987) found no difference in
110 patients undergoing abdominal hysterectomy. Hovorka
and others (1989) anaesthetised 150 patients for
laparoscopy using either isoflurane and N20, enflurane and
N20 or isoflurane and air and the incidence of emesis in
the first 24 hours in these groups was 54%, 48% and 52%
respectively. Overall, the emetic effect of N20 is still
unclear and further study is needed.
It is possible that N20 is a weak initiator of
malignant hyperpyrexia (MH) because this occurred in a
patient given only N20 (Ellis and others 1975). However
this must be very rare because N20 is often used whilst MH
is relatively rare. Because N20 has sympathomimetic
effects, it may make the symptoms of MH worse by causing
peripheral vasoconstriction which will decrease heat loss
through the skin. Its use in known MH susceptible patients
is still unclear.
The effects of N20 on the liver are also uncertain.
Minor increases in plasma lactate dehydrogenase isoenzymes
concentrations suggestive of mild liver damage were seen
in 8 patients receiving 70% N20 and methohexitone (Prys-
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Roberts and others 1983). Two groups were anaesthetised
using either halothane or halothane and N20 in a pressure
chamber and plasma hepatic enzyme concentrations increased
in the second group (Pratilas and others 1978). This may
have been caused by N20, but high oxygen concentrations
may have prevented it. The postal study of dentists by
Cohen and others (1980) showed that the incidence of
hepatic disease was increased in both dentists and
chairside assistants who had been exposed to N20, and that
its severity was dose dependent. However, this study has
many faults including inaccurate recall, responder bias,
and difficulty in obtaining a diagnosis. Lampe and others
(1990) found that 60% N20 when given to 100 patients
undergoing hip replacement caused no abnormalities in
liver function tests (alanine aminotransferase, bilirubin
and alkaline phosphatase). Problems with this trial
include small numbers, a relatively short duration of
exposure, and the liver function tests may have been too
insensitive. More work needs to be done on the effects of
N20 on the liver.
There is no evidence of nephrotoxicity in humans
exposed to N20 although the study of Cohen and others
(1980) showed an increase in renal lithiasis in both
dentists and their assistants exposed to high
concentrations of N20 which occurred in a dose dependent
manner.
There is evidence that N20 can acutely affect the
central nervous system in addition to its chronic actions.
It is a cerebral circulatory and metabolic stimulant
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(Sabake 1978) with effects additive to those of volatile
anaesthetics (Editorial 1987b). This stimulant effect may
be dangerous in compromised patients.
In conclusion, N20 has many potential side effects
although several are still unproven and require further
investigation. It is expensive to manufacture, store and
use. It has caused deaths from both contamination and
hypoxia. It can support combustion and may increase
environmental pollution of the atmosphere. It is a weak
anaesthetic. It has detrimental effects on the
cardiovascular and respiratory systems and may interfere
with post-operative recovery. It is readily soluble in
blood resulting in both diffusion hypoxia and diffusion
into body spaces and tracheal cuffs. It may increase the
incidence of nausea and vomiting and perhaps influence the
progress of MH. It has been implicated in causing hepatic
and renal disease and may have adverse effects on the
central nervous system.
Why is it used if it has all these side effects? It
has several advantages, some of which have already been
discussed. It is the only available potent analgesic with
a fast onset and recovery. Both induction of anaesthesia
and recovery are rapid and the depth of anaesthesia can be
quickly changed by adjusting the inspired concentration.
It is non irritating and odourless and is pleasant to
inhale.
However, its principal advantage comes from the fact
that MAC values are additive. Volatile anaesthetics whilst
being more potent are also more toxic and N20 can reduce
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the concentrations needed for anaesthesia. Combining
inhalational anaesthetics has additive effects on
anaesthesia (Cullen 1986). Seventy percent N20 reduced
halothane MAC by 61% (Siadman and Eger 1964) and
isoflurane MAC by 60% (Stevens and others 1975) . For each
1% N20 used, the MAC of the added anaesthetic is reduced
by approximately 1%. Additionally, N20 produces amnesia
and it is possible that without N20 there could be an
increase in awareness during surgery.
Recently, evidence has shown that N20 does not have a
linear effect in reducing the MACs of other inhalation
drugs. Cole and others (1990) showed that in rats,
exposure to high concentrations of N20 had less of an
impact in decreasing volatile anaesthetic concentrations
needed to maintain a standard anaesthetic depth than would
have been expected from its effect at lower
concentrations. This suggests that it has more powerful
effects at lower concentrations than at higher ones.
Possibly there is less advantage in using 70% N20 rather
than 50%.
The main volatile anaesthetics will now be discussed
and their advantages and disadvantages over N20 assessed.
New drugs not yet readily available will then be
mentioned. Intravenous (IV) techniques, both continuous
and bolus methods, will finally be discussed.
Three volatile anaesthetics are used in modern
anaesthesia, halothane, enflurane and isoflurane. All are
halogenated and possess similar properties although these
do vary greatly. All are relatively stable compounds
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except halothane which decomposes when exposed to
ultraviolet light and certain metals and requires 0.01%
thymol as a stabiliser. However, they are all metabolised
in the body unlike N20. Halothane is metabolised most (20-
45%), then enflurane (2.5-8.5%) with isoflurane being
relatively stable (0.2%)(Carpenter and others 1986).
Metabolism of these drugs produces compounds which are
biologically active and these will be described later.
Storage is easier, cheaper and cleaner than N20
because no cylinders are needed. All are volatile and
vaporise in high concentrations at room temperature
although separate vaporisers are needed for each volatile
drug. Modern vaporisers are accurate although are often
only capable of vaporising low concentrations of drug (a
safety feature) and this may too low to allow induction or
maintainance of a suitable level of anaesthesia without
the addition of N20. New vaporisers are available which
are able to produce a higher concentration of anaesthetic
(i.e. 7% enflurane).
Volatile anaesthetics need a carrier gas and
normally this is a mixture of N20 and oxygen. Without N20,
three mixtures could be used, 100% oxygen or oxygen with
nitrogen or air. Pure oxygen has two advantages. No
delivery errors can occur and the patient can never
receive a hypoxic mixture. Additionally, the patient will
always be fully oxygenated and have a large reservoir of
oxygen. Its disadvantages include the expense, storage and
delivery of oxygen, the increased possibility of fires and
oxygen toxicity. It can increase the incidence of
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absorption collapse (Winter and Smith 1972) and may injure
the lung in a time and dose dependent manner due to
production of oxygen radicals (Clark and Lambersten 1971).
Whilst most anaesthetics are too brief for damage to
occur, using 100% oxygen in prolonged cases may lead to
toxicity. Using nitrogen requires extra pipelines or
cylinders and it is a hypoxic gas. Oxygen and air mixtures
will prevent this problem.
The volatile anaesthetics are not flammable or
explosive. All are more potent anaesthetics than N20 (MACs
for halothane, enflurane and isoflurane are 0.75, 1.68 and
1.15) and can be used alone without N20 to produce an
acceptable depth of anaesthesia. However, they all have a
lower blood/gas partition coefficient than N20 (halothane,
enflurane and isoflurane have values of 2.4, 1.9 and 1.4
respectively (Stewart and others 1973)) and induction and
uptake by these drugs is considerably slower. Two others
factors also reduce the speed of induction. None have a
2nd gas effect and both enflurane and isoflurane have
unpleasant odours and irritate the upper respiratory
tract. All are considerably more soluble in fat than N20
(Stewart and others 1973) and large body depots can build
up resulting in a slow and prolonged recovery.
They have greater effects on the cardiovascular and
respiratory systems than N20. Halothane and enflurane
depress cardiac output whilst isoflurane has only a minor
effect (Shimosato and others 1982). All cause some
peripheral vasodilation, especially isoflurane. Overall,
mean blood pressure decreased 45%, 40% and 25%
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respectively with 1.5 MAC when compared to N20 (Calverley
and others 1978) . Further increases in inspired
concentrations progressively decrease the blood pressure
in contrast to N20. In compromised patients (shocked, old,
etc) this decrease may be fatal. This effect often limits
how much of these powerful anaesthetics can be given.
Halothane, and to a lesser extent enflurane,
sensitises the heart to catecholamines (both endogenous
and exogenous) resulting in an increase in arrhythmias
(Munsen and Tucker 1975). Isoflurane may possibly cause a
coronary artery "steal" syndrome resulting in myocardial
ischaemia. It has been recommended that it should not be
used in patients with coronary vessel disease (Editorial
1987a). Cerebral blood flow autoregulation is impaired
when more than 0.6 MAC enflurane and halothane is given
whilst isoflurane is safe in doses up to 1.1 MAC (Todd and
Drummond 1984). The increase in cerebral blood flow that
occurs results in dangerous increases in intracranial
pressure.
They have similar effects on the respiratory system,
depressing ventilation with a decrease in tidal volume and
an increase in respiratory rate. One big advantage over
N20 is that they all decrease airway resistance due to a
direct bronchodilatory effect (Gold and others 1983). They
increase mucus production and depress ciliary movement
(Forrest and Chambers 1983) . There is a profound dose
dependent depression of respiratory control although this
is similar to N20. There is greater depression of the
hypoxic drive with its total abolition when 1.0 MAC of
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drug is given.
They have other undesirable side effects. All cause a
dose dependent relaxation of uterine muscle resulting in
excessive blood loss after anaesthesia for retained
placenta, Caesarean operation and evacuation of the uterus
(Munsen and Embro 1977). They all cause moderate skeletal
muscular relaxation in a dose related fashion due to both
a central and a post-junctional effect (Fogdall and Miller
1975) . They have no analgesic action and only a general
depression of the nervous system will reduce pain.
They also have toxic effects. Enflurane can cause
epileptiform changes in the EEG especially with hypocarbia
and its use has been contraindicated in epileptics
(Soderberg and Grattidge 1977). Halothane is known to
cause liver toxicity with an incidence of 1 in 7,000-
30,000 halothane anaesthetics (Brown and Gandolfi 1987).
This has resulted in the Committee on the Safety of
Medicine warning anaesthetists that halothane should not
be reused within 3 months in any single patient and that
it should not be used if the patient has had a previous
history of jaundice or fever after a halothane
anaesthetic. Enflurane has also been linked to hepatic
damage although the incidence is much lower (Eger and
others 1986). As yet, there is little evidence that
isoflurane is hepatotoxic. Enflurane is partially
metabolised in the body to produce fluoride which can
cause renal toxicity and it is suggested that enflurane
should not be used in patients with renal failure (Jones
1984). Metabolism of halothane produces bromide ions which
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can result in the patient being excessively sedated
(Tinker and others 1976). The volatile anaesthetics can
initiate MH and using them is contraindicated in patients
who may suffer from it (Harrison 1987).
Because all are halogenated hydrocarbons, they can
pollute the atmosphere. However, they only contribute
about 0.01% of all toxic compounds released into the air
(Brown and others 1989). Because their atmospheric lives
are relatively short (1-2 years), they are regarded as
being "ozone friendly" (Editorial 1989).
In conclusion, these 3 drugs are powerful
anaesthetics and have the potential to fully anaesthetise
patients without the need for N20. They have some
advantages over N20 being stable with long shelf lives,
are more convenient to store, can allow greater
concentrations of oxygen to be given, cause muscle
relaxation, and are bronchodilators. They have no effect
on the body spaces and are ozone friendly. However, they
also have many disadvantages. They are highly metabolised
in the body, require a carrier gas, are expensive, have a
high solubility in both blood and lipid and therefore
blood concentrations will change only slowly. They are
irritant, have no analgesic actions, relax uterine muscles
and cause increases in intracranial pressure. However,
more importantly, they are powerful cardiorespiratory
depressants and can cause organ toxicity and MH. These
disadvantages contraindicate their use in certain
surgical procedures and also may limit how much can be
given in other cases especially when the patient is ill.
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New volatile anaesthetic drugs are available
(sevoflurane and desflurane) and these may be more
suitable. However, it appears that they have little
advantage over the present drugs. Sevoflurane has a low
blood/gas coefficient (0.6) which gives a smooth induction
(Morisaki and others 1988). It is metabolised like
enflurane although no organ toxicity has been seen (Cook
and others 1975). However, it depresses the
cardiorespiratory systems in a dose dependent manner
(Kazama and Ikeda 1988).
Desflurane has a low boiling point (23°C) and
requires a special vaporiser. It is less potent than the
other drugs (MAC 5.4) with a low blood/gas partition
coefficient (0.4), is non-irritating and gives a rapid
smooth induction with sensitive control of depth (Jones
and others 1990). It appears to have cardiorespiratory
effects similar to isoflurane (Weiskopf and others 1989).
Could these new drugs fully replace N20? Induction
and recovery is faster than the older drugs. However, they
have similar cardiovascular side effects to the older
drugs. Because they have only been used clinically in a
relatively few patients, it is possible that they have
other toxic effects that have not been discovered. Hence,
all the volatile drugs that are either available or soon
to be available are not fully suitable to be used alone
for all types of anaesthesia.
Will intravenous drugs replace N20? At present they
are used to maintain anaesthesia in 2 ways, to supplement
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inhalational methods or alone as a total intravenous
anaesthetic technique (either continuous infusion or bolus
injection). Three groups are used: opioids, induction
agents and benzodiazepines and other sedatives. Each group
will be briefly discussed and then its role in replacing
N20 assessed. An ideal infusion drug should be readily
soluble in water, be concentrated (to avoid excess fluid
administration), not metabolised by light, not absorbed by
plastic and cause no venous damage. It should able to
vary anaesthetic depth quickly, have no prolonged action
and have little effect on the cardiovascular and
respiratory systems (Dundee and Wyant 1988).
Opioids are frequently used before, during and after
anaesthesia. They were given as pre-medication in 41% and
intra-operatively in 28% of 64,645 anaesthetics (Duthie
and Nimmo 1987). Many different types are available which
vary in both potency and duration of action. Some are pure
agonists and others act as partial antagonists. However,
all have adverse effects that limit their use in
anaesthesia.
All opioids cause dose dependent respiratory
depression and decrease the hypercarbic ventilatory
response (Daykin and others 1986) . The cough and sigh
reflexes are inhibited decreasing secretion removal. Post¬
operative hypoventilation can occur. Atelectasis is
common and carbon dioxide retention can cause
cardiovascular problems. Severe hypoxia may result.
Respiratory depression is often prevented by naloxone,
although this drug has only a short life. Other side
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effects of naloxone include nausea and vomiting,
restlessness, pruritus, and left ventricular failure.
Sequential analgesia (combinations of opioid agonists and
partial antagonists) may provide good analgesia with no
respiratory depression (Cook and others 1982). Opioids
have a sedative effects resulting in prolonged recovery
times. Over a 4 year period, 119 cardiac arrests occurred
in France which were related to anaesthesia. Half occurred
post-operatively and these were mainly due to unrecognised
respiratory depression (Pottecher and others 1984) .
Chest rigidity can occur when high dose opioids are
given which may make ventilation difficult or interfere
with surgical access. Induction agents and volatile
anaesthetics can reduce rigidity (Christian and others
1983). It is well recognised that the incidence of nausea
and vomiting is increased by opioids. For example, women
undergoing dilatation and curettage had an increase in the
incidence of nausea from 22% to 65% if morphine was given
(Rubin and Winston 1950).
Opioids are useful in anaesthesia. They cause no
cardiovascular instability and minimally depress the
cardiac output and blood pressure. They do not sensitise
the heart to catecholamines and have no effect on organ
blood flow. They cause no pollution and do not induce MH.
They provide good post-operative analgesia and allow
artificial ventilation.
Can opioids produce satisfactory anaesthesia when
used by themselves? After a lorazepam pre-medication (0.08
— 1
or 0.04 mg.kg ), patients were paralysed and an
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alfentanil infusion was started. Responses to intubation
and painful stimuli were assessed and it was found that
lorazepam was needed to reduce the response because
alfentanil alone was unable to suppress haemodynamic
responses (Hug and others 1988). This is expected because
opioids have specific effects at receptors whilst
anaesthetic drugs have a more generalised effect. Opioids
have too selective an action for general anaesthesia. It
appears that other drugs are required with opioids for
complete anaesthesia (Editorial 1983).
They do reduce the amount of other drugs required for
anaesthesia. If morphine or fentanyl were given, the dose
requirements for volatile anaesthetics decreased by 65%
(Murphy and Hug 1982) . Whilst they may be given with
volatile anaesthetics to deepen anaesthesia,
cardiovascular depression still occurs because they can
interact with volatile anaesthetics and benzodiazepines
(White 1985).
In summary, opioids are poor anaesthetics when used
alone and other drugs are needed. They have serious side
effects, the most important being respiratory depression
which may last for many hours.
Benzodiazepines (BZ) have been used in combination
with opioids. They are sedatives and in higher doses,
hypnotics and act by depressing the excitability of the
limbic system due to an agonist action on specific BZ
receptors. This is similar to that of the opioids and
contrasts with the non specific action of general
anaesthetics (Richards and Mohler 1984) . Many different
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types exist, all with similar properties, but they do vary
in their time of onset and duration of action. They are
extremely safe having a very wide therapeutic index.
For intravenous anaesthesia, 3 different drugs are
used, diazepam, midazolam and lorazepam. All have similar
actions although their time of onset and duration of
actions are different due to their different solubilities,
protein bindings and metabolism. Diazepam is given as an
emulsion (diazemuls), midazolam is water soluble and
lorazepam reguires an organic solvent. Midazolam has a
short duration of action when compared to diazepam whilst
lorazepam acts for a long time.
All reduce the MAC of inhalational anaesthetic drugs.
Diazepam reduced the MAC of halothane by up to 34%, but
further doses had no effect suggesting a ceiling effect
(Perisho and others 1971). Similar reductions were seen
with midazolam (Melvin and others 1982). They have
important amnesic properties with midazolam and diazepam
giving an intense, short lived amnesia whilst that for
lorazepam lasted longer. No retrograde amnesia is seen.
(Dundee and Wilson 1980). They have no analgesic
properties.
They have no major effect on the cardiovascular
system and cause only a mild decrease in systemic vascular
resistance (Al-Khudhairi and others 1982) with little
effect on cardiac output. Midazolam and diazepam have been
safely used in high risk cardiac cases (Kuwar and others
1983) . The overall effect is much less than that of the
IV induction agents. They have little effect on either
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coronary or cerebral blood flow (Hilfibier and others
1980). They have little effect on the respiratory system,
but in high doses, will decrease the hypercapnic response
(Forster and others 1980). They cause an increase in the
incidence of respiratory obstruction when the patient is
sedated (Dixon and Thornton 1973).
Therefore they are hypnotic drugs with few side
effects. Can they be used clinically in general
anaesthesia in place of N20? Like opioids, it is
impossible to use them as the sole anaesthetic drug
because they have no analgesic potential and they have a
ceiling on their anaesthetic properties (Pelisho 1971).
They can be used as intravenous induction drugs producing
a smooth induction although the onset is slow and
unpredictable (Halliday and others 1985). They have
little cardiovascular instability when used as induction
drugs and therefore may be the drug of choice for sick
patients. They may have prolonged effects after surgery
resulting in delayed recovery. Fentanyl was given with
either midazolam or thiopentone for short operations and
recovery was prolonged in the midazolam group (Fragen and
Caldwell 1983). Specific reversal of the sedative actions
of BZ is now possible using flumazanil although, like
naloxone, it has a short duration of action and is
expensive.
They are commonly used for pre-medication producing
anxiolysis, sedation and amnesia. They have been used with
opioids in cardiac anaesthesia although awareness is a
recognised complication (Hilgenberg 1981). Overall, BZ
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have few serious side effects although are poor
anaesthetic drugs. They are not used for anaesthesia by
themselves, but have been used with other drugs.
The 3rd group of drugs are the IV induction agents.
Only a few are suitable for infusion techniques as defined
by Dundee and Wyant (1988) although all have been used for
shorter cases by bolus injection. Thiopentone rapidly
accumulates and repeated doses will prolong recovery.
Methohexitone has a faster rate of metabolism although it
is still extensively redistributed and can accumulate
delaying recovery (Hudson and others 1983). Etomidate was
a popular infusion drug until it was found to cause
adreno-cortical suppression (Sears and others 1983) and
its product licence for infusion has been withdrawn.
Althesin was believed to be the best drug available until
it too was withdrawn due to hypersensitivity reactions.
Two drugs are used for IV infusions in modern
anaesthesia, propofol and ketamine. Propofol is a phenol
derivative formulated as an emulsion. It has many features
which make it a suitable drug for IV anaesthesia
including fast recovery after its use. It causes
cardiovascular depression and this can limit its use in
compromised patients. Propofol infusions at twice the
minimum infusion rate decreased blood pressure more than
methohexitone or N20 (Prys-Roberts and others 1982) . It
has no known toxic effects and it is recommended for
general anaesthesia both with opioids and inhalational
agents (Healy 1985).
Ketamine is both a powerful analgesic and hypnotic
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allowing it to be used by itself as an anaesthetic. Side
effects include emergence delirium and post-operative
dreams. Benzodiazepine pre-medications overcome these
central nervous effects although delayed recovery may
occur. (Lilburn and others 1978).
Total intravenous anaesthesia (TIVA) was initially
popular because it was thought that chronic exposure of
theatre personnel to inhalational agents (both N20 and
volatile anaesthetics) could have toxic effects. Other
reasons for its development include certain operations
where it is difficult to administer inhalation agents
(access, high oxygen concentrations required, the use of
high frequency ventilation, etc) or where inhalational
anaesthetics are not safe (cranial operations, etc). The
problems of TIVA include awareness, prolonged recovery,
cardiorespiratory depression, technical difficulty and
cost of new equipment. TIVA is being used more and more
and is no longer confined to enthusiasts.
Awareness may be a problem with intravenous
anaesthesia especially when modern muscle relaxants are
given. Both N20 and the volatile drugs have good amnesic
qualities. Sixty six percent N20 is more effective than
50% and the addition of enflurane abolished any awareness.
(Farnsworth 1978). N20 may abolish the incidence of
awareness (Editorial 1982). Opioids cause no amnesia
(Hilgenberg 1981). Grell and others (1970) showed that
the addition of 50% N20 to oxygen-fentanyl prevented post¬
operative recall in 500 patients. However, in contrast to
this, 20% of all awareness cases reported to the defence
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unions were due to an abnormally low inspired
concentration of N20 being given (Hargrove 1987) and 70%
of these were a result of faulty anaesthetic technigue
with most involving a N20:oxygen:opioid anaesthetic. Is
too much reliance being placed on N20? Induction agents
provide a greater degree of protection. Fifty five
patients undergoing major gynaecological surgery received
either N20 (66%) with fentanyl 0.25 mg at induction or an
etomidate infusion with air. Temazepam was used for
premedication, thiopentone for induction and vecuronium
provided muscle relaxation. Incremental doses of 0.1 mg
fentanyl were given if clinically indicated. Using the
isolated forearm technigue, 44% who received N20 were
found to be awake during some part of the operation
compared to 7% for the etomidate group (Russel 1986) . It
appears that N20 has potent amnesic gualities although
awareness can be prevented by other drugs except opioids.
Patients undergoing surgery for major trauma may be
especially susceptible to awareness because the patient is
often haemodynamically unstable and anaesthesia must be
light. Fifty one trauma patients were studied, some
received only a muscle relaxant and others an inhalational
agent and occasionally N20. Ten individuals were aware, 6
having had received no anaesthetic for at least 20 minutes
(Bogetz and Katz 1984). Early use of benzodiazepines may
have helped to prevent this. Lack of N20 may therefore
result in an increase in the incidence of awareness.
Recovery is theoretically faster when N20 is used as
compared to intravenous drugs. However, N20 is usually
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given with other drugs and recovery is mainly influenced
by these drugs. Recovery may be prolonged with longer
operations if N20 is not used, although a fast recovery
may not be clinically useful. Recovery is important in
short cases. Ninety-four day case patients received
either intravenous fentanyl and propofol infusion or
fentanyl with enflurane and 66% N20. Both groups had
similar recovery times, but there was a lower incidence of
vomiting without N20 (Price and others 1988). Therefore,
it is probable that awareness and recovery may not be an
important problem when N20 is not used.
There is, as yet, insufficient evidence about the
balance between the benefits and dangers of not using N20
to make an objective assessment about banning its use in
anaesthesia. Therefore any opinion must be subjective.
There are learning difficulties with any new technigue.
Anaesthetists are familiar with inhalational anaesthesia
and feel able to measure anaesthetic depth accurately when
using it. However, a fear of learning new technigues is no
reason for failure to adopt superior treatments.
There are certain anaesthetics were N20 has been
proven to be contraindicated. There are indications that
it may be toxic to certain individuals including women in
early pregnancy and the sick patient. A safe delivery
method is important to prevent hypoxia. Its lack of
potency requires the use of additional drugs. Theatre
pollution can be a problem especially during short cases
and because there are suitable intravenous drugs for this
type of surgery, a strong case for the abolition of N20
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may be made in this type of surgery.
With intermediate length cases or with
cardiovascularly unstable patients N20 may still have an
important role. A major advantage of N20 is the number of
cases in which it has been given with no obvious
detrimental effect. This has been taken as an indication
of its safety although the occasional severe problem may
have been missed. Its other advantages include it being a
analgesic and its cardiorespiratory stability. Recently
work by Eger and others (1990) has indicated that some of
its potential side effects are not as severe as was once
thought. Indeed, he now suggests that it is a safe drug
and should still be used by anaesthetists.
More work is needed to investigate both its side
effects and its toxic effects. For the latter, how much
exposure is required before clinically important
consequences occur? Are there identifiable groups of
patients who are more susceptible to its effects? Does N20
contribute to the morbidity of patients by reducing an
individual's ability to fight infections and repair
wounds? Are sick patients more vulnerable? Does it cause a
pollution hazard and are pregnant women especially
vulnerable? Are there better methods of preventing MS
inhibition?
There are questions still to be answered about N20
and anaesthesia. Does it increase emesis, can other
methods of preventing awareness be used, does it have
hepato-renal toxic effects, does it cause increased lung
problems and has it detrimental effects on the bowel?
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These and similar questions still need to be
answered. This thesis has shown that N20 can have an
effect on an important metabolic pathway in lower exposure
doses than was previously thought and that this effect
varies between individuals. Anaesthetists appear to be
unaffected. This work, combined with other studies has
made me believe that while N20 still has a place in
anaesthesia, this may not be true for much longer,
especially with the development of cheap easily controlled
infusion techniques. Instead of N20 being used routinely
for all anaesthetics perhaps it used be reserved for
specific indications. Definite evidence of early toxicity
or the discovery of a new, safer inhalational or
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dU test Deoxyuridine suppression test





















PPM Parts per million
RNA Ribonucleic acid
RR relative risk




SCE Sister chromatid exchanges
THF Tetrahydrofolate
TS Thymidine synthase
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